/[Periodic Report] Atomic Hi-Tech: 2026 Semi-Annual Report

NEWS

[Periodic Report] Atomic Hi-Tech: 2026 Semi-Annual Report

NEEQ

2026/08/28

Announcement number: 2026-032 Securities code: 430005 Securities abbreviation: Atom Hi-Tech Sponsoring broker: GF Securities

Atomic Hi-Tech NEEQ: 430005 Atomic Hi-Tech Co., Ltd.

Semi-annual report

2026

Important tips

The company’s controlling shareholders, actual controllers, directors and senior managers guarantee that the information contained in this report does not contain any false records or misleading information.

sexual statements or major omissions, and shall bear individual and joint liability for the authenticity, accuracy and completeness of its contents.

Zhang Yiming, the person in charge of the company, Zhang Lida, the person in charge of accounting work, and Xiao Huafang, the person in charge of the accounting department (accounting supervisor), guarantee that half of

The financial report in the annual report is true, accurate and complete.

3. This semi-annual report has been reviewed and approved by the board of directors of the listed company, and there are no directors who did not attend the review.

4. This semi-annual report has not been audited by an accounting firm.

This semi-annual report involves forward-looking statements such as future plans, which does not constitute the company’s substantive commitment to investors. Investors and relevant persons

Adequate risk awareness should be maintained and the differences between plans, forecasts and commitments should be understood.

This semi-annual report has reported on the company in "Section 2 Accounting Data and Operations" - "VII. Analysis of Major Risks Faced by the Company"

The major risk factors during the reporting period will be analyzed. Investors are advised to read carefully.

1. Business Overview

(1) Realization of business model and business plan

The company's industry is pharmaceutical manufacturing; its main products are radiopharmaceuticals, radioactive sources, radioactive medical devices, radioactive labeled compounds and tracers, etc. The company is committed to the industrialization of nuclear application technology. It has the largest production and R&D base of radioisotope products in my country with a wide range of products, and has successfully passed qualification certifications such as GMP, "Quality, Environmental and Occupational Health and Safety Management System" and "Military Industry Unit Safety Standardization Level 1". After years of development, the company has accumulated momentum for further development and has certain strength in scientific research, development and operation. It has a scientific research, production and operation team with strong R&D capabilities, and has formed a certain reputation in the country. The company's customers are mainly major hospitals. As a leading enterprise in domestic isotope technology, the radioactive drugs developed by the company provide convenience for the early diagnosis of cancer and the examination of thyroid, tumor and other diseases; it has made great contributions in the treatment of thyroid cancer and bone tumors. Through a business model that places equal emphasis on R&D and sales, the company has strengthened its R&D and sales capabilities and created its own brand. The company sells goods through a commercial sales model. The main source of income is the sales revenue of the company's main products and technical service revenue.

(2) Industry situation

In the first half of 2026, the radiopharmaceutical (nuclear medicine) industry has received more and more attention due to the resonance of top-level policy design, capital catalysis and underlying technological breakthroughs.

In terms of policy and supervision, the top-level design has been implemented and the compliance threshold for the entire chain has been comprehensively improved. The nuclear medicine industry welcomes national strategic support. The "Fifteenth Five-Year Plan for National Health" released in July 2026 clearly proposed for the first time "accelerating the research and development and application of radioactive drugs" and "supporting the development and application of innovative drugs and medical devices throughout the chain", marking the industry's shift from policy-driven to industry and policy-driven. At the same time, industry supervision has been further tightened. The State Administration for Market Regulation has included the revision of the "Radioactive Drug Management Measures" as a key legislative task in 2026, and has refined supervision on production, circulation, radiation safety and other links to promote an overall increase in industry compliance thresholds.

The popularity of capital continues to grow, with large-amount financings occurring frequently. The popularity of the primary market has reached a new high, and capital has accelerated its concentration in companies with upstream nuclide production capabilities and new α-nuclide labeled drug pipeline layouts. In the first half of 2026, many domestic nuclear medicine companies received financing worth RMB 100 million. Internationally, nuclear medicine company Curium Pharma issued a takeover bid for Lantheus Holdings, with a base valuation of US$7 billion. If this transaction is finally completed, it will surpass Bristol-Myers Squibb's US$4.1 billion acquisition of RayzeBio in 2023, becoming the largest merger and acquisition transaction in the global nuclear medicine industry in recent years. In addition, multinational pharmaceutical companies are accelerating their localization in the Chinese market. AstraZeneca signed a cooperation memorandum with Guangzhou and plans to build a radioconjugated drug production and supply base in Guangzhou. The base will specialize in the production of radioconjugated drugs, and the new base plans to produce a radioconjugated drug based on actinium-225 for the treatment of prostate cancer.

In terms of R&D pipelines, Chinese companies are accelerating to catch up, showing a trend of differentiated layout of targets. Industry data shows that as of March 2026, the total number of oncology-related nuclear drug pipelines in the world exceeds 2,000 (including preclinical to NDA stages), and China’s total oncology nuclear drug pipelines

The number accounts for about 40% of the world. In terms of target layout, China has demonstrated a differentiated competitive strategy. The number of FAP targets in China’s research pipeline exceeds that of PSMA.

Ranked first; at the same time, PD-L1, αvβ3 and other targets also occupy a high proportion in China’s pipeline.

The localization of upstream nuclide preparation is accelerated, and the problem of medical isotopes is accelerated. In March 2026, the Institute of High Energy Physics of the Chinese Academy of Sciences

Thanks to the China Spallation Neutron Source, the Curie-level mass production of medical-grade α-isotopes has been achieved for the first time, marking the automatic release of core therapeutic nuclides such as actinium-225 and radium-223.

Main supply has entered a new stage.

(3) Identification status related to innovation attributes

√Applicable □Not applicable

"Specialized, Specialized and New" certification √National level □Provincial (municipal) level

"Single Champion" recognition □National level □Provincial (municipal) level

"High-tech enterprise" certification √Yes

Details: In March 2023, the company obtained the Beijing "Specialized, Specialized and New" small and medium-sized enterprise certificate, certificate number: 2023ZJTX0119, valid for 3 years. The review and certification will be completed in March 2026. In October 2023, the company once again obtained the high-tech enterprise certificate, certificate number: GR202311000772, valid for 3 years.

On July 1, 2025, the company won the title of national-level specialized and new "Little Giant" enterprise

No., valid for 3 years.

2. Main accounting data and financial indicators

Unit: Yuan

Profitability for the current period Same period last year Increase/decrease ratio %

Operating income 938,008,646.62 830,842,389.41 12.90% Gross profit margin% 57.62% 54.99% -

Attributable to shareholders of listed companies

167,021,784.90 133,087,970.90 25.50% Net profit

Attributable to shareholders of listed companies

158,419,936.33 131,568,896.21 20.41% net profit after deducting non-recurring gains and losses

Weighted average return on equity -

Rate % (based on attributable to listed companies 5.81% 4.96%

Calculation of the company’s shareholders’ net profit)

Weighted average return on equity -

Rate % (attributed to the listed company

5.51% 4.90%

Shareholders’ deduction for extraordinary losses

Calculation of net profit after earnings)

Basic earnings per share 1.03 0.82 25.61%

Solvency ability End of the current period End of the previous year Increase or decrease ratio %

Total assets 5,438,587,541.53 5,134,551,997.11 5.92% Total liabilities 2,216,439,958.92 2,022,363,464.42 9.60% attributable to shareholders of the listed company

2,866,345,605.14 2,783,464,871.60 2.98% Net assets

Attributable to shareholders of listed companies

17.72 17.20 3.02% Net assets per share

Asset-liability ratio % (parent company) 34.38% 31.48% -

Asset-liability ratio % (consolidated) 40.75% 39.39% -

Current ratio 1.71 1.73 -

Interest coverage ratio 24.02 19.12 -

Operational conditions Current period Same period last year Increase/decrease ratio %

cash flow from operating activities

55,541,567.43 1,868,372.13 2,872.73% Net amount

Accounts receivable turnover ratio 0.78 0.75 -

Inventory turnover ratio 3.01 2.82 -

Growth situation Current period Same period last year Increase/decrease ratio %

Growth rate of total assets % 5.92% 5.46% -

Operating income growth rate% 12.90% 4.24% -

Net profit growth rate% 26.13% 4.55% -

3. Financial situation analysis

(1) Analysis of assets and liabilities

Unit: Yuan End of current period End of previous year

Item Percentage of change in total assets Percentage of change in total assets Amount

Proportion % Proportion %

Monetary funds 648,191,701.24 11.92% 657,639,089.19 12.81% -1.44% Notes receivable 30,826,380.63 0.57% 35,256,130.93 0.69% -12.56% Accounts receivable 1,183,041,557.18 21.75% 1,047,117,959.99 20.39% 12.98% Receivables financing 15,082,826.35 0.28% 15,137,831.91 0.29% -0.36%Advance payment 36,250,146.81 0.67% 45,513,361.92 0.89% -20.35% Other receivables 46,504,881.24 0.86% 11,336,817.03 0.22% 310.21% Inventory 134,182,800.53 2.47% 87,671,182.90 1.71% 53.05%Other current assets 73,392,283.28 1.35% 63,952,829.58 1.25% 14.76% Long-term receivables 43,992,551.52 0.81% 42,940,509.05 0.84% 2.45% Long-term equity investment 547,849,980.45 10.07% 542,882,255.78 10.57% 0.92% Investment real estate 13,437,626.72 0.25% 15,370,386.32 0.30% -12.57%Fixed assets 1,333,462,945.13 24.52% 1,089,187,139.84 21.21% 22.43%Construction in progress 540,891,617.68 9.95% 702,247,101.61 13.68% -22.98%Right-of-use assets 7,445,129.51 0.14% 10,960,195.14 0.21% -32.07%Intangible assets 247,409,532.24 4.55% 252,595,799.76 4.92% -2.05%Development expenses 286,654,756.88 5.27% 259,746,178.90 5.06% 10.36% Goodwill 20,619,741.62 0.38% 20,619,741.62 0.40% 0.00% Long-term prepaid expenses 2,742,372.92 0.05% 3,976,758.36 0.08% -31.04% Deferred income tax assets 106,211,374.99 1.95% 88,672,315.28 1.73% 19.78% Other non-current assets 120,397,334.61 2.21% 141,728,412.00 2.76% -15.05% Short-term borrowings 315,995,188.01 5.81% 314,146,946.19 6.12% 0.59% Notes payable 0.00 0.00% 8,778,000.00 0.17% -100.00% Accounts payable 70,653,346.25 1.30% 70,598,877.35 1.37% 0.08% Contract liabilities 54,167,380.26 1.00% 64,670,007.17 1.26% -16.24% Employee compensation payable 50,585,878.63 0.93% 68,901,146.26 1.34% -26.58% Taxes payable 58,041,735.17 1.07% 47,503,344.43 0.93% 22.18% Other payables 699,902,496.41 12.87% 532,869,120.61 10.38% 31.35% Non-payment due within one year

13,623,955.43 0.25% 15,929,162.14 0.31% -14.47%Current liabilities

Other current liabilities 7,234,100.23 0.13% 9,324,310.54 0.18% -22.42% Long-term borrowings 636,574,454.03 11.70% 587,767,741.90 11.45% 8.30% Lease liabilities 4,545,150.59 0.08% 4,798,037.66 0.09% -5.27% Long-term payables 57,337,964.71 1.05% 57,763,644.97 1.12% -0.74% Long-term employee salaries payable

32,994,781.76 0.61% 28,569,781.76 0.56% 15.49%

Estimated liabilities 117,474,183.67 2.16% 114,735,203.43 2.23% 2.39% Deferred income 92,842,384.58 1.71% 91,116,705.38 1.77% 1.89% Deferred income tax liabilities 4,466,959.19 0.08% 4,891,434.63 0.10% -8.68%

Reasons for major changes in the project

(1) Other receivables: The balance at the end of the period was 46.5049 million yuan, an increase of 35.1681 million yuan over the end of the previous year, an increase of 310.21%. main

The reason is that there was a new dividend receivable of RMB 29.828 million in this period.

(2) Inventory: The ending balance was 134.1828 million yuan, an increase of 46.5116 million yuan over the end of the previous year, an increase of 53.05%. The main reason is

Sales and inventory preparation, this period newly added Calei source inventory.

(3) Right-of-use assets: The balance at the end of the period was 7.4451 million yuan, a decrease of 3.5151 million yuan from the end of the previous year, a decrease of 32.07%. main reason

When the financial lease expires, the right-of-use assets are transferred to fixed assets.

(4) Long-term deferred expenses: The balance at the end of the period was 2.7424 million yuan, a decrease of 1.2344 million yuan from the end of the previous year, a decrease of 31.04%. main reason

Because there are fewer new deferred items in this period, the book value decreases as the original items are amortized.

(5) Notes payable: The balance at the end of the period was 0.00 million yuan, a decrease of 8.778 million yuan compared with the end of the previous year, a decrease of 100.00%. The main reason is tickets

Payment is due.

(6) Other payables: The balance at the end of the period was 699.9025 million yuan, an increase of 167.0334 million yuan over the end of the previous year, an increase of 31.35%. Lord

The main reason is the newly added dividend payable of RMB 94.0991 million in this period.

(2) Business situation analysis

Profit composition

Unit: yuan for the current period and the same period last year

Items for the current period and the same period last year accounted for operating income accounted for operating income

Amount Amount Change in amount %

Proportion % Proportion %

Operating income 938,008,646.62 - 830,842,389.41 - 12.90% Operating cost 397,534,158.24 42.38% 373,926,100.69 45.01% 6.31% Gross profit margin 57.62% - 54.99% - -

Taxes and surcharges 14,630,780.56 1.56% 10,884,616.87 1.31% 34.42%Sales expenses 200,657,369.81 21.39% 157,313,842.83 18.93% 27.55%Administrative expenses 73,593,100.58 7.85% 79,221,306.17 9.54% -7.10%R&D expenses 66,424,384.41 7.08% 63,901,411.29 7.69% 3.95%Financial expenses 6,701,935.39 0.71% 7,822,884.62 0.94% -14.33%Other income 10,818,479.05 1.15% 2,044,768.39 0.25% 429.08%Investment income 34,795,772.58 3.71% 32,101,493.01 3.86% 8.39% Credit impairment loss -8,203,299.30 -0.87% -5,419,793.09 -0.65% -51.36% Asset impairment loss -7,249,859.85 -0.77% 3,016,177.39 0.36% -340.37% Asset disposal income -7,537.94 0.00% 1,230,866.06 0.15% -100.61% Operating profit 208,620,472.17 22.24% 170,745,738.70 20.55% 22.18%Non-operating income 471,928.27 0.05% 9,268.38 0.00% 4,991.81%Non-operating expenses 53,815.97 0.01% 83,613.44 0.01% -35.64%Total profit 209,038,584.47 22.29% 170,671,393.64 20.54% 22.48%Net profit 186,193,281.72 19.85% 147,620,829.23 17.77% 26.13%Other comprehensive income

-3,708,000.00 -0.40% -1,000.00 0.00% 370,700.00% net amount after tax

Reasons for major changes in the project

(1) Taxes and surcharges: This period is 14.6308 million yuan, an increase of 3.7462 million yuan over the same period last year, an increase of 34.42%. The main reason is

Revenue increased this period.

(2) Other income: this period was 10.8185 million yuan, an increase of 8.7737 million yuan compared with the same period last year, an increase of 429.08%. The main reason is based on

Scientific research subsidies increased during the period.

(3) Credit impairment loss: this period was -8.2033 million yuan, an increase of 2.7835 million yuan, or 51.36%, compared with the same period last year. main reason

This is because the expected loss rate growth is measured based on the expected credit loss model of accounts receivable in this period.

(4) Asset impairment loss: -7.2499 million yuan in this period, an increase of 10.266 million yuan, or 340.3%, from the same period last year. main

The reason is that the inventory impairment amount is measured using the lower of cost and net realizable value.

(5) Income from asset disposal: this period was -7,500 yuan, a decrease of 1,238,400 yuan compared with the same period last year, a decrease of 100.61%. main reason

Because the lease was terminated early in the same period last year, gains and losses on the disposal of right-of-use assets were recognized.

(6) Non-operating income: This period was 471,900 yuan, an increase of 462,700 yuan over the same period last year, an increase of 4,991.81%. The main reason is violation of

Contract income (income from non-daily operating activities) increased.

(7) Non-operating expenses: This period was 53,800 yuan, a decrease of 29,800 yuan compared with the same period last year, a decrease of 35.64%. The main reason is late payment fees

reduce.

(8) Net amount of other comprehensive income after tax: -3.708 million yuan for the current period, a decrease of 3.707 million yuan compared with the same period last year.

370,700.00%. The main reason is that changes in actuarial assumptions lead to changes in remeasurement of defined benefit plans.

Income composition

Unit: Yuan

Item Amount for the current period Amount for the previous period Change percentage %

Main business income 938,008,646.62 830,842,389.41 12.90% Other business income

Main business costs 397,534,158.24 373,926,100.69 6.31% Other business costs

Analysis by product category

√Applicable □Not applicable

Unit: Yuan Operating income ratio Operating cost ratio

Gross profit margin compared to previous categories/projects Operating income Operating costs Gross profit margin % Increase in the same period last year Compared with the same period last year

Year-on-year increase or decrease

Increase or decrease % Decrease %

Radiopharmaceuticals 853,914,769.14 336,747,659.22 60.56% 17.76% 13.85% 1.34% Sales and inspection

business

Sales of radioactive sources 75,060,676.73 53,200,074.69 29.12% 9.66% 10.58% -0.59% and technical services

business

Irradiation services 3,486,279.95 3,923,330.63 -12.54% 3.46% 73.05% -45.26%Radiation protector 0.00 0.00 0.00% -100.00% -100.00% -Materials and construction engineering

Process business

Special equipment production 5,546,920.80 3,663,093.70 33.96% -27.91% 11.55% -23.36% Production and sales and its

other business

Analysis by region

□Applicable √Not applicable

Reasons for changes in revenue composition

Due to the adjustment of industrial structure, the atomic company Hubei Zhongxun Medical Supplies Industrial Co., Ltd. was no longer included in the scope of consolidation at the end of last year, so this period does not involve radiation protection equipment and construction engineering business.

The cost of irradiation services increased by 73.05% year-on-year in the current period, mainly due to changes in product structure, increased technical project transformation business, and rising material costs.

(3) Cash flow analysis

Unit: Yuan

Item Amount for the current period Amount for the previous period Change ratio % Net cash flow generated from operating activities 55,541,567.43 1,868,372.13 2,872.73% Net cash flow generated from investing activities -16,125,432.49 -116,116,748.18 86.11% Net cash flow generated from financing activities 40,584,070.87 102,705,927.01 -60.49%Cash flow analysis

The net cash flow generated from operating activities in the current period was 55.5416 million yuan, an increase of 53.6732 million yuan or 2872.73% over the same period last year. The main reason was that the cash received from selling goods and providing services increased by 95.6156 million yuan compared with the same period last year, and various taxes and fees paid increased by 26.3383 million yuan compared with the same period last year.

The net cash flow generated by the company's operating activities this year was 55.5416 million yuan, and the net profit realized this year was 186.1933 million yuan. The main reasons for the difference were (1) the investment income in the current year's income statement was 34.7958 million yuan, which was a profit generated from investment activities; (2) the inventory increased by 51.3506 million yuan year-on-year.

The net cash flow generated from investing activities in the current period was -16.1254 million yuan, an increase of 99.9913 million yuan or 86.11% over the same period last year. This was mainly due to the increase in cash received from other investment activities and the recovery of time deposits of more than three months in the current period of 86.2614 million yuan. The cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets increased by 16.9892 million yuan compared with the same period last year, mainly for payments for projects under construction.

The net cash flow generated from financing activities in this period was RMB 40.5841 million, a decrease of RMB 62.1219 million or 60.49% compared with the same period last year. The main reason was that the inflow of borrowings in this period decreased by RMB 91.331 million compared with the same period last year. The cash paid for other financing activities decreased by RMB 36.3423 million year-on-year, mainly due to the payment of RMB 33.40 million for equity acquisition last year.

4. Investment status analysis

(1) Major holding subsidiaries and joint-stock companies

√Applicable □Not applicable

Unit: Princess Yuan Gong

Company Company Registered Capital Total Assets Net Assets Operating Income Net Profit Name Category Industry

The nature of the company's pharmaceutical company Pinxing and

84,320,000.00 436,326,135.49 311,918,988.44 93,433,606.29 18,791,775.16 Pharmaceutical services business

limited

Public

Division

Guangzhou Guangkong Fangzhou stock shooting market Zi Xingyuan Pharmaceutical Co., Ltd. has high quality and scientific service colleagues

16,800,000.00 162,912,351.56 106,628,198.44 59,591,329.70 15,215,254.36

element

doctor

medicine

Yes

limited

Public

Division

Beijing Enterprises releases shares in Beijing, shoots twins, Yuan Yuan, public sector peers

Su 11,000,000.00 79,317,947.02 52,626,719.72 97,557,999.13 12,893,894.20 Technology

technique

Yes

limited

Public

Division

deep ginseng

200,000,000.00 4,531,823,006.16 2,555,766,184.05 782,560,698.38 188,430,470.18Zhen Stock Market Publicity

Chinese medicine

Nuclear product

sea

Got

power

give birth to

thing

Branch

technology

Yes

limited

Public

Division

Business analysis of major participating companies

√Applicable □Not applicable

Company name Relevance to the company's business Purpose of holding Shenzhen CNNC Haideway Biotechnology Co., Ltd. Both belong to the nuclear technology application industry, and the products of both parties are companies that obtain investment income. They are the same in terms of nuclide types, product uses, etc.

Each is different.

Acquisition and disposal of subsidiaries during the reporting period □ Applicable √ Not applicable

(2) Investment in financial products

□Applicable √Not applicable

(3) Structured entities controlled by the company

□Applicable √Not applicable

Explanation of key audit matters

□Applicable √Not applicable

6. Corporate Social Responsibility

√Applicable □Not applicable

Atomic High-tech Co., Ltd. has always practiced the corporate purpose of "developing nuclear medicine and benefiting mankind" and fully integrated social responsibility into its operations.

Manage the entire process, adhere to the bottom line of compliance operations, coordinate quality and safety, ecological environmental protection, employee protection and social contribution, and effectively fulfill the corporate social responsibility

responsibility, using nuclear technology to protect people's health and serve social development.

(1) Quality assurance and medical services

The company strictly adheres to the lifeline of drug quality, strictly follows the "Good Manufacturing Practice for Drugs", and establishes a full-process and full-chain quality control system to ensure the safe, effective and stable supply of radioactive drugs. Continue to lay out and optimize the national radioactive pharmaceutical production and distribution network, improve the logistics system for short half-life nuclear medicines, expand the scope of medical services, improve distribution operation efficiency, strive to improve the accessibility of nuclear medicines at grassroots and remote areas, promote the universalization of nuclear medicine diagnosis and treatment services, effectively ensure the demand for clinical drugs, and facilitate the implementation of the Healthy China strategy.

(2) Safety production and ecological environmental protection

The company has always regarded nuclear safety and safe production as top priorities, improved the safety production and radiation protection management system, consolidated the safety responsibilities of all employees, carried out safety training, hidden danger investigation and emergency drills on a regular basis, and continued to improve the safety management level. During the reporting period, no safety, environmental protection and radiation-related liability accidents occurred. Strictly implement ecological and environmental protection laws and regulations, standardize the collection, storage and disposal of radioactive "three wastes", achieve closed-loop management of the entire process, adhere to green production, energy conservation and carbon reduction, strictly adhere to ecological protection red lines, and promote the coordinated development of industry and environment.

(3) Employee rights and career development

The company strictly abides by labor and security laws and regulations, protects the legitimate rights and interests of employees in accordance with the law, continues to improve the salary and welfare system, labor protection and occupational health management mechanisms, implements occupational health monitoring for radioactive positions, and organizes special physical examinations regularly to protect employees' occupational safety and physical and mental health. The company has established diversified talent training and clear career development channels, and regularly carries out job skills improvement training to help employees grow in their careers. We strive to create a safe, equal, harmonious and progressive working environment, stabilize the talent team, and fully mobilize the enthusiasm and initiative of employees and officers to start a business.

(4) Social contribution and compliance governance

The company insists on operating in compliance with laws and regulations, improves corporate governance, actively accepts social supervision, and safeguards the legitimate rights and interests of investors and related parties. Actively participate in the construction of industry standards and technical exchanges to promote the healthy development of the nuclear medicine industry; always adhere to the development concepts of honest management and fair cooperation, and empower the upstream and downstream of the industry chain to advance collaboratively. At the same time, the company proactively fulfills its social responsibilities, actively performs social welfare, responds to local public welfare and emergency support needs, gives back to the society with practical actions, and achieves win-win development between the company and society.

In the future, the company will continue to deepen its social responsibility practices, continuously improve its responsibility management level, fulfill its mission as a listed company with higher standards, and create greater value for society, the industry and the public.

7. Analysis of major risks faced by the company

Name of major risk matters Brief description of major risk matters

In the process of producing radioactive sources, radioactive drugs and other products, the company will bring "three

"Waste" disposal problems, as well as possible radiation protection safety risks in the production process. If the processing does not meet the standards, you will face penalties from relevant national departments, which will also have serious consequences for the company's normal operations.

Measures that have been taken or planned to be taken: In accordance with the provisions of relevant laws and regulations, and in accordance with the requirements of the Ministry of Environmental Protection and other competent authorities, the company has established and improved the radiation protection management system, implemented radiation protection measures, and established relevant emergency plans. Through the implementation of job responsibility systems, the implementation of rules and regulations, and the investigation and management of potential safety hazards, the company has prevented the occurrence of various safety production accidents.

The company's operating income mainly comes from radioactive drugs. If there are serious problems with product quality, it will have serious consequences for the company's normal operations.

Measures taken or planned to be taken: The company has taken a series of risks to improve and ensure product quality.

We have taken measures directly related to certifying product quality and completed the certification of the "three systems in one" of quality, environment and occupational health and safety management systems, making efforts to further improve the company's quality management level and improve product quality.

Have there been any significant changes in major risks in this period: No major changes have occurred in major risks in this period

Is there a risk of being transferred out of the innovation layer?

□Yes √No

Section 3 Major Events

1. Index of major events

Matter Yes or No Index whether there are any litigation or arbitration matters √Yes □No 3.2. (1) Whether there is provision of guarantees √Yes □No 3.2. (2) Whether external loans are provided □Yes √No

Is there any situation where shareholders and their related parties occupy or transfer the company’s funds, assets and other resources? □ Yes √ No 3. 2. (3) Sources

Whether there are related transactions √Yes □No 3.2. (4) Whether there are acquisitions, sales of assets, or external investments that have been reviewed and approved by the shareholders’ meeting □Yes √No

and business mergers that occurred during the reporting period

Is there an equity incentive plan, employee stock ownership plan or other employee incentive measures? Yes √No

Is there any share repurchase matter □Yes √No

Whether there are any disclosed commitments □Yes √No 3.2.(5) Whether there are assets that have been sealed, detained, frozen or mortgaged or pledged √Yes □No 3.2.(6) Whether there are matters subject to investigation and punishment □Yes √No

Is there any breach of trust? □Yes √No

Are there any other major matters that should be disclosed? Yes √No

2. Details of major events

(1) Litigation and arbitration matters

Litigation and arbitration matters that occurred during the reporting period

√Applicable □Not applicable

Unit: Yuan Nature Cumulative amount Proportion of net assets at the end of the period %

As the plaintiff/applicant 0 0.00% As the defendant/respondent 3,126,929.08 0.10% As the third party 0 0.00%

Total 3,126,929.08 0.10%

Major litigation and arbitration matters disclosed in the form of temporary announcements

The company had no major litigation or arbitration matters during the reporting period

(2) Guarantee matters that occur in the company

Provide guarantees for listed companies and subsidiaries within the scope of consolidated statements

√Yes □No

Unit: yuan quilt

guarantor

Guarantee period Yes

whether yes

For hanging No

shoes

The public card has been

Being accused of being accused

must

Preface Guarantee Actual performance of guarantee Any shares Purchase guarantee amount Guarantee balance required

No. Amount of insurance liability Category East, Withdrawal

People start and end type actual supervision

decide

Start and stop control

policy

People and measures

Cheng

its control

preface

Made

enterprise

south already

Beijing affairs

Before

son and

2022 2030

High time

6 years 6 years 6 years old

1 15,000,000.00 14,800,000.00 200,000.00 Month Month Yes Medical related General practice

10 10 and medicine

day day

Yes

limited

Public

Division

Xu has

state affairs

Before

son and

2022 2030

High time

5 years 5 years 5 years old

2 6,000,000.00 4,148,000.00 1,852,000.00 Month Month Yes Medical related General practice

27 27 and medicine

day day

Yes

limited

Public

Division

On 2024 2030 already

sea year events

Bu Yuan 10 10 1 ago

3 60,000,000.00 1,386,033.37 58,613,966.63 Yes Shenzi Month Month General And

Jike 18 17 hours

Xing day day Lu

pharmaceutical industry

Yes

limited

Public

Division

Shantou Jitou Shiyuan Qianzi and

2023 2028

High time

Year 1 Year 1 No medical practice 1 5,600,000.00 2,100,000.00 3,500,000.00 Month Month Yes Medical related General practice

12 12 and medicine

day day

Yes

limited

Public

Division

Fu Jizhou Shiyuan Qianzi Jigao 2023 2033 hours

Unprofessional Year 8 Years 8 One Year 5 30,100,000.00 20,650,000.00 9,450,000.00 Yes Medical-related Month April 3 General Practice

and medicine day day

Yes

limited

Public

Division

Gui Jiyang Shiyuan Qianzi 2033 and

2023

senior year

Year 9 Unprofessional 10 One 6 29,750,000.00 26,618,882.63 3,131,117.37 Month Yes Medical related Month General practice

12 and medicine 30

day

Someday

limited

Public

Division

New 2023 2033 One Already Not 7 25,840,000.00 17,628,395.73 8,211,604.27 Yes

Xinjiang year year general affairs involving the original 11 11 years ago and children month month and high school 16 16 hours science day day performing medicine practicing medicine

Yes

limited

Public

Division

Xi'an Shiyuan Qianzi and

2023 2031

High time

Year 7 Year 7 No medical practice 18,937,825.00 8,963,057.65 9,974,767.35 Month Month Yes Medical related General practice

17 16 and medicine

day day

Yes

limited

Public

Division

Nan Jing Shi Yuan Qianzi 2023 2030 and senior years

Unscientific 11 11 One Lu 9 17,600,000.00 17,520,000.00 80,000.00 Yes Medical related Month Month Normal practice

and medicine 30 30

Yes day day

limited

Public

Division

Xu Jizhou Shi Yuan ago

2024 2031

son and

Year 1 Year 1 Not high One hour 10 4,688,000.00 3,520,000.00 1,168,000.00 Month Month Yes Science-related General performance

15 15 and medical practice

day day

medicine

Yes

limited

Public

Division

Zheng Jizhou Shiyuan Qianzi and

2024

High 2033 hours

Year 6 Unprofessional Year 6 One Resume 11 35,000,000.00 1,723,231.80 33,276,768.20 Month Yes Medical-related Month 1 General practice

13 days of medicine

day

Yes

limited

Public

Division

Nan Jijing Shiyuan Qianzi and Gao 2026 2027 hours

Unprofessional Year 3 Years 3 One Year 12 4,000,000.00 2,400,000.00 1,600,000.00 Yes Medical-related Month 6 Month 6 General practice

and medicine day day

Yes

limited

Public

Division

Gui Jiyang Shiyuan Qianzi and

2025 2026

High time

Year 7 Year 7 No medical practice 13 12,750,000.00 5,780,000.00 6,970,000.00 Month Month Yes Medical related General practice

30 29 and medicine

day day

Yes

limited

Public

Division

sea 2025 2040 has spoken year year events

Bu Yuan 12 12 One First 14 55,000,000.00 3,510,036.70 51,489,963.30 Yes Shenzhen Month Month General and

and high 30 29 Shi Ke day day Lu

medical practice

medicine

Yes

limited

Public

Division

Total -

320,265,825.00 130,747,637.88 189,518,187.12 - - - - -Total

Performance of guarantee contracts that may bear or have assumed joint liability for repayment

None

Summary of guarantees provided by the company

Unit: Yuan

Summary of items Guarantee amount Guarantee balance Guarantees provided by the listed company during the reporting period (including guarantees for on-balance sheet subsidiaries) 320,265,825.00 189,518,187.12 The company and its on-balance sheet subsidiaries provide guarantees for shareholders, actual controllers and related parties of the listed company 0.00 0.00

The company directly or indirectly provides guarantees for guaranteed persons whose asset-liability ratio exceeds 70% (excluding the principal number) 0.00 0.00

The amount of the company's total guarantees exceeding 50% of the net assets (excluding the principal amount) 0.00 0.00 The company provides guarantees for companies that go off balance sheet during the reporting period 0.00 0.00

Guarantee situations that should be highlighted

□Applicable √Not applicable

(3) Occupation or transfer of company funds, assets and other resources by shareholders and their related parties

During the reporting period, the company did not have any shareholders or its related parties occupying or transferring the company's funds, assets and other resources.

(4) Related transactions of the company during the reporting period

Unit: Yuan

Daily related transactions Estimated amount Amount incurred Purchasing raw materials, fuel, power, receiving services 600,000,000.00 69,329,159.81 Selling products, commodities, providing services 330,000,000.00 62,524,696.51 Types of daily related transactions that are applicable to the company as stipulated in the company's articles of association

Others 1,050,000,000.00 734,172,076.02

Other major related transactions Amount under consideration Transaction amount Acquisition and sale of assets or equity

Joint external investments with related parties

Provide financial assistance

provide guarantee

Entrusted financial management

Related transactions of Enterprise Group Finance Company Estimated amount Amount incurred Deposits 850,000,000.00 664,889,484.78 Loans 100,000,000.00 66,598,000.00 Necessity and continuity of major related transactions and their impact on the company’s production and operations

(1) The estimated amount of daily related transactions for purchasing raw materials, fuel, and power, and receiving services was RMB 600,000,000.00, and the actual amount incurred was RMB 69,329,159.81. Operating lease is RMB 324,736.26.

(2) The estimated amount of other daily related transactions is 1,050,000,000.00 yuan, of which financial leasing business is carried out with related parties such as CNNC Financial Leasing Co., Ltd. (hereinafter referred to as "China National Nuclear Leasing"), and the new amount of financial leasing shall not exceed 1 00,000,000.00 yuan, the maximum balance shall not exceed 100,000,000.00 yuan; the maximum daily deposit balance is expected to not exceed 850,000,000.00 yuan; the related loan limit shall be 100,000,000.00 yuan.

The actual amount incurred was RMB 734,172,076.02, including the maximum daily deposit balance of the company and its subsidiaries in the settlement account of CNNC Finance Company of RMB 664,889,484.78, the financial leasing business with CNNC Financial Leasing Co., Ltd. of RMB 2,684,591.24, and the maximum loan balance of CNNC Finance Company in the current period of RMB 66,598,000.00.

The company expects that the resolution on daily related transactions in 2026 has been submitted to the shareholders' meeting for review in accordance with the company's articles of association and regulatory requirements, but has not been passed. For details of the relevant indicative announcement, please refer to the "Atomic High-tech: Indicative Announcement on the Rejection of the Resolution at the 2025 Annual Shareholders Meeting" (Announcement Number: 2026-028) disclosed by the company on the National Small and Medium Enterprises Share Transfer System website.

(5) Performance of commitments

The company has no disclosed commitments

(6) Assets that have been seized, detained, frozen or mortgaged or pledged

Unit: Yuan Rights Restricted Category Ratio of Total Assets

Asset name Asset category Book value Reason for occurrence

Type Example%

Monetary funds Monetary funds Frozen 12,000.00 0.00% Performance bond fixed assets Fixed assets Mortgage 199,974,061.07 3.68% Mortgage-guaranteed borrowings Intangible assets Intangible assets Mortgage 11,175,048.14 0.21% Mortgage-guaranteed borrowings

Total - - 211,161,109.21 3.89% -

The impact of restricted asset rights on the company

None

Section 4 Share changes and shareholder status

1. Common stock capital situation

(1) Common stock capital structure

Unit: Shares at the beginning of the period and at the end of the period

Nature of shares Changes in the current period

Quantity Proportion % Quantity Proportion % Total number of shares without sales limit 161,353,813 99.73% -153,926 161,199,887 99.64% without sales limit Among them: controlling shareholder, actual control 112,422,362 69.49% 0 112,422,362 69.49% conditional shares Person

Shares Directors and senior executives 139,364 0.09% -120,283 19,081 0.01% Core employees 0 0% 0 0 0% Total number of restricted shares 430,323 0.27% 153,926 584,249 0.36% Restricted shares Among them: controlling shareholder, actual control 0 0% 0 0 0% conditional shares people

Shares Directors and senior executives 430,323 0.27% 153,926 584,249 0.36% Core employees 0 0% 0 0 0% Total share capital 161,784,136 - 0 161,784,136 -

Number of common shareholders 1,422

Changes in share capital structure

□Applicable √Not applicable

(2) Information about the top ten shareholders of ordinary shares

Unit: Share

end of term

Mo Zhimo

hold hold

There are stocks at the end of the period.

The preface of the company is limited to holding at the end of the period and is unlimited at the end of the period.

Number of shares held at the beginning of the period Changes in shareholdings Number of shares held at the end of the period Qualitative name Ratio of shares Number of shares sold

% shares pledged and frozen

Number of shares

number of servings

Quantity

Quantity 1 Medium

country

112,422,362.00 0 112,422,362.00 69.49 0 112,422,362.00 0 0 same

radiate

Co., Ltd. 2 China National Nuclear Corporation’s Fourth Research Facility

4,000,000.00 0 4,000,000.00 2.47 0 4,000,000.00 0 0 Ji Engineering Co., Ltd. 3 Zheng Lan 2,825,000.00 0 2,825,000.00 1.75 0 2,825,000.00 0 0 Ying 4 Shanghai Guide Xingyuan Private Equity Fund Management 700,000.00 1,580,000.00 2,280,000.00 1.41 0 2,280,000.00 0 0 Management Co., Ltd. - Guide Shangyuan Private Equity Investment Fund 5 Li Hong 2,668,502.00 -826,520.00 1,841,982.00 1.14 0 1,841,982.00 0 0 wave 6 Tang

1,000,100.00 0 1,000,100.00 0.62 0 1,000,100.00 0 0 Ge 7 Zou Ai 994,107.00 0 994,107.00 0.61 0 994,107.00 0 0 Zhi 8 Li Xiao 993,200.00 0 993,200.00 0.61 0 993,200.00 0 0Hang9 Beijing Guide Venture Capital Management Co., Ltd. 800,000.00 0 800,000.00 0.49 0 800,000.00 0 0 Company - Guide Small Animal Venture Capital Private Equity

gold

10 sheets

Li 750,000.00 -90,000.00 660,000.00 0.41 0 660,000.00 0 0 peak

Total 127,153,271 - 127,816,751 79.00 0 127,816,751 0 0

Description of the top ten shareholders of common stock

√Applicable □Not applicable

The company's controlling shareholder, China Tongfu, is related to the second largest shareholder, Henan Fourth Institute. The actual controllers of China National Nuclear Corporation and the Fourth Nuclear Research Institute are both China National Nuclear Corporation. There is no related relationship among the other top ten shareholders.

Changes in controlling shareholders and actual controllers There were no changes in controlling shareholders and actual controllers during the reporting period

3. Arrangements for special voting rights

□Applicable √Not applicable

Section 5 Changes in Directors, Senior Management and Core Employees

1. Directors and senior managers

(1) Basic situation

Unit: Share

Start and end date of appointment Hold at the beginning of the period Ordinary at the end of the period

Year of birth Number of shares held at the end of the period Common name Position Gender Ordinary shares Shareholding ratio Month Start date End date Number of shares held

Number of shares %

period period

Zhang Jun Director Male 1971 2024 2026 0 0 0 0 % Flag Chief May February 9 March 11

day

Zhang Yi Director Male 1981 2026 0 0 0 0 % Chief November March 27

day

Luo Xu Director Male 1976 2026 26,643 7,000 33,643 0.02% June June 23

day

Luo Xu General Manager Male 1976 2026 26,643 7,000 33,643 0.02%

Li June June 8

Zhao Jing Director Male 1977 2022 0 0 0 0% July August 15

day

Zhao Jing General Manager Male 1977 2022 2026 0 0 0 0% Manager July August 15 June 7

day

Hu Wei Director Male 1971 2024 0 0 0 0% October May 15

day

Fan Guo Director Male 1970 2025 2026 0 0 0 0% People October March 28 June 7

day

Han Quan Director Male 1967 2025 0 0 0 0% Win December March 28

day

Li Chun Independent Male 1955 2025 0 0 0 0 % Lin Director May June 30

day

Geng Wei Independent Male 1976 2025 0 0 0 0 % Director May June 30

day

Gao Yi Director Female 1980 2022 0 0 0 0% Qiong December August 15

day

Sui Yan Vice President Female 1972 2022 2026 39,686 0 39,686 0.02% Ying Manager April August 30 August 26

day day

Li Guo Vice President Male 1975 2024 0 0 0 0% Xiang Manager November January 25

day

Zhang Xue Vice President Male 1983 2024 0 0 0 0% Feng Manager October April 24

day

Qian Zhi Director Male 1967 2025 0 0 0 0% far August December 19

day

Zhang Li General Association Male 1989 2025 0 0 0 0 % Total April November 25

division, day

general law

Law Gu

Ask,

director

meeting secret

book

Deng Xue Vice President Male 1976 2026 0 0 0 0% Song Manager April August 27

day

Note: The company’s board of directors received the resignation report submitted by Deputy General Manager Ms. Sui Yanying on August 26, 2026.

The resignation shall take effect from now on. For details, please refer to "Atomic Hi-Tech: Senior Management Resignations" disclosed by the company on the National Equities Exchange and Quotations website.

Announcement" (Announcement No.: 2026-033).

The company held the 25th meeting of the seventh board of directors on August 27, 2026, and appointed Deng Xuesong as the company’s deputy general manager. Specific content

For details, please refer to the "Atomic Hi-Tech: Announcement on the Appointment of Senior Management Personnel" disclosed by the company on the National Equities Exchange and Quotations website (Announcement No.:

2026-034).

Relationship between Directors, Senior Management and Shareholders

The company's controlling shareholder, China Tonghe, is related to the actual controller, China National Nuclear Corporation, and the second largest shareholder, the Fourth Institute of Nuclear Power Engineering. CNNC is the

The actual controller of the National Institute of Radiology, the Institute of Atomic Energy and the Fourth Institute of Nuclear Power. Company directors Han Quansheng and Qian Zhiyuan are appointed as full-time directors of CNNC; company director Gao

Yi Qiong is appointed as the Chief of the Comprehensive Section of the Industrial Development Division of the Institute of Atomic Energy; Director Hu Wei is appointed as the Chief Accountant of the Fourth Institute of Nuclear Energy.

On August 14, 2025, the company’s seventh board of directors and management will expire. Since the members of the company's new board of directors have not yet been finalized, the current board of directors will continue to perform their duties until the date when the members of the new board of directors are elected through the shareholders' meeting. The senior managers will also continue to perform their duties until the new board of directors.

Ends on the date of appointment of members of a senior management team.

(2) Changes

√Applicable □Not applicable

Name Position at the beginning of the period Type of change Position at the end of the period Reason for change

Zhang Junqi, Chairman, resigned - The Company's Board of Directors received the resignation report submitted by Chairman Mr. Zhang Junqi on March 11, 2026, and the resignation will be effective from March 11, 2026. Fan Guomin, Director, resigned - The Company's Board of Directors received the resignation report submitted by Director Mr. Fan Guomin on June 7, 2026. The resignation will be effective from June 7, 2026.

Zhao Jing Director, General Manager Resigned Director The company’s board of directors received the resignation report submitted by Mr. Zhao Jing, the general manager, on June 7, 2026. The resignation will be effective from June 7, 2026.

Zhang Yiming - New Director and Chairman On March 27, 2026, the company's first extraordinary shareholders' meeting in 2026 elected Mr. Zhang Yiming as the company's director; on March 30, 2026, the 22nd meeting of the company's seventh board of directors elected Mr. Zhang Yiming as the company's chairman.

Luo Xu - New Director and General Manager The 24th meeting of the company's seventh board of directors reviewed and approved on June 8, 2026, the appointment of Mr. Luo Xu as the company's general manager; on June 23, 2026, the company's second extraordinary shareholders' meeting in 2026 elected Mr. Luo Xu as the company's director.

Professional background, main work experience, etc. of new directors and senior managers during the reporting period

√Applicable □Not applicable

Mr. Zhang Yiming, born in November 1981, has worked in the Automation Room of Beijing Radiation Safety Technology Center since 2006; Safety and Quality Department of China Tongradio Co., Ltd.; Deputy Director and Party Committee Member (temporary position) of Dalian Institute of Applied Technology of Nuclear Industry; China Tongluo Co., Ltd. Deputy manager and manager of the Safety and Environmental Protection Quality Department; deputy general manager of Atomic High-tech Co., Ltd.; general manager, deputy party secretary, and party committee secretary of the Beijing Branch of China Tongradio Co., Ltd.; secretary of the party committee of Atomic High-tech Co., Ltd., and currently serves as secretary of the party committee and chairman of the board of directors of Atomic High-tech Co., Ltd.

Mr. Luo Xu, born in June 1976, has worked in Room 52 of the Institute of Isotope of the China Institute of Atomic Energy since 1999; Deputy General Manager of the Industrial Business Department and Marketing Department of Atomic High-Tech Co., Ltd.; Deputy General Manager of Shenzhen Sicam Isotope Co., Ltd.; Atomic High-Tech Co., Ltd. Co., Ltd. Vice President and Deputy General Manager; General Manager, Deputy Secretary of the Party Committee, Chairman and Secretary of the Party Committee of Chengdu CNNC Qualcomm Isotope Co., Ltd.; General Manager of the Market Development Department of China Radiation Co., Ltd.; Currently Director, General Manager and Deputy Secretary of the Party Committee of Atomic High-Tech Co., Ltd.

(3) Equity incentives for directors and senior managers

□Applicable √Not applicable

2. Employee situation

(1) Basic information of current employees (the company and its holding subsidiaries)

Classification by nature of work Number of people at the beginning of the period New in this period Decreased in this period Number of people at the end of the period Management personnel 121 3 12 112 Production personnel 455 6 10 451 Sales personnel 51 1 0 52 Technical personnel 579 4 6 577 Financial personnel 57 4 20 41 Administrative personnel 94 20 2 112

Total employees 1,357 38 50 1,345

(2) Basic situation and changes of core employees (the company and its holding subsidiaries)

□Applicable √Not applicable

Section 6 Financial Accounting Report

1. Audit report

Whether to audit No

2. Financial statements

(1) Consolidated balance sheet

Unit: Yuan

Item Notes June 30, 2026 Current assets as of December 31, 2025:

Monetary funds 5. 1 648,191,701.24 657,639,089.19 Settlement reserves

Loan funds

trading financial assets

Derivative financial assets

Notes receivable V. 2 30,826,380.63 35,256,130.93 Accounts receivable V. 3 1,183,041,557.18 1,047,117,959.99 Accounts receivable financing V. 5 15,082,826.35 15,137,831.91 Advance payment 5. 7 36,250,146.81 45,513,361.92 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 5.6 46,504,881.24 11,336,817.03 Including: interest receivable

Dividends receivable 5. 6.1 29,828,047.91 0.00 Financial assets purchased under resale agreements

Inventory 5.8 134,182,800.53 87,671,182.90 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 5.9 73,392,283.28 63,952,829.58

Total current assets 2,167,472,577.26 1,963,625,203.45 Non-current assets:

Granting loans and advances

debt investment

Other debt investments

Long-term receivables V. 10 43,992,551.52 42,940,509.05 Long-term equity investment V. 11 547,849,980.45 542,882,255.78 Other equity instrument investments

Other non-current financial assets

Investment real estate V. 12 13,437,626.72 15,370,386.32 Fixed assets V. 13 1,333,462,945.13 1,089,187,139.84 Construction in progress V. 14 540,891,617.68 702,247,101.61 Productive biological assets

oil and gas assets

Right-of-use assets V. 15 7,445,129.51 10,960,195.14 Intangible assets V. 16 247,409,532.24 252,595,799.76 Including: data resources

Development expenditure 6.1 286,654,756.88 259,746,178.90 Including: data resources

Goodwill V. 17 20,619,741.62 20,619,741.62 Long-term deferred expenses V. 18 2,742,372.92 3,976,758.36 Deferred income tax assets V. 19 106,211,374.99 88,672,315.28 Other non-current assets 5. 20 120,397,334.61 141,728,412.00 Total non-current assets 3,271,114,964.27 3,170,926,793.66

Total assets 5,438,587,541.53 5,134,551,997.11 Current liabilities:

Short-term borrowings 5. 22 315,995,188.01 314,146,946.19 Borrowings from the Central Bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities

Notes payable V. 23 0.00 8,778,000.00 Accounts payable V. 24 70,653,346.25 70,598,877.35 Advance receipts V. 26

Contract liabilities 5. 27 54,167,380.26 64,670,007.17 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable V. 28 50,585,878.63 68,901,146.26 Taxes payable V. 29 58,041,735.17 47,503,344.43 Other payables V. 25 699,902,496.41 532,869,120.61 Including: interest payable

Dividends payable 5. 25.1 94,099,116.15 3,750,000.00 Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year V. 30 13,623,955.43 15,929,162.14 Other current liabilities V. 31 7,234,100.23 9,324,310.54

Total current liabilities 1,270,204,080.39 1,132,720,914.69 Non-current liabilities:

insurance contract reserves

Long-term borrowings 5. 32 636,574,454.03 587,767,741.90 Bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities V. 33 4,545,150.59 4,798,037.66 Long-term payables V. 34 57,337,964.71 57,763,644.97 Long-term employee benefits payable V. 35 32,994,781.76 28,569,781.76 Estimated liabilities V. 36 117,474,183.67 114,735,203.43 Deferred income 5. 37 92,842,384.58 91,116,705.38 Deferred income tax liabilities 4,466,959.19 4,891,434.63 Other non-current liabilities

Total non-current liabilities 946,235,878.53 889,642,549.73

Total liabilities 2,216,439,958.92 2,022,363,464.42 Owners’ equity:

Share capital 5. 38 161,784,136.00 161,784,136.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve V. 39 567,737,197.58 567,737,197.58 Less: treasury shares

Other comprehensive income V. 40 -21,479,600.00 -17,771,600.00 Special reserve V. 41 65,947,477.16 55,781,412.37 Surplus reserve V. 42 81,512,642.07 81,512,642.07 General risk reserve

Undistributed profits 5. 43 2,010,843,752.33 1,934,421,083.58 Total owners’ equity attributable to the parent company 2,866,345,605.14 2,783,464,871.60 Minority shareholders’ equity 355,801,977.47 328,723,661.09 Total owners’ equity 3,222,147,582.61 3,112,188,532.69

Total liabilities and owners’ equity 5,438,587,541.53 5,134,551,997.11

Legal representative: Zhang Yiming Person in charge of accounting work: Zhang Lida Head of accounting department: Xiao Huafang

(2) Balance sheet of the parent company

Unit: Yuan

Item Notes June 30, 2026 Current assets as of December 31, 2025:

Monetary funds 79,006,246.84 252,979,569.89 Trading financial assets

Derivative financial assets

Notes receivable 771,435.00 1,575,085.00 Accounts receivable 17.1 684,137,461.14 527,019,451.14 Accounts receivable financing 13,445,456.35 14,832,731.91 Prepayments 20,024,905.41 8,963,025.46 Other receivables 17.2 95,725,071.07 56,875,973.12 Including: interest receivable

Dividends receivable 30,028,047.91 200,000.00 Financial assets purchased under resale agreements

Inventory 107,480,403.08 58,174,494.50 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 24,238,489.88 19,236,567.02

Total current assets 1,024,829,468.77 939,656,898.04 Non-current assets:

debt investment

Other debt investments

Long-term receivables 43,992,551.52 42,940,509.05 Long-term equity investment XVII.3 1,992,414,270.36 1,962,984,466.34 Other equity instrument investments

Other non-current financial assets

investment real estate

Fixed assets 112,552,611.91 110,897,046.74 Construction in progress

productive biological assets

oil and gas assets

Right-of-use assets 2,750,669.93 4,147,308.11 Intangible assets 48,851,599.17 51,122,124.38 Including: data resources

Development expenditure 286,654,756.88 259,746,178.90 Including: data resources

goodwill

Long-term deferred expenses 1,087,215.89 2,371,062.53 Deferred income tax assets 54,228,870.26 48,487,369.92 Other non-current assets 8,880,713.67 8,792,515.92 Total non-current assets 2,551,413,259.59 2,491,488,581.89

Total assets 3,576,242,728.36 3,431,145,479.93 Current liabilities:

Short-term borrowings 300,175,000.00 300,192,500.00 Trading financial liabilities

Derivative financial liabilities

Notes payable 0.00 8,778,000.00 Accounts payable 86,034,865.13 59,223,580.26 Advance payments

Contract liabilities 50,718,041.19 45,747,864.28 Financial assets sold and repurchased

Employee benefits payable 40,176,662.10 38,728,333.36 Taxes payable 16,792,405.17 20,004,059.11 Other payables 342,385,513.53 262,407,955.36 Including: interest payable

Dividends payable 90,599,116.15 0.00 Liabilities held for sale

Non-current liabilities due within one year 6,589,188.98 6,362,511.63 Other current liabilities 6,593,345.36 6,919,477.36

Total current liabilities 849,465,021.46 748,364,281.36 Non-current liabilities:

Long-term borrowings 160,856,542.74 122,888,114.64 Bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 1,671,615.66 1,631,640.47 Long-term payables 45,850,692.52 44,529,937.80 Long-term employee benefits payable 32,994,781.76 28,569,781.76 Estimated liabilities 116,725,686.24 114,004,603.43 Deferred income 21,974,148.37 20,054,148.37 Deferred income tax liabilities

Other non-current liabilities

Total non-current liabilities 380,073,467.29 331,678,226.47

Total liabilities 1,229,538,488.75 1,080,042,507.83 Owners’ equity:

Share capital 161,784,136.00 161,784,136.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 583,767,062.58 583,767,062.58 minus: treasury shares

Other comprehensive income -21,479,600.00 -17,771,600.00Special reserve 3,359,687.93 563,368.75 Surplus reserve 80,892,068.00 80,892,068.00General risk reserve

Undistributed profits 1,538,380,885.10 1,541,867,936.77 Total owners’ equity 2,346,704,239.61 2,351,102,972.10

Total liabilities and owners’ equity 3,576,242,728.36 3,431,145,479.93

(3) Consolidated income statement

Unit: Yuan

Project Notes January-June 2026 January-June 2025

Total operating income 938,008,646.62 830,842,389.41 Including: operating income 5. 44 938,008,646.62 830,842,389.41 Interest income

Premiums earned

Fee and commission income

Total operating costs 759,541,728.99 693,070,162.47 Including: operating costs 5. 44 397,534,158.24 373,926,100.69 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges V. 45 14,630,780.56 10,884,616.87 Sales expenses V. 46 200,657,369.81 157,313,842.83 Administrative expenses V. 47 73,593,100.58 79,221,306.17 R&D expenses V. 48 66,424,384.41 63,901,411.29 Financial expenses 5. 49 6,701,935.39 7,822,884.62 Including: interest expenses 9,079,995.65 7,100,884.99

Interest income 1,382,817.16 1,215,609.37 plus: other income V. 50 10,818,479.05 2,044,768.39 Investment income (losses are listed with "-") V. 51 34,795,772.58 32,101,493.01 Including: investment income from associates and joint ventures 34,795,772.58 32,101,493.01

Financial assets measured at amortized cost are derecognised

Recognized gains (losses are listed with "-")

Exchange gains (losses are listed with "-")

Net exposure hedging income (losses are listed with a “-” sign)

Gains from changes in fair value (losses are listed with a “-” sign)

Credit impairment losses (losses are listed with "-") 5. 52 -8,203,299.30 -5,419,793.09 Asset impairment losses (losses are listed with "-") 5. 53 -7,249,859.85 3,016,177.39

Income from asset disposal (losses are listed with "-") 5. 54 -7,537.94 1,230,866.06

Operating profit (losses are listed with "-") 208,620,472.17 170,745,738.70 plus: non-operating income 5. 55 471,928.27 9,268.38 minus: non-operating expenses 5. 56 53,815.97 83,613.44
Total profits (total losses are listed with "-") 209,038,584.47 170,671,393.64 Less: income tax expenses 5. 57 22,845,302.75 23,050,564.41
Net profit (net loss is listed with "-") 186,193,281.72 147,620,829.23 Among them: the net profit realized by the merged party before the merger

(1) Classification by business continuity: - - -

Net profit from continuing operations (net loss is listed with "-") 186,193,281.72 147,620,829.23
Net profit from discontinued operations (net loss is listed with "-")

(2) Classification by ownership: - - -

Profit and loss of minority shareholders (net loss is listed with "-") 19,171,496.82 14,532,858.33
Net profit attributable to owners of the parent company 167,021,784.90 133,087,970.90
Net after-tax amount of other comprehensive income -3,708,000.00 -1,000.00

(1) Other comprehensive income attributable to owners of the parent company

-3,708,000.00 -1,000.00 Net after tax

Other comprehensive income that cannot be reclassified to profit or loss -3,708,000.00 -1,000.00 (1) Changes in remeasurement of defined benefit plan -3,708,000.00 -1,000.00 (2) Other comprehensive income that cannot be reclassified to profit or loss under the equity method

(3) Changes in fair value of other equity instrument investments

(4) Changes in the fair value of the company’s own credit risk

(5) Others

Other comprehensive income that will be reclassified into profit and loss

(1) Other comprehensive income that can be converted to profit or loss under the equity method

(2) Changes in fair value of other debt investments

(3) Financial assets are reclassified and included in other comprehensive income

Amount

(4) Credit impairment provisions for other debt investments

(5) Cash flow hedging reserve

(6) Translation differences of foreign currency financial statements

(7) Others

(2) After-tax other comprehensive income attributable to minority shareholders

net amount

Total comprehensive income 182,485,281.72 147,619,829.23

(1) Total comprehensive income attributable to owners of the parent company 163,313,784.90 133,086,970.90

(2) Total comprehensive income attributable to minority shareholders 19,171,496.82 14,532,858.33

8. Earnings per share:

(1) Basic earnings per share (yuan/share) 1.03 0.82

(2) Diluted earnings per share (yuan/share) 1.03 0.82

Legal representative: Zhang Yiming Person in charge of accounting work: Zhang Lida Head of accounting department: Xiao Huafang

(4) Income statement of the parent company

Unit: Yuan

Project Notes January-June 2026 January-June 2025

Operating income 17.4 447,124,744.78 395,908,397.24 Less: operating costs 17.4 235,104,611.54 203,228,325.07 Taxes and surcharges 3,850,127.58 3,852,136.62 Sales expenses 82,784,273.27 66,950,852.84Administrative expenses 37,189,861.87 36,865,903.99R&D expenses 38,702,706.71 34,524,158.28Financial expenses 5,370,685.65 6,889,422.98 Including: interest expense 6,470,248.99 5,241,022.91

Interest income 442,922.34 232,905.90 plus: other income 9,357,344.16 920,179.24 Investment income (losses are listed with "-") 17.5 39,540,736.67 31,239,325.57 Including: investment income from associates and joint ventures 34,262,851.93 31,105,172.74

Financial assets measured at amortized cost are derecognised

Recognized gains (losses are listed with "-")

Exchange gains (losses are listed with "-")

Net exposure hedging income (losses are listed with a “-” sign)

Gains from changes in fair value (losses are listed with a “-” sign)

Credit impairment losses (losses are listed with "-") -1,800,929.03 -247,631.68 Asset impairment losses (losses are listed with "-") -7,061,548.03

Asset disposal income (losses are listed with "-") 1,208,766.06

Operating profit (losses are listed with "-") 84,158,081.93 76,718,236.65 Plus: non-operating income 449,947.36 0.66 Less: non-operating expenses 278.68
Total profits (total losses are listed with "-") 84,608,029.29 76,717,958.63 Less: income tax expenses -2,504,035.19 3,793,285.91
Net profit (net loss is listed with "-") 87,112,064.48 72,924,672.72

(1) Net profit from continuing operations (net loss is filled in with "-"

87,112,064.48 72,924,672.72 columns)

(2) Net profit from discontinued operations (net loss is filled in with "-"

column)

Net amount of other comprehensive income after tax -3,708,000.00 -1,000.00

(1) Other comprehensive income that cannot be reclassified to profit or loss -3,708,000.00 -1,000.00 1. Changes in remeasurement of defined benefit plan -3,708,000.00 -1,000.00 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method

Changes in fair value of other equity instrument investments
Changes in the fair value of the company’s own credit risk

5.Others

(2) Other comprehensive income that will be reclassified into profit and loss

Other comprehensive income that can be converted to profit or loss under the equity method
Changes in fair value of other debt investments
Financial assets are reclassified and included in other comprehensive income.

Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation differences of foreign currency financial statements

7.Others

Total comprehensive income 83,404,064.48 72,923,672.72

7. Earnings per share:

(1) Basic earnings per share (yuan/share)

(2) Diluted earnings per share (yuan/share)

(5) Consolidated cash flow statement

Unit: Yuan

Project Notes January-June 2026 January-June 2025

1. Cash flow generated from operating activities:

Cash received from sales of goods and provision of services 919,944,273.65 824,328,729.98 Net increase in customer deposits and interbank deposits

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax refunds received 155,930.19 19,196.15 Other cash received related to operating activities 5. 59.1 46,578,590.08 51,723,997.12

Subtotal of cash inflows from operating activities 966,678,793.92 876,071,923.25 Cash paid for purchasing goods and receiving services 444,617,501.69 451,509,357.14 Net increase in customer loans and advances

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in financial assets held for trading purposes

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 215,830,281.04 215,782,279.67 Various taxes paid 132,587,019.20 106,248,761.35 Other cash paid related to operating activities 5. 59.2 118,102,424.56 100,663,152.96 Subtotal of cash outflows from operating activities 911,137,226.49 874,203,551.12

Net cash flow generated from operating activities 55,541,567.43 1,868,372.13

2. Cash flow generated from investing activities:

Recover cash received on investments

Cash received from investment income 0.00 0.00 Recovery from disposal of fixed assets, intangible assets and other long-term assets

50.00 3,500.00 net cash

Net cash received from disposal of subsidiaries and other business units 589,390.00

Received other cash related to investing activities 5. 59.3 86,261,411.25 566,839.00

Subtotal of cash inflows from investing activities 86,850,851.25 570,339.00 Payment for purchase and construction of fixed assets, intangible assets and other long-term assets

102,976,283.74 85,987,087.18 in cash

Cash paid for investments

Net increase in mortgage loans

Net cash received from subsidiaries and other business units

Payment of other cash related to investing activities 5. 59.4 0.00 30,700,000.00 Subtotal of cash outflows from investing activities 102,976,283.74 116,687,087.18

Net cash flow generated from investing activities -16,125,432.49 -116,116,748.18

3. Cash flow generated from financing activities:

Cash received from investment 6,100,000.00 2,450,000.00 Including: Cash received by subsidiaries from investment from minority shareholders 6,100,000.00 2,450,000.00 Cash received from borrowings 66,986,115.26 158,317,055.05 Cash received from issuing bonds

Received other cash related to financing activities 5.59.5 1,150,000.00 10,760,000.00

Subtotal of cash inflows from financing activities 74,236,115.26 171,527,055.05 Cash paid to repay debts 18,862,578.36 15,326,770.27 Cash paid to distribute dividends, profits or pay interest 11,547,643.60 13,910,227.71 Including: Dividends and profits paid by subsidiaries to minority shareholders 250,000.00 4,000,000.00 Other cash payments related to financing activities 5. 59.6 3,241,822.43 39,584,130.06 Subtotal of cash outflows from financing activities 33,652,044.39 68,821,128.04

Net cash flow generated from financing activities 40,584,070.87 102,705,927.01

Impact of exchange rate changes on cash and cash equivalents -60,837.27 23,405.04
Net increase in cash and cash equivalents 79,939,368.54 -11,519,044.00 plus: opening balance of cash and cash equivalents 568,240,332.70 571,944,327.87
Closing balance of cash and cash equivalents 648,179,701.24 560,425,283.87

Legal representative: Zhang Yiming Person in charge of accounting work: Zhang Lida Head of accounting department: Xiao Huafang

(6) Cash flow statement of the parent company

Unit: Yuan

Project Notes January-June 2026 January-June 2025

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 362,272,817.62 343,964,796.03 Tax refunds received

Other cash received related to operating activities 45,106,617.84 40,684,576.14

Subtotal of cash inflows from operating activities 407,379,435.46 384,649,372.17 Cash paid for purchasing goods and receiving services 329,763,029.46 226,934,641.64 Cash paid to and for employees 122,565,674.99 123,134,366.21 Various taxes paid 35,692,717.19 36,158,197.15 Other cash paid related to operating activities 55,026,494.87 34,330,678.29 Subtotal of cash outflows from operating activities 543,047,916.51 420,557,883.29

Net cash flow from operating activities -135,668,481.05 -35,908,511.12

2. Cash flow generated from investing activities:

Recover cash received on investments

Cash received from investment income 5,000,000.00 0.00 Income from disposal of fixed assets, intangible assets and other long-term assets

Net cash returned

Net cash received from disposal of subsidiaries and other business units 589,390.00

Other cash received related to investing activities 225,396.51 6,150,068.72

Subtotal of cash inflows from investing activities 5,814,786.51 6,150,068.72 Expenses for purchase and construction of fixed assets, intangible assets and other long-term assets

43,221,776.07 29,520,932.27 paid in cash

Cash paid for investment 24,995,000.00 44,250,000.00 Net cash paid to acquire subsidiaries and other business units

Other cash payments related to investing activities 4,933,000.00 12,690,000.00 Subtotal of cash outflows from investing activities 73,149,776.07 86,460,932.27

Net cash flow generated from investing activities -67,334,989.56 -80,310,863.55

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Cash received from borrowing 39,721,500.00 109,942,503.61 Cash received from issuing bonds

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 39,721,500.00 109,942,503.61 Cash paid to repay debts 1,645,600.24 0.00 Cash paid to distribute dividends, profits or pay interest 5,482,427.13 3,037,412.61 Cash paid to other financing activities 0.00 1,632,533.77 Subtotal of cash outflows from financing activities 7,128,027.37 4,669,946.38

Net cash flow generated from financing activities 32,593,472.63 105,272,557.23

Impact of exchange rate changes on cash and cash equivalents -52,125.07 7,665.13
Net increase in cash and cash equivalents -170,462,123.05 -10,939,152.31 plus: opening balance of cash and cash equivalents 249,468,369.89 154,222,534.68
Balance of cash and cash equivalents at the end of the period 79,006,246.84 143,283,382.37

3. Notes to Financial Statements

(1) Index of additional notes

Matter Yes or No Index 1. Have the accounting policies adopted in the semi-annual report changed from the financial statements of the previous year? □ Yes √ No

2． Whether the accounting estimates used in the semi-annual report have changed from the financial statements of the previous year? □Yes √No

Is there any error correction in the previous period? Yes √ No 4. Does the business operation have seasonal or cyclical characteristics? □ Yes √ No 5. Have there been any changes in related parties with controlling relationships? □Yes √No 6. Has the scope of consolidation in the consolidated financial statements changed? □ Yes √ No 7. Is there any issuance, repurchase and repayment of securities? Yes √ No 8. Is there any distribution of profits to owners? √Yes □No 5. 43 9. Whether segment reports are disclosed in accordance with the relevant provisions of accounting standards □ Yes √ No 10. Are there any non-adjusting matters between the semi-annual balance sheet date and the approval of the semi-annual financial report? Yes √ No
Are there any contingent liabilities that occurred after the balance sheet date of the previous year? □Yes √No and changes in contingent assets
Is there any change in corporate structure? □Yes √No13. Whether significant long-term assets are transferred or sold □Yes √No14. Have there been any changes in significant fixed assets and intangible assets? □Yes √No15. Is there any significant research and development expenditure □Yes √No16. Is there any significant asset impairment loss □Yes √No17. Whether there are estimated liabilities √Yes □No 5. 36 Notes Index Explanation

On June 30, 2026, the company's 2026 annual shareholders' meeting reviewed and approved the company's "2025 Equity Distribution Plan": the company plans to distribute 5.60 yuan (including tax) to all shareholders for every 10 shares based on the total share capital of 161,784,136 shares at the end of 2025. This equity distribution is expected to distribute a total cash dividend of 90,599,116.16 yuan. For details, please refer to Note 5.43 Undistributed Profit.

According to national laws and administrative regulations, international conventions, etc., enterprises have obligations such as environmental protection and ecological restoration. The company is responsible for the disposal or disposal of production line sites, radioactive source storage sites, and used radioactive sources. In 2016, the Company determined the final value and accrual period of the disposal fee based on the "China's Individual Cost Standards for Disposal Fees and Waste Source Disposal Fees for Same-radiation Fixed Assets". It is assumed that the disposal fee accrual period for production line sites and radioactive source storage sites is 70 years, and cobalt 60 for irradiation stations is The accrual period for radioactive source disposal fees is 20 years. The discount rate is calculated based on the long-term bank loan interest rate (4.9%) in the same period to calculate the present value, and the original value of the fixed asset disposal fees is determined based on this. The fixed asset disposal fees will be accrued in the current period when the fixed assets reach the intended usable condition. At the same time, the actual interest rate method is used to calculate the interest expenses that should be included in the financial expenses, thereby determining the amount of the disposal fees included in the estimated liabilities. Fixed asset disposal costs are depreciated using the straight-line method, with a residual value rate of "0" and the depreciation period is implemented in accordance with the accounting regulations of CNNC. For details, please refer to Note V. 36 Estimated liabilities.

(2) Notes to financial statement items

1. Basic information of the company

Atomic High-tech Co., Ltd. (hereinafter referred to as the company, collectively referred to as the Group when including subsidiaries) was approved by the Ministry of Finance in January 2001 on issues related to the management of state-owned equity of Beijing Atomic High-tech Nuclear Technology Application Co., Ltd. (preparatory work) "Approval" (Caiqi [2001] No. 33) and the State Economic and Trade Commission's "Reply on Approving the Establishment of Beijing Atomic High-tech Nuclear Technology Application Co., Ltd." in May 2001 (State Economic and Trade Enterprise Reform [2001] 359 Approved by the China Institute of Atomic Energy as the main sponsor, it is a joint-stock company jointly established by four legal entities including Beijing Capital Technology Investment Co., Ltd., Fubon Asset Management Co., Ltd., Shandong Zibo Huaguang Ceramics Co., Ltd., CNNC Fourth Research and Design Engineering Co., Ltd., and two natural persons, Shu Weiguo and Lu Zhongcheng.

In July 2006, in accordance with the relevant provisions of the "Measures for Confirmation of the Qualifications of Non-Listed Co., Ltd. of Zhongguancun Science and Technology Park Co., Ltd. to apply for the pilot share quotation transfer", the Zhongguancun Science and Technology Park Management Committee issued the "Letter Concerning Approval of Atomic High-tech Co., Ltd.'s Application to Enter the Securities Company's Agency Share Transfer System for the Pilot Stock Quotation Transfer" (Zhongguancun Science and Technology Park Letter [2006] No. 25), confirming that the company has the qualifications of a pilot enterprise for share quotation transfer. Recommended by GF Securities Co., Ltd. and approved by the Securities Association of China (China Securities Association Letter [2006] No. 206), the company's shares were listed for quotation and transfer on the agency stock transfer system on July 28, 2006. The stock code is 430005, and the stock abbreviation is "Atom Hi-Tech".

In May 2011, due to the adjustment of the group company's industrial planning and deployment, the company's controlling shareholder was changed from the China Institute of Atomic Energy to China Tongradio Co., Ltd. (hereinafter referred to as China Tongradio).

The total share capital of the company when it was established was RMB 34,000,000.00. After this change, as of June 30, 2026, the company's share capital was RMB 161,784,136.00.

On April 13, 2026, the company obtained the enterprise legal person business license with the unified social credit code 91110108726341461X renewed by the Beijing Haidian District Market Supervision and Administration Bureau, with a registered capital of 16 , 1.784136 million yuan, the legal representative is Zhang Yiming, the registered address is Room 105, South Room 1, Floor 1, Building 1, No. 66 Changwa Middle Street, Haidian District, Beijing, and the business address is No. 1, Sanqiang Road, Xinzhen Street Office, Fangshan District, Beijing.

The Group belongs to the pharmaceutical manufacturing industry and is mainly engaged in the industrialization of nuclear application technology. Its main products are radiopharmaceuticals, radioactive sources, radioactive medical devices, radioactive labeled compounds and tracers, etc.

The controlling shareholder of the company is China National Nuclear Corporation (hereinafter referred to as China National Nuclear Corporation), and the ultimate controller is China National Nuclear Corporation (hereinafter referred to as CNNC).

2. Basis for preparation of financial statements

Basics of preparation

The Group's financial statements are prepared based on actual transactions and events and in accordance with the "Accounting Standards for Business Enterprises" and their application guidelines, interpretations and other relevant regulations promulgated by the Ministry of Finance (hereinafter collectively referred to as the "Accounting Standards for Business Enterprises"), as well as the relevant disclosure provisions of the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") "Information Disclosure and Preparation Rules for Companies that Offer Securities to the Public No. 15 - General Provisions for Financial Reports" (revised in 2023).

Going concern

If the group has a recent history of profitable operations and is supported by financial resources, it is reasonable to prepare financial statements on a going concern basis.

3. Important accounting policies and accounting estimates

The specific accounting policies and accounting estimates formulated by the Group based on actual production and operation characteristics include provisions for bad debts of receivables, provisions for inventory depreciation, depreciation of fixed assets, depreciation of right-of-use assets, amortization of intangible assets, capitalization conditions for research and development expenses, abandonment expenses of estimated liabilities, accrual of sales service fees, and recognition and measurement of revenue from the design, manufacturing and installation services of irradiation devices and medical construction projects, etc.

Statement on compliance with corporate accounting standards

These financial statements comply with the requirements of the Accounting Standards for Business Enterprises and truly, accurately and completely reflect the financial status, operating results, cash flow and other relevant information of the Company and the Group.

Accounting period

The Group's accounting period is from January 1 to December 31 in the Gregorian calendar.

Business cycle

The operating cycle of the Group is 12 months.

Accounting standard currency

The Group uses RMB as its functional accounting currency.

Determination method and selection basis of materiality criteria

The Group prepares and discloses financial statements in compliance with the materiality principle. The matters disclosed in the notes to the financial statements involve the judgment of materiality standards and the determination methods and selection basis of the materiality standards are as follows:

This matter is in this financial

Involving the judgment of importance standards

Disclosure matters in the notes to the statements: Method for determining materiality standards and selection basis disclosures

exposed position

Important individual provision for bad debts is accurate. The amount of individual provision accounts for the total amount of bad debt provisions for various types of receivables.

Five, 3. (2)

The amount of single recovery or reversal of important bad receivables in the current period accounts for more than 10% of the total amount of all types of receivables and the amount is greater than 500,000 yuan.

Five, 3. (3)

The account preparation is recovered or transferred back more than 10% and the amount is greater than 1 million yuan

The single write-off amount of important accounts receivable in this period accounts for the total bad debt provisions of various types of receivables.

Five, 3. (4)

Important projects under construction that account for more than 10% of sales and the amount is greater than 1 million yuan 5. 14.1(2) The budget of a single project is greater than 70 million yuan

Five, 7 (1)

Important forecasts for accounts aged more than one year

24(2) Prepayments/accounts payable/other payments/accounts payable/other payables with single aging exceeding 1 year
25.2 (2) The amount of accounts payable/advance receipts/contract liabilities is greater than 1 million yuan. Payment/advance receipts/contract liabilities

Five, 26 (2)

Important capitalized R&D projects where the ending balance of a single project accounts for 20% of the ending balance of development expenditures 6. 1. (1)

Above and the amount is greater than 15 million yuan

The net assets of subsidiaries account for 4% of the Group’s consolidated net assets, and important non-wholly owned subsidiaries 8. 1. (2)

Significant joint ventures or associates

1. (1) Enterprises with an investment cost of more than 50 million yuan in a single company

Important Commitments and Contingent Events 13.14 A single event accounts for 10% of the Group’s consolidated net assets

Accounting treatment methods for business combinations under the same control and those not under the same control

(1) Business merger under common control

If the enterprises participating in the merger are ultimately controlled by the same party or the same parties before and after the merger and the control is not temporary, it is a business merger under the same control.

As the merging party, the assets and liabilities acquired by the Group in a business combination under common control are measured at the book value of the merged party in the consolidated statements of the ultimate controlling party on the date of merger. The difference between the book value of the net assets acquired and the book value of the merger consideration paid (or the total face value of the shares issued) shall be adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings shall be adjusted.

(2) Business combination not under common control

If the parties involved in the merger are not ultimately controlled by the same party or the same parties before and after the merger, it is a business merger not under the same control.

As the purchaser, the Group's identifiable assets, liabilities and contingent liabilities of the acquiree acquired in a business combination not under common control are measured at fair value on the acquisition date. If the merger cost is greater than the fair value share of the acquiree's identifiable net assets acquired in the merger, the difference is recognized as goodwill; if the merger cost is less than the fair value share of the acquiree's identifiable net assets acquired in the merger, the fair value of each identifiable asset, liability and contingent liability acquired in the merger, and the merger cost will first be reviewed. After review, if the merger cost is still less than the fair value share of the acquiree's identifiable net assets acquired in the merger, the difference will be included in the non-operating income of the current period of the merger.

Judgment standards for control and preparation methods of consolidated financial statements

The consolidation scope of the Group's consolidated financial statements is determined on the basis of control, including the Company and all subsidiaries controlled by the Company. The Group's criteria for determining control are that the Group has power over the investee, enjoys variable returns by participating in the investee's relevant activities, and has the ability to use its power over the investee to affect its return amount.

When preparing consolidated financial statements, if the accounting policies or accounting periods adopted by a subsidiary and the Company are inconsistent, necessary adjustments will be made to the financial statements of the subsidiary in accordance with the Company's accounting policies or accounting periods.

The impact of internal transactions between the Company and its subsidiaries and between subsidiaries on the consolidated financial statements is eliminated upon consolidation. The share of the subsidiary's owner's equity that does not belong to the parent company and the share of the current period's net profit and loss, other comprehensive income and total comprehensive income that belong to minority shareholders are listed in the consolidated financial statements under the items "Minority shareholders' equity, minority shareholders' profit and loss, other comprehensive income attributable to minority shareholders and total comprehensive income attributable to minority shareholders" respectively.

For subsidiaries acquired through business mergers under common control, their operating results and cash flows will be included in the consolidated financial statements from the beginning of the current period of merger. When preparing comparative consolidated financial statements, adjustments are made to relevant items in the previous year's financial statements, and the reporting entity formed after the merger is deemed to have existed since the time when the ultimate controlling party began to control.

For subsidiaries acquired through business combinations not under common control, operating results and cash flows will be included in the consolidated financial statements from the date the group obtains control. When preparing consolidated financial statements, the financial statements of subsidiaries are adjusted based on the fair value of each identifiable asset, liability and contingent liability determined on the acquisition date.

Cash and cash equivalents

Cash in the Group's cash flow statement refers to cash on hand and deposits that can be used for payment at any time. Cash equivalents in the cash flow statement refer to investments that have a holding period of no more than 3 months, are highly liquid, are easily convertible into known amounts of cash, and have little risk of changes in value.

Foreign currency business

When the Group's foreign currency transactions are initially recognized, the foreign currency amount is converted into the recording currency amount using the spot exchange rate on the date of the transaction. On the balance sheet date, foreign currency monetary items are converted into the accounting functional currency using the spot exchange rate on the balance sheet date. The resulting translation differences are directly included in the current profit and loss, except for the exchange differences arising from special foreign currency borrowings for the purchase, construction or production of assets that meet the capitalization conditions, which are treated according to the capitalization principle.

Financial instruments

(1) Recognition and derecognition of financial instruments

The Group recognizes a financial asset or financial liability when it becomes a party to a financial instrument contract.

When the following conditions are met, the recognition of a financial asset (or a part of a financial asset, or a part of a group of similar financial assets) is derecognised, that is, the previously recognized financial asset is transferred out of the balance sheet: 1) The right to receive cash flows from the financial asset expires; 2) The right to receive the cash flow from the financial asset is transferred, or the right to receive cash flows from the financial asset is transferred. Under the "Hand-Hand Agreement", the Company assumes the obligation to pay the cash flows received in full to a third party in a timely manner; and substantially transfers substantially all risks and rewards of ownership of financial assets, or although substantially neither transfers nor retains substantially all risks and rewards of ownership of financial assets, it gives up control of the financial assets.

Financial liabilities are derecognised if the obligation for the financial liability has been performed, canceled or expired. If an existing financial liability is replaced by another financial liability with substantially different terms from the same creditor, or almost all of the terms of the existing liability are substantially modified, such replacement or modification is treated as derecognition of the original liability and recognition of a new liability, and the difference is included in the current profit and loss.

Buying and selling financial assets in a regular manner is recognized and derecognized based on transaction date accounting. Trading date refers to the date when the Group commits to buy or sell financial assets.

(2) Classification and measurement methods of financial assets

Upon initial recognition, the Group's financial assets are classified into financial assets measured at amortized cost and financial assets measured at fair value through other comprehensive income based on the Group's business model for managing financial assets and the contractual cash flow characteristics of the financial assets. All affected related financial assets will be reclassified if and only when the Group changes its business model for managing financial assets.

When judging the business model, the Group considers the way in which the enterprise evaluates and reports the performance of financial assets to key management personnel, the risks that affect the performance of financial assets and their management methods, and the way in which relevant business managers are remunerated. When assessing whether to collect contractual cash flows as the goal, the Group analyzes and judges the reasons, time, frequency and value of sales of financial assets before their maturity date.

When judging the characteristics of contract cash flows, the Group judges whether the contract cash flows are only the payment of principal and interest based on the outstanding principal, including (when evaluating the correction of the time value of money, judging whether there is a significant difference compared with the benchmark cash flow/for financial assets containing early repayment characteristics, judging whether the fair value of the early repayment characteristics is very small, etc.).

Financial assets are measured at fair value upon initial recognition. However, if accounts receivable or notes receivable arising from the sale of goods or provision of services do not contain a significant financing component or do not consider the financing component that does not exceed one year, they will be initially measured based on the transaction price.

The subsequent measurement of a financial asset depends on its classification:

Financial assets measured at amortized cost

Financial assets that meet the following conditions at the same time are classified as financial assets measured at amortized cost: ① The business model for managing the financial assets is to collect contractual cash flows as the goal. ②The contractual terms of the financial asset stipulate that the cash flow generated on a specific date is only the payment of principal and interest based on the outstanding principal amount. Such financial assets use the effective interest rate method to recognize interest income, and any gains or losses arising from their derecognition, modification or impairment are included in the current profits and losses. The Group's financial assets in this category mainly include: monetary funds, accounts receivable, notes receivable, and other receivables.

Debt instrument investments measured at fair value and changes included in other comprehensive income

If a financial asset meets the following conditions at the same time, it is classified as a financial asset measured at fair value with changes included in other comprehensive income: ① The business model for managing the financial asset aims at both collecting contract cash flows and selling the financial asset. ②The contractual terms of the financial asset stipulate that the cash flow generated on a specific date is only the payment of principal and interest based on the outstanding principal amount. Interest income on such financial assets is recognized using the effective interest rate method. Except for interest income, impairment losses and exchange differences, which are recognized as current profits and losses, other changes in fair value are included in other comprehensive income. When a financial asset is derecognised, the accumulated gains or losses previously included in other comprehensive income are transferred out of other comprehensive income and included in the current profit and loss. The Group's financial assets in this category mainly include: receivables financing.

(3) Classification, recognition basis and measurement method of financial liabilities

The Group's financial liabilities are classified as: financial liabilities measured at amortized cost upon initial recognition. Transaction costs related to financial liabilities measured at amortized cost are included in their initial recognition amount.

The subsequent measurement of financial liabilities depends on their classification:

Financial liabilities measured at amortized cost

Financial liabilities measured at amortized cost are subsequently measured based on the amortized cost using the actual interest rate method.

(4) Impairment of financial instruments

Based on expected credit losses, the Group performs impairment treatment on financial assets and contract assets measured at amortized cost and recognizes loss provisions.

Measurement of expected credit losses

Expected credit losses refer to the weighted average of the credit losses of financial instruments with the risk of default as the weight. Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the Group discounted at the original effective interest rate, that is, the present value of all cash shortfalls.

Lifetime expected credit losses refer to the expected credit losses caused by all possible default events that may occur during the entire expected life of a financial instrument. Expected credit losses within the next 12 months refer to the expected credit losses caused by default events on financial instruments that may occur within 12 months after the balance sheet date (if the expected duration of the financial instrument is less than 12 months, the expected duration), and are part of the expected credit losses throughout the duration.

For receivables such as accounts receivable, notes receivable, financing receivables, contract assets and other receivables that do not contain significant financing components due to daily operating activities such as selling goods and providing services, the Group uses simplified measurement methods and measures loss provisions based on an amount equivalent to the expected credit losses during the entire duration.

For lease receivables, receivables containing significant financing components and contract assets, the Group chooses to use a simplified measurement method and measure loss provisions based on an amount equivalent to the expected credit losses during the entire duration.

Except for the above-mentioned financial assets (such as debt investments, other debt investments, other receivables), loan commitments and financial guarantee contracts other than the simplified measurement methods, the Group adopts a general method (three-stage method) to calculate expected credit losses. At each balance sheet date, the Group assesses whether its credit risk has increased significantly since initial recognition. If the credit risk has not increased significantly since initial recognition, it is in the first stage. The Group measures loss provisions at an amount equivalent to the expected credit losses in the next 12 months, and calculates interest income based on the book balance and actual interest rate; if the credit risk has increased significantly since initial recognition but has not yet occurred. If credit impairment occurs, it is in the second stage. The Group measures loss provisions at an amount equivalent to the expected credit losses during the entire duration, and calculates interest income based on the book balance and the actual interest rate; if credit impairment occurs after initial recognition, it is in the third stage. The Group measures loss provisions at an amount equivalent to the expected credit losses during the entire duration, and calculates interest income based on amortized cost and the actual interest rate.

When the Group uses the expected credit loss model to assess the impairment of financial instruments and contract assets, it infers the expected changes in the debtor's credit risk based on historical repayment data and combined with economic policies, macroeconomic indicators, industry risks and other factors. Different estimates may affect the provision of impairment provisions, and the impairment provisions that have been provided may not be equal to the actual amount of future impairment losses.

Combination categories and determination basis for accruing impairment provisions based on combinations of credit risk characteristics

The Group assesses the expected credit losses of financial instruments on an individual and collective basis. When assessing on a collective basis, the Group divides financial instruments into different groups based on common credit risk characteristics. The common credit risk characteristics adopted by the Group include: type of financial instrument, credit risk rating, geographical location of the debtor, industry of the debtor, overdue information, aging of receivables, etc.

 Combination categories and determination basis of accounts receivable (and contract assets)

The Group groups accounts receivable (and contract assets) based on the similarity and correlation of credit risk characteristics based on information such as age, nature of payment, credit risk exposure, and historical payment collection. For accounts receivable (and contract assets), the Group determines that aging is the main factor affecting credit risk. Therefore, the Group refers to historical credit loss experience and prepares a comparison table between the aging of accounts receivable and the default loss rate as a basis for assessing its expected credit losses. The Group determines the aging of accounts based on the invoicing date.

 Combination categories of notes receivable and basis for determination

Based on the common risk characteristics of the credit risk of the acceptor of notes receivable, the Group divides them into different combinations and determines the accounting estimation policy for expected credit losses: a. For bank acceptance bills where the acceptor is a listed commercial bank, the Group evaluates such accounts to have low credit risk and does not recognize expected credit losses; b. For bank acceptance bills and commercial acceptance bills where the acceptor is an unlisted commercial bank, the expected loss rate is confirmed with reference to the Group's accounts receivable policy and loss provisions are made, which is the same as the group classification of accounts receivable.

 Combination categories and determination basis of other receivables

The Group's other receivables mainly include deposits and guarantees receivable, accounts receivable from related parties, etc. Based on the nature of receivables and the credit risk characteristics of different counterparties, the Group divides other receivables into 4 combinations, specifically: deposits and guarantee deposits, current accounts, social security and annuity advances and others.

According to the judgment standard for single provision of bad debt impairment provision

If the credit risk characteristics of a certain customer are significantly different from those of other customers in the portfolio, or the customer's credit risk characteristics change significantly, for example, if the customer encounters serious financial difficulties and the expected credit loss rate of the amount receivable from the customer is significantly higher than the expected credit loss rate of the account's aging and overdue range, etc., the Group will make a separate provision for losses on the amount receivable from the customer.

Write-off of impairment provisions

When the Group no longer reasonably expects to recover all or part of the contractual cash flows of a financial asset, the Group directly writes down the book balance of the financial asset. If a financial asset that has been written down is later recovered, the reversal of the impairment loss will be included in the profit and loss of the current period of recovery.

(5) Recognition basis and measurement method of financial asset transfer

For financial asset transfer transactions, if the Group has transferred almost all risks and rewards of the ownership of the financial assets to the transferee, the financial assets will be derecognised; if the Group has retained almost all the risks and rewards of the ownership of the financial assets, the financial assets will not be derecognized; if the Group has neither transferred nor retained the financial assets If the financial asset owner has substantially all the risks and rewards of property ownership, and if it gives up control of the financial asset, the financial asset will be terminated and the assets and liabilities incurred shall be recognized. If the control of the financial asset is not given up, the relevant financial assets shall be recognized according to the extent of its continued involvement in the transferred financial assets, and the relevant liabilities shall be recognized accordingly.

If the overall transfer of financial assets meets the conditions for derecognition, the book value of the transferred financial assets on the date of derecognition will be combined with the amount corresponding to the derecognition portion of the consideration received for the transfer and the cumulative amount of changes in fair value originally directly included in other comprehensive income (the financial assets involved in the transfer also meet the following conditions: ① Set The group's business model for managing the financial assets aims at both collecting contractual cash flows and selling the financial assets; ② The contractual terms of the financial assets stipulate that the cash flow generated on a specific date is only the difference between the sum of the principal and the interest based on the outstanding principal amount and is included in the current profit and loss.

If a partial transfer of a financial asset meets the conditions for derecognition, the overall book value of the transferred financial asset will be apportioned between the derecognized part and the unrecognized part according to their respective relative fair values, and the consideration received due to the transfer and the cumulative amount of changes in fair value originally included in other comprehensive income that should be apportioned to the derecognized part shall be the amount corresponding to the derecognized part (financial funds involved in the transfer The asset meets the following conditions at the same time: ① The group's business model for managing the financial asset aims at both collecting contractual cash flows and selling the financial asset; ② The contractual terms of the financial asset stipulate that the cash flow generated on a specific date is only the sum of the principal and interest based on the outstanding principal amount.), and the difference between the overall book value of the aforementioned financial assets is included in the current profit and loss.

If the company continues to be involved by providing financial guarantees for the transferred financial assets, the assets formed by the continued involvement will be recognized based on the lower of the book value of the financial assets and the amount of financial guarantees. The amount of financial guarantee refers to the maximum amount that will be required to be repaid out of the consideration received.

(6) Distinguishing between financial liabilities and equity instruments and related treatment methods

The Group distinguishes financial liabilities from equity instruments according to the following principles: (1) If the Group cannot unconditionally avoid delivering cash or other financial assets to fulfill a contractual obligation, then the contractual obligation meets the definition of financial liabilities. Although some financial instruments do not explicitly contain terms and conditions for the obligation to deliver cash or other financial assets, they may indirectly form contractual obligations through other terms and conditions. (2) If a financial instrument must be settled or can be settled with the Group's own equity instruments, it is necessary to consider whether the Group's own equity instruments used to settle the instrument are used as a substitute for cash or other financial assets, or to enable the holder of the instrument to enjoy the remaining equity in the issuer's assets after deducting all liabilities. If it is the former, the instrument is a financial liability of the issuer; if it is the latter, the instrument is an equity instrument of the issuer. In certain circumstances, a financial instrument contract stipulates that the Group must or can use its own equity instruments to settle the financial instrument, and the amount of the contractual rights or contractual obligations is equal to the number of its own equity instruments that can be obtained or required to be delivered multiplied by its fair value at settlement. Regardless of whether the amount of the contractual rights or obligations is fixed or is based entirely or partially on changes in variables other than the market price of the Group's own equity instruments (such as interest rates, the price of a certain commodity or the price of a certain financial instrument), the contract is classified as a financial liability.

The Group takes into account all terms and conditions agreed between group members and holders of financial instruments when classifying financial instruments (or their components) in the consolidated statements. An instrument shall be classified as a financial liability if the Group as a whole has an obligation as a result of the instrument to deliver cash, other financial assets, or to settle in another manner that causes the instrument to become a financial liability.

If a financial instrument or its component is a financial liability, the Group shall include the relevant interest, dividends (or dividends), gains or losses, and gains or losses arising from redemption or refinancing into the current profits and losses.

(7) Offset of financial assets and financial liabilities

The Group's financial assets and financial liabilities are presented separately in the balance sheet and do not offset each other. However, when the following conditions are met at the same time, the net amount after offsetting each other will be presented in the balance sheet: (1) The Group has the legal right to offset the recognized amount, and the legal right is currently enforceable; (2) The Group plans to settle on a net basis, or to realize the financial assets and pay off the financial liabilities at the same time.

11.Inventory

The Group's inventories mainly include raw materials, turnover materials, self-made semi-finished products and products in progress, goods in stock, goods shipped, etc. Recyclable materials refer to low-value consumables, packaging and other materials that can be used multiple times but do not meet the definition of fixed assets.

Inventories are initially measured at cost. Inventory costs include purchasing costs, processing costs and other costs. Inventories are subject to a perpetual inventory system, and inventories are valued at actual cost when acquired; when inventory is received or issued, the actual cost is determined using the weighted average method. Low-value consumables and packaging materials are amortized using the one-time write-off method.

On the balance sheet date, inventories are measured at the lower of cost and net realizable value. If the inventory cost is higher than its net realizable value, a provision for inventory depreciation is made and included in the current profit and loss. Net realizable value refers to the estimated selling price of inventory in daily activities minus the estimated costs to be incurred upon completion, estimated sales expenses and related taxes.

The Group usually accrues inventory depreciation provisions for radioactive source products based on individual inventory items. For radiopharmaceutical raw materials with large quantities and low unit prices, inventory depreciation provisions are made according to the inventory category. For inventories that are related to product series produced and sold in the same region, have the same or similar end use or purpose, and are difficult to measure separately from other items, provision for inventory depreciation is made on a consolidated basis. When determining its net realizable value, it is determined based on the estimated selling price of the entire inventory portfolio minus the estimated selling expenses and related taxes.

12.Contract assets and contract liabilities

(1) Contract assets

Contract assets refer to the right to receive consideration for which the Group has transferred goods to customers, and this right depends on factors other than the passage of time. For the determination method and accounting treatment method of expected credit losses of contract assets, please refer to the above-mentioned Note 3.10 Financial asset impairment related content.

(2) Contract liabilities

Contract liabilities reflect the Group's obligation to transfer goods to customers for consideration received or receivable from customers.

Contract assets and contract liabilities under the same contract are presented on a net basis.

Assets related to contract costs

(1) Method for determining the amount of assets related to contract costs

The Group's assets related to contract costs include contract performance costs. Contract performance costs are presented separately in inventories and other non-current assets based on their liquidity.

Contract performance costs, that is, the costs incurred by the Group to perform the contract, are recognized as an asset as contract performance costs if they do not fall within the scope of relevant accounting standards such as inventories, fixed assets or intangible assets and meet the following conditions: The costs are directly related to a current or expected contract, including direct labor, direct materials, manufacturing expenses (or similar expenses), costs clearly borne by the customer, and other costs incurred solely because of the contract; this cost increases the Group's future resources for fulfilling performance obligations; this cost is expected to be recovered.

(2) Amortization of assets related to contract costs

The Group's assets related to contract costs are amortized on the same basis as the commodity revenue recognition related to the assets and included in the current profit and loss.

(3) Impairment of assets related to contract costs

If the book value of the assets related to the contract cost of the Group is higher than the difference between the following two items, the Group will make an impairment provision for the excess and recognize it as an asset impairment loss: ① The remaining consideration that the enterprise expects to obtain for transferring the goods related to the asset; ② The estimated cost to be incurred in transferring the related goods. After the impairment provision is made, if the factors of impairment in the previous period change, causing the difference between the above two items to be higher than the book value of the asset, the asset impairment provision that was originally made will be reversed and included in the current profit and loss, but the book value of the asset after the reversal shall not exceed the book value of the asset on the date of reversal if no impairment provision is made.

Long-term equity investment

The Group's long-term equity investments include investments in subsidiaries, investments in associates and equity investments in joint ventures.

(1) Judgment of significant impact

The Group's equity investments that have a significant impact on the investee are investments in associates. Significant influence means that the Group has the power to participate in decision-making on the financial and operating policies of the investee, but it is not able to control or jointly control the formulation of these policies with other parties. When the company directly or indirectly through subsidiaries owns more than 20% but less than 50% of the voting rights of the invested unit, it is generally considered to have significant influence on the invested unit, unless there is clear evidence that the group cannot participate in the invested unit's production and operation decisions or form control over the invested unit. If the Group holds less than 20% of the voting rights of the invested unit, the Group considers that it has a significant influence on the invested unit, such as if the Group has representatives on the board of directors or similar authority of the invested unit/participates in the formulation process of the financial and operating policies of the invested unit/has important transactions with the invested unit/sends management personnel to the invested unit/provides key technical information to the invested unit, etc.

(2) Accounting treatment method

The Group initially measures long-term equity investments acquired based on the initial investment cost.

For long-term equity investments obtained through business combinations under common control, the initial investment cost is the share of the book value of the combined party's net assets in the final controlling party's consolidated statements on the date of merger; if the book value of the net assets of the combined party on the date of merger is negative, the initial investment cost is determined as zero.

For long-term equity investments obtained through business mergers not under common control, the merger cost shall be regarded as the initial investment cost.

Except for long-term equity investments formed through business mergers, long-term equity investments acquired by payment of cash shall be considered as the initial investment cost based on the actual purchase price paid and expenses, taxes and other necessary expenses directly related to the acquisition of the long-term equity investment.

The Company's investments in subsidiaries are accounted for using the cost method in individual financial statements. When using the cost method, long-term equity investments are valued at the initial investment cost. When additional investment is made, the book value of the long-term equity investment cost is increased based on the fair value of the cost paid for the additional investment and the related transaction costs incurred. Cash dividends or profits declared by the investee to be distributed shall be recognized as investment income for the current period based on the amount to which the investee shall be entitled.

The Group's investments in joint ventures and associates are accounted for using the equity method. When using the equity method, if the initial investment cost of a long-term equity investment is greater than the share of the fair value of the investee's identifiable net assets at the time of investment, the book value of the long-term equity investment will not be adjusted; if the initial investment cost of a long-term equity investment is less than the share of the fair value of the investee's identifiable net assets at the time of investment, the difference will be adjusted to the book value of the long-term equity investment and included in the current profit and loss of the investment.

For long-term equity investments accounted for using the equity method for subsequent measurement, during the period when the investment is held, the book value of the long-term equity investment will be increased or decreased accordingly with changes in the owner's equity of the investee. When confirming the share of the investee's net profits and losses, the fair value of the investee's identifiable assets when the investment is obtained is used as the basis, in accordance with the Group's accounting policies and accounting periods, and the unrealized internal transaction gains and losses arising from transactions with associates and joint ventures that do not constitute business are offset to calculate the portion attributable to the Group according to the share (internal transaction losses are asset impairment losses, the full amount is recognized), and the net profit of the investee is recognized after adjustment. The Group recognizes net losses incurred by the investee until the book value of the long-term equity investment and other long-term interests that essentially constitute the net investment in the investee are reduced to zero, unless the Group has the obligation to bear additional losses.

When a long-term equity investment is disposed of, the difference between its book value and the actual price obtained shall be included in the current investment income.

Investment real estate

The Group's investment properties refer to properties held to earn rentals or capital appreciation, or both, including houses and buildings. Measured using cost model.

The Group's investment properties use the average life method to calculate depreciation or amortization. The estimated service life, net residual value rate and annual depreciation (amortization) rate of various types of investment properties are as follows:

Category Depreciation life (years) Estimated residual value rate (%) Annual depreciation rate (%) Houses and buildings 20 5 4.75

Fixed assets

The Group's fixed assets are tangible assets held for the production of goods, provision of labor services, leasing or operation and management, with a useful life of more than one year and a unit value of more than 2,000 yuan.

Fixed assets are recognized when the economic benefits related to them are likely to flow to the Group and their costs can be measured reliably. The Group's fixed assets include houses and buildings, machinery and equipment, electronic equipment, transportation equipment, office equipment and others. The Group accrues depreciation on all fixed assets except those that have been fully depreciated and are still in use. The average life method is used when calculating depreciation. The classified depreciation life, estimated net residual value rate and depreciation rate of the Group’s fixed assets are as follows:

Serial number Category Depreciation life (years) Estimated residual value rate (%) Annual depreciation rate (%) 1 Houses and buildings 15-40 0-5 2.38-6.67 2 Machinery and equipment 5-20 0-5 4.75-20.00 3 Electronic equipment 3-10 0-5 9.50-33.33 4 Transportation equipment 5-10 0-5 9.50-20.00 5 Office equipment 3-10 0-5 9.50-33.33 6 Others 3-20 0-5 4.75-33.33

At the end of each year, the Group reviews the estimated useful life, estimated net residual value and depreciation method of fixed assets. If any changes occur, they will be treated as changes in accounting estimates.

17.Construction in progress

The cost of construction in progress is determined based on actual project expenditures, including various necessary project expenditures incurred during the construction period, borrowing costs that should be capitalized before the project reaches its intended usable state, and other related expenses.

From the date when a project under construction reaches its intended usable state, the estimated value will be transferred to fixed assets based on the project budget, cost or actual project cost, etc., and depreciation will be accrued from the next month. The difference in the original value of the fixed assets will be adjusted after the completion settlement procedures are completed.

Projects under construction will be transferred to fixed assets when they reach the intended usable state. The standards are as follows:

Item Standards for carrying forward fixed assets

Houses and buildings actually come into use

Complete installation and debugging of machinery and equipment, meet design requirements and complete trial production

Borrowing costs

The Group capitalizes the borrowing costs directly attributable to the construction or production of assets that meet the capitalization conditions and includes them in the cost of the relevant assets. Other borrowing costs are included in the current profits and losses. The assets determined by the Group to meet the capitalization conditions include borrowing costs for projects under construction that require more than one year of acquisition, construction or production activities to reach the intended usable or salable state. Capitalization begins when asset expenditures have been incurred, borrowing costs have been incurred, and the acquisition, construction or production activities necessary to bring the assets to the intended usable or salable state have begun; when the acquisition, construction or production of assets that meet the capitalization conditions reaches the intended usable or salable state, capitalization stops, and the borrowing costs incurred thereafter are included in the current profit and loss. If an asset that meets the capitalization conditions is abnormally interrupted during the acquisition, construction or production process and the interruption lasts for more than 3 months, the capitalization of borrowing costs will be suspended until the acquisition, construction or production activities of the asset are restarted.

In each accounting period within the capitalization period, the Group recognizes the capitalized amount of borrowing costs in accordance with the following method: if it borrows special borrowings, it shall be determined based on the interest expenses actually incurred in the current period, minus the interest income obtained from unused borrowed funds deposited in banks or investment income obtained from temporary investments; if it occupies general borrowings, it shall be determined based on the weighted average of asset disbursements exceeding the part of special borrowings multiplied by the capitalization rate of the occupied general borrowings, in which the capitalization rate shall be calculated and determined based on the weighted average interest rate of general borrowings.

Intangible assets

The Group's intangible assets, including software, land use rights, patented technology, non-patented technology, etc., are measured at the actual cost when acquired. Among them, purchased intangible assets are based on the actual price paid and other related expenses as the actual cost; for intangible assets invested by investors, the actual cost is determined based on the value stipulated in the investment contract or agreement. However, if the value stipulated in the contract or agreement is unfair, the actual cost is determined based on the fair value.

(1) Useful life and its determination basis, estimation, amortization method or review procedure

Land use rights are amortized on average over the transfer period from the date of transfer; software, patented technology, and non-patented technology intangible assets are amortized on average in installments based on the shortest of the expected use life, the beneficial life specified in the contract, and the effective life specified by law.

The amortization amount is included in the relevant asset cost and current profit and loss according to its beneficiary objects. The estimated useful life and amortization method of intangible assets with limited service life are reviewed at the end of each year. If there are changes, they will be treated as changes in accounting estimates.

(2) Scope of aggregation of R&D expenditures and related accounting treatment methods

The scope of the Group's R&D expenditures includes employee salaries of R&D personnel, direct investment costs, technical service fees, depreciation and amortization expenses, other expenses, etc.

The Group divides the expenditures on internal research and development projects into expenditures in the research phase and expenditures in the development phase based on the nature of the expenditures on internal research and development projects and whether there is great uncertainty in whether the intangible assets will eventually be formed from the R&D activities. Before drug research and development enters the clinical trial stage, it is the research stage of drug research and development, and the period from the beginning of clinical trials to obtaining drug registration approval is the development stage. Expenditures in the research phase are included in the current profit and loss when incurred. Expenditures in the development phase are capitalized when the following conditions are met at the same time: the Group assesses that it is technically feasible to complete the intangible asset so that it can be used or sold; the Group has the ability to complete the intangible asset and use or sell it. Intention; the intangible assets are expected to bring economic benefits to the Group; the Group has sufficient technical, financial and other resource support to complete the development of the intangible assets and has the ability to use or sell the intangible assets; the expenditures attributable to the development stage of the intangible assets can be measured reliably. Expenditures in the development phase that do not meet the capitalization conditions are included in the current profits and losses when incurred. Normally, the Group meets the capitalization conditions when it obtains approval for phase III clinical trials, and subsequent development phase expenditures are capitalized.

Impairment of long-term assets

The Group inspects long-term equity investments, investment real estate measured using the cost model, fixed assets, construction in progress, right-of-use assets, intangible assets with limited useful lives and other items on each balance sheet date. When there are signs of impairment, the Group conducts an impairment test. Goodwill, intangible assets with indefinite useful lives, and development expenditures that have not yet reached their intended usable state are subject to impairment testing at the end of each year regardless of whether there are signs of impairment.

(1) Impairment of non-current assets other than financial assets (except goodwill)

When the Group conducts impairment testing, it determines its recoverable amount based on the higher of the asset's fair value minus disposal costs and the present value of the asset's expected future cash flows. After impairment testing, if the book value of the asset exceeds its recoverable amount, the difference is recognized as impairment loss.

The Group estimates the recoverable amount on the basis of a single asset. If it is difficult to estimate the recoverable amount of an individual asset, the Group determines the recoverable amount of the asset group to which the asset belongs. The identification of an asset group is based on whether the main cash inflow generated by the asset group is independent of the cash inflows of other assets or asset groups.

The net amount of fair value less disposal expenses is determined by referring to the sales agreement price or observable market price of similar assets in orderly transactions that occurred on the measurement date, minus the incremental costs directly attributable to the disposal of the asset. When estimating the present value of future cash flows, management determines the present value of future cash flows based on the estimated future cash flows generated during the continued use of the asset and upon final disposal, and selects an appropriate discount rate.

(2) Impairment of goodwill

For goodwill formed by business combinations, the Group will allocate its book value to relevant asset groups in a reasonable manner from the date of purchase. If it is difficult to allocate it to relevant asset groups, it will allocate it to relevant asset group combinations. When conducting an impairment test on a relevant asset group or combination of asset groups that contains goodwill, if there are signs of impairment in the asset group or combination of asset groups that are related to goodwill, first conduct an impairment test on the asset group or combination of asset groups that does not contain goodwill, calculate the recoverable amount, and compare it with the relevant book value to confirm the corresponding impairment loss; then conduct an impairment test on the asset group or combination of asset groups that does not contain goodwill. Conduct an impairment test on the group combination and compare the book value with the recoverable amount. If the recoverable amount is lower than the book value, the impairment loss will first be deducted from the book value of the goodwill allocated to the asset group or asset group combination, and then the book value of other assets will be deducted in proportion to the proportion of the book value of other assets in the asset group or asset group combination except goodwill.

Once the impairment loss of the above assets is recognized, it will not be reversed in subsequent accounting periods.

Long-term deferred expenses

The Group's long-term deferred expenses include expenses for more than one year that have been paid by the Group but should be amortized in this period and subsequent periods, such as office decoration and leased asset improvements. These expenses are amortized evenly during the benefit period. If the long-term deferred expense item cannot benefit future accounting periods, all the amortized value of the item that has not been amortized will be transferred to the current profit and loss. The amortization periods of long-term deferred expenses are:

Serial number Category Amortization period (years)

1 Expenditures for improvements to leased assets 3-20

2 Office decoration expenses 3-5

3 Other expenses 3-10

22.Employee compensation

The Group's employee remuneration includes short-term remuneration, post-employment benefits, termination benefits and other long-term benefits.

Short-term remuneration mainly includes employee wages, bonuses, allowances and subsidies, employee welfare fees, social insurance premiums such as medical insurance premiums, work-related injury insurance premiums and maternity insurance premiums, housing provident funds, labor union funds and employee education funds, and other short-term remuneration. During the accounting period when employees provide services, the actual short-term remuneration is recognized as a liability and included in the current profit and loss or related asset costs according to the beneficiary object.

Post-employment benefits mainly include basic pension insurance premiums and unemployment insurance, which are classified into defined contribution plans and defined benefit plans according to the risks and obligations borne by the company. For defined contribution plans, the deposits paid to a separate entity on the balance sheet date in exchange for services provided by employees during the accounting period are recognized as liabilities, and included in the current profit and loss or related asset costs according to the beneficiary object.

The Group's defined benefit plan provides partial post-employment benefits to existing retirees, retirees and current employees in addition to the basic pension and basic medical systems stipulated by the state.

The Group operates a defined benefit pension plan which requires contributions to independently managed funds. The plan is unfunded and the cost of providing the benefit under the defined benefit plan is calculated using the expected accumulated benefit unit method. Remeasurements arising from a defined benefit pension plan, including actuarial gains or losses, changes in the impact of the asset ceiling (net of the amount included in the net interest on the net liability of the defined benefit plan) and the return on plan assets (net of the amount included in the net interest on the net liability of the defined benefit plan), are recognized immediately in the balance sheet and are included in shareholders' equity through other comprehensive income in the period in which they occur and are not transferred back to profit or loss in subsequent periods. The Group recognizes past service costs as current expenses on the earlier of the date the defined benefit plan is modified and the date the relevant restructuring expenses or termination benefits are recognized. The net interest amount is calculated by multiplying the net liabilities or net assets of the defined benefit plan by the discount rate. The Group includes the following changes in the net obligations of the defined benefit plan into the current profits and losses, including: service costs, including current service costs, past service costs and settlement gains or losses; net interest, including interest income on plan assets, interest expenses on plan obligations and interest affected by the asset ceiling.

Termination benefits arise when the Group terminates the labor relationship with employees before the expiration of their labor contracts, or proposes compensation in order to encourage employees to voluntarily accept redundancy.

If the Group provides dismissal benefits to employees, when the Group is unable to unilaterally withdraw the dismissal benefits provided due to the labor relationship termination plan or layoff proposal, or when the Group recognizes the costs or expenses related to the restructuring involving the payment of dismissal benefits, whichever is earlier, the employee compensation liabilities arising from the dismissal benefits will be recognized and included in the current profit and loss.

Other long-term benefits are mainly for the Group to establish enterprise annuity funds, which are jointly paid by the Group and individuals. The company's contribution is based on 8% of the total salary of the previous year and is deducted from the group's costs. The individual contribution is based on 2% of the employee's basic pension insurance payment base for the year, which is withheld and paid by the group from the employee's salary.

Estimated liabilities

When the business related to pending litigation or arbitration, warranty-type quality assurance, recycling and disposal of radioactive production facilities and other contingencies simultaneously meets the following conditions, the Group will recognize it as a liability: the obligation is a current obligation borne by the Group; the performance of the obligation is likely to result in the outflow of economic benefits from the enterprise; and the amount of the obligation can be measured reliably.

Estimated liabilities are initially measured based on the best estimate of the expenditure required to fulfill the relevant current obligations, and factors such as risks, uncertainties, and time value of money related to contingencies are comprehensively considered. The Group reviews the current best estimates on the balance sheet date and adjusts the book value of estimated liabilities.

Estimates of the recovery and disposal of radioactive production facilities involve the amount and timing of future expenditures, as well as inflation and discount rates that reflect current market assessments of the time value of money and the risks specific to the liability. The Group considers factors including future production plans, useful lives of relevant assets and radiation levels to determine the scope, amount and timing of recycling and disposal of radioactive production facilities. Determining these factors involves the Group's judgment and estimated liabilities may ultimately differ from actual expenditures. Due to technological progress, legal requirements or changes in the market environment, the fulfillment of the disposal obligation of specific fixed assets may result in changes in estimated liabilities caused by changes in the amount of expenditure, estimated disposal time, discount rate, etc. For the reduction of estimated liabilities, the Group deducts the cost of fixed assets to the limit of the book value of the fixed asset. For an increase in estimated liabilities, the cost of the fixed asset is increased.

Revenue recognition principles and measurement methods

(1) General principles

The Group recognizes revenue when it fulfills its performance obligations in the contract, that is, when the customer obtains control of the relevant goods or services. Obtaining control over relevant goods or services means being able to direct the use of the goods or the provision of the services and obtain almost all economic benefits from them.

Performance obligations refer to the Group's commitment in the contract to transfer clearly distinguishable goods to customers. If the Group's performance obligations meet one of the following conditions, they are performance obligations within a certain period of time; otherwise, they are performance obligations at a certain point in time: ① The customer obtains and consumes the economic benefits brought by the Group's performance while the Group performs the contract; ② The customer can control the goods under construction during the Group's performance; ③ The goods produced during the Group's performance have irreplaceable uses, and the Group has the right to collect payment for the cumulative performance part that has been completed so far during the entire contract period.

For performance obligations fulfilled within a certain period of time, the Group recognizes revenue based on the performance progress within that period of time. When the progress of contract performance cannot be reasonably determined, if the costs incurred by the Group are expected to be compensated, revenue will be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined.

For performance obligations fulfilled at a certain point in time, the Group recognizes revenue at the point when the customer obtains control of the relevant goods. When the Group determines whether a customer has obtained control of a commodity, it comprehensively considers the following signs: ① The Group has a current right to receive payment for the commodity, which means that the customer has a current payment obligation for the commodity; ② The Group has transferred the legal ownership of the commodity to the customer, that is, the customer already has legal ownership of the commodity; ③ The Group The commodity has been physically transferred to the customer, which means that the customer has physically taken possession of the commodity; ④ The Group has transferred the major risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the major risks and rewards of ownership of the commodity; ⑤ The customer has accepted the commodity; ⑥ Other signs indicating that the customer has obtained control of the commodity.

The Group determines whether the Group is the principal responsible person or agent when engaging in transactions based on whether it has control over the goods before transferring them to the customer. If the Group is able to control the goods before transferring them to customers, then the Group is the principal responsible person and recognizes revenue based on the total consideration received or receivable; otherwise, the Group is an agent and recognizes revenue based on the amount of commissions or fees that it is expected to be entitled to receive. This amount should be determined based on the net amount of the total consideration received or receivable after deducting the price payable to other related parties, or based on the established commission amount or ratio.

(2) Specific methods

The Group's operating income mainly includes income from sales of goods and income from provision of labor services.

①Income from sales of goods

The Group is engaged in the manufacturing and sales of diagnostic and therapeutic radiopharmaceuticals, medical and industrial radioactive source products, medical equipment and other products. The Group recognizes revenue when the products are delivered to customers and the customers gain control of the relevant products.

According to the sales contracts signed between the Group and its customers, the Group fulfills its performance obligations by transferring goods to customers. Based on the comprehensive consideration of the above general principles describing the signs of transfer of control of performance obligations performed at a certain point in time, the Group recognizes revenue at the point when the goods are delivered and the customer accepts them and recognizes the transaction price based on the total consideration that it is expected to be entitled to receive.

②Income from providing services

The irradiation services the Group engages in involve the disinfection and sterilization of medical devices, cosmetics, food and drugs and the modification of polymer materials. After the Group completes the irradiation sterilization work, it delivers the subject matter to the customer and recognizes revenue after confirmation by the customer. The Group provides services in the design, manufacturing and installation of irradiation devices and medical construction projects. Since customers can control the goods under construction during the performance of the Group's contracts and meet the conditions for performance obligations to be fulfilled within a certain period of time, revenue is recognized based on the performance progress.

The Group recognizes the transaction price based on the total consideration that the Group expects to be entitled to receive as agreed in the contract.

Government subsidies

Government subsidies are recognized when the conditions attached to them can be met and received. If the government subsidy is a monetary asset, it shall be measured according to the actual amount received. For a subsidy allocated according to a fixed quota standard, or when there is conclusive evidence at the end of the year that it can meet the relevant conditions stipulated in the fiscal support policy and it is expected to receive fiscal support funds, it shall be measured according to the amount receivable; if the government subsidy is a non-monetary asset, it shall be measured according to the fair value. If the fair value cannot be obtained reliably, it shall be measured according to the nominal amount (1 yuan).

The Group's government subsidies include asset-related government subsidies and income-related government subsidies. Among them, asset-related government subsidies refer to government subsidies obtained by the Group for the purchase, construction or other formation of long-term assets; income-related government subsidies refer to government subsidies other than asset-related government subsidies. If the subsidy objects are not clearly specified in government documents, the Group will make judgments based on the above distinction principles. If it is difficult to distinguish, the whole group will be classified as income-related government subsidies.

Government subsidies related to assets are recognized as deferred income and are included in current profits and losses in installments within the useful life of the relevant assets in a reasonable and systematic manner. If the relevant assets are sold, transferred, scrapped or damaged before the end of their useful life, the undistributed balance of relevant deferred income will be transferred to the profit and loss of the current period of asset disposal.

Government subsidies related to income that are used to compensate for relevant costs, expenses or losses in subsequent periods are recognized as deferred income and included in the current profits and losses in the period in which the relevant costs, expenses or losses are recognized. Government subsidies related to daily activities shall be included in other income according to the economic business essence. Government subsidies unrelated to daily activities are included in non-operating income and expenses.

If the Group obtains a policy-based preferential loan interest subsidy, the accounting treatment shall be carried out in accordance with the following principles: (1) The finance department allocates interest-subsidy funds to the lending bank and the finance department directly allocates the interest-subsidy funds to the Group. If the finance department allocates interest-subsidy funds to the lending bank and the lending bank provides loans to the Group at a policy-based preferential interest rate, the Group shall use the actual loan amount received as the entry value of the loan, and calculate relevant borrowing costs based on the loan principal and the policy-based preferential interest rate. (2) The finance department will directly allocate interest discount funds to the Group, and the Group will use the corresponding interest discount to offset related borrowing costs.

Deferred income tax assets and deferred income tax liabilities

The Group's deferred income tax assets and deferred income tax liabilities are calculated and recognized based on the difference (temporary difference) between the tax bases of assets and liabilities and their book values.

The Group recognizes deferred income tax liabilities for all taxable temporary differences except in the following situations: (1) Temporary differences arise from the initial recognition of goodwill or the initial recognition of assets or liabilities arising from non-business merger transactions that affect neither accounting profits nor taxable income (or deductible losses); (2) Taxable temporary differences related to investments in subsidiaries and associates, the Group is able to control the time when the temporary differences are reversed and the temporary differences are likely not to be reversed in the foreseeable future.

The Group recognizes deferred income tax assets to the extent that it is probable that it will obtain future taxable income that can be used to offset deductible temporary differences, deductible losses and tax credits.

The Group recognizes deferred income tax assets for all unused deductible losses to the extent that it is probable that sufficient taxable income will be available against which the deductible losses can be utilized. Management uses a lot of judgment to estimate the time and amount of taxable income in the future, and combines tax planning strategies to determine the amount of deferred income tax assets that should be recognized, so there is uncertainty.

On the balance sheet date, deferred income tax assets and deferred income tax liabilities are measured according to the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled.

27.Leasing

(1) Identification of lease

On the contract inception date, the Group evaluates whether the contract is a lease or contains a lease. A contract is or contains a lease if one party to the contract transfers the right to control the use of one or more identified assets for a certain period in exchange for consideration.

If the contract contains multiple separate leases at the same time, the Group will split the contract and conduct accounting treatment for each separate lease. If the contract contains both lease and non-lease parts, the Group will separate the lease and non-lease parts for accounting treatment. Each leasing part is accounted for in accordance with the leasing standards, and the non-lease part is accounted for in accordance with other applicable enterprise accounting standards.

(2) The Group as lessee

Lease confirmation

Except for short-term leases and leases of low-value assets, the Group recognizes right-of-use assets and lease liabilities for leases on the start date of the lease period.

Right-of-use assets refer to the Group's right as a lessee to use the leased assets during the lease term, and are initially measured at cost. The cost includes: ① the initial measurement amount of the lease liability; ② the lease payment amount paid on or before the start date of the lease term minus the amount related to the lease incentive that has been enjoyed; ③ the initial direct costs incurred; ④ the costs expected to be incurred to dismantle and remove the leased asset, restore the site where the leased asset is located, or restore the leased asset to the state agreed upon in the lease terms (except for those incurred for the production of inventory). If the Group remeasures lease liabilities in accordance with the relevant provisions of the lease standards, the book value of the right-of-use assets will be adjusted accordingly.

The Group depreciates right-of-use assets on a straight-line basis based on the expected consumption pattern of the economic benefits related to the right-of-use assets. If it is reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, depreciation will be accrued over the remaining useful life of the leased asset; if it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, depreciation will be accrued during the shorter of the lease term and the remaining useful life of the leased asset. The depreciation amount accrued shall be included in the cost of the relevant assets or the current profits and losses according to the purpose of the right-of-use assets.

The Group initially measures lease liabilities based on the present value of the unpaid lease payments at the beginning of the lease term. Lease payments include: ① fixed payments and substantive fixed payments, net of amounts related to lease incentives; ② variable lease payments that depend on an index or ratio; ③ the exercise price of the purchase option when the Group reasonably determines that it will exercise the purchase option; ④ the lease term reflects the payment required to exercise the lease termination option when the Group will exercise the lease termination option; ⑤ the amount expected to be paid based on the residual value of the guarantee provided by the Group.

When calculating the present value of lease payments, the Group uses the incremental borrowing rate as the discount rate because it is unable to determine the interest rate implicit in the lease. The Group calculates the interest expense of the lease liability in each period during the lease term based on a fixed periodic interest rate and includes it in the current profit and loss, except for those that should be capitalized.

After the start date of the lease period, when the Group recognizes the interest on the lease liability, it increases the carrying amount of the lease liability; when it pays the lease payment, it reduces the carrying amount of the lease liability. When the actual fixed payment amount changes, the expected amount payable of the guaranteed residual value changes, the index or ratio used to determine the lease payment changes, the evaluation results or actual exercise of the purchase option, lease renewal option or termination option change, the Group remeasures the lease liability based on the present value of the changed lease payment.

Short-term leasing and leasing of low-value assets

For short-term leases with a lease term not exceeding 12 months and low-value asset leases with a lower value when the individual leased assets are new assets, the Group chooses not to recognize right-of-use assets and lease liabilities. The Group will include the lease payments for short-term leases and low-value asset leases into the relevant asset costs or current profits and losses in each period during the lease term using the straight-line method or other systematic and reasonable methods.

Sale and leaseback

As the seller and lessee in the sale and leaseback transaction, the Group evaluates whether the transfer of the relevant underlying assets constitutes a sale based on specific basis.

If the Group determines that it does not constitute a sale, the Group will continue to recognize the transferred assets and at the same time recognize a financial liability equal to the transfer income.

If it constitutes a sale, the Group measures the right-of-use assets formed by the sale and leaseback based on the portion of the original asset's book value related to the right-of-use obtained through the leaseback, and only recognizes related gains or losses for the rights transferred to the lessor.

(3) The Group is the lessor

As a lessor, if a lease transfers substantially all the risks and rewards related to the ownership of the leased asset, the Group classifies the lease as a finance lease, otherwise it is classified as an operating lease.

Operating lease

During each period of the lease term, the Group uses the straight-line method to recognize the lease receipts from operating leases as rental income.

The initial direct expenses incurred by the Group in connection with operating leases are capitalized into the cost of the underlying assets of the lease, and are included in the current profits and losses in installments during the lease term on the same recognition basis as rental income. Variable lease payments obtained by the Group related to operating leases that are not included in the lease receipts are included in the current profit and loss when they actually occur.

If an operating lease changes, the Group will account for it as a new lease starting from the effective date of the change, and the amount of lease receipts received in advance or receivable related to the lease before the change is regarded as the amount of receipts from the new lease.

Fair value measurement

The Group invests in equity instruments on each balance sheet date. Fair value refers to the price that can be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date.

For assets and liabilities measured or disclosed at fair value in financial statements, the fair value level to which they belong is determined based on the lowest level input value that is significant to the overall fair value measurement: the first level input value is the unadjusted quoted price in the active market for the same asset or liability that can be obtained on the measurement date; the second level input value is the directly or indirectly observable input value of the relevant assets or liabilities in addition to the first level input value; the third level input value is the unobservable input value of the relevant asset or liability.

At each balance sheet date, the Group reassesses the assets and liabilities recognized in the financial statements that continue to be measured at fair value to determine whether there is a transition between fair value measurement levels.

For financial instruments traded in active markets, the Group determines its fair value based on active market quotations; for financial instruments not traded in active markets, the Group uses valuation techniques to determine its fair value, and the valuation model used is mainly a discounted cash flow model. The input values of valuation technology mainly include: risk-free interest rate, credit premium and liquidity premium for debt type; valuation multiplier and liquidity discount for equity type.

The fair value of Level 3 is determined based on the Group's valuation model, such as a discounted cash flow model. The Group also considers the initial transaction price, recent transactions of the same or similar financial instruments, or entirely third-party transactions of comparable financial instruments. As of June 30, 2026, Level 3 financial assets measured at fair value used significant unobservable input values such as discount rates when valuing them, but their fair values were not significantly sensitive to reasonable changes in these significant unobservable input values.

Changes in important accounting policies and accounting estimates

(1) Changes in important accounting policies

During the reporting period, the Group did not need to disclose changes in accounting policies.

(2) Changes in important accounting estimates

During the reporting period, the Group had no changes in accounting estimates that needed to be disclosed.

4. Taxes

1.Main tax types and tax rates

Type of tax Tax calculation basis Tax rate

Value-added tax Sales of goods or provision of taxable services 13%, 6%

If the tax is assessed on an ad valorem basis, 30% will be deducted from the original value of the property.

Property tax is calculated at 1.2% of the residual value; if it is levied on rent, it is charged at 12% and 1.2% based on the rent.

12% of income is calculated and paid

Urban maintenance and construction tax. The amount of turnover tax payable is 7%. Education fee surcharge is 5%. The amount of turnover tax payable is 3%.

Local education surcharge turnover tax payable 2%

Corporate income tax: taxable income 15%, 20%, 25%

Explanation of taxpayers with different corporate income tax rates:

Name of taxpayer Income tax rate (%) The company 15 Shanghai Atomic Hi-Tech Isotope Pharmaceutical Co., Ltd. (hereinafter referred to as: Shanghai Sinovac) 15 Guangzhou Atomic Hi-Tech Isotope Pharmaceutical Co., Ltd. (hereinafter referred to as: Guangzhou Hi-Tech) 15 Paite (Beijing) Technology Co., Ltd. (hereinafter referred to as Paite Technology) 15 Shijiazhuang Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Shijiazhuang Hi-Tech) 15 Tianjin Atomic Hi-Tech Isotope Pharmaceutical Co., Ltd. (hereinafter referred to as: Tianjin Hi-Tech) 15 Taiyuan Atom Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Taiyuan Hi-Tech) 15 Chongqing Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Chongqing Hi-Tech) 15 Sichuan Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Sichuan Hi-Tech) 15 Shenyang Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Shenyang Hi-Tech) 15 Nanning Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Nanning Hi-Tech) 15 Ningbo Junan Pharmaceutical Technology Co., Ltd. (hereinafter referred to as: Ningbo Junan) 15 Kunming Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Kunming Hi-Tech) 15 Xi'an Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Xi'an Hi-Tech) 15 Shantou Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Shantou Hi-Tech) 15 Changsha Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Changsha Hi-Tech) 15 Xuzhou Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as: Xuzhou Hi-Tech) 15 Beijing Atomic High-tech Fuyuan Industry and Trade Co., Ltd. (hereinafter referred to as: Fuyuan Industry and Trade) 20 Beijing Atomic High-tech Jinhui Radiation Technology Application Co., Ltd. (hereinafter referred to as: Jinhui Radiation) 20 Other taxpayers other than the above 25

Tax benefits

2.1 Corporate income tax

The company and some of its subsidiaries enjoy relevant national preferential policies for high-tech enterprises and are levied corporate income tax at a rate of 15%, as follows:

Unit name Certificate issuing authority Certificate number Validity period

Beijing Municipal Science and Technology Commission, Beijing Municipal Finance

Our company GR202311000772 2023-2025 Political Bureau, State Administration of Taxation Beijing Municipal Taxation Bureau

Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance

Shanghai Sinovac GR202331000425 2023-2025 Political Bureau, State Administration of Taxation Shanghai Municipal Taxation Bureau

Guangdong Provincial Department of Science and Technology, Guangdong Provincial Department of Finance,

Guangzhou Hi-Tech GR202444006208 2024-2026 State Administration of Taxation Guangdong Provincial Taxation Bureau

Beijing Municipal Science and Technology Commission, Beijing Municipal Finance

Pat Technology GR202511005251 2025-2027

Political Bureau, State Administration of Taxation, Beijing Municipal Taxation Bureau

Shijiazhuang High Hebei Provincial Department of Science and Technology, Hebei Provincial Department of Finance, GR202313004381 2023-2025 Section State Administration of Taxation Hebei Provincial Taxation Bureau

Tianjin Municipal Science and Technology Bureau, Tianjin Municipal Finance Bureau,

Tianjin Hi-Tech GR202312001126 2023-2025 State Administration of Taxation Tianjin Municipal Taxation Bureau

Shanxi Provincial Department of Science and Technology, Shanxi Provincial Department of Finance,

Taiyuan High-tech GR202414000039 2024-2026 State Administration of Taxation Shanxi Provincial Taxation Bureau

Liaoning Provincial Department of Science and Technology, Liaoning Provincial Department of Finance,

Shenyang Hi-Tech GR202321001700 2023-2025 State Administration of Taxation Liaoning Provincial Taxation Bureau

Department of Science and Technology of Guangxi Zhuang Autonomous Region, Guangxi

Nanning High-Tech Department of Finance of Zhuang Autonomous Region, State Administration of Taxation GR202445000145 2024-2026

Guangxi Zhuang Autonomous Region Taxation Bureau

Ningbo Municipal Science and Technology Bureau, Ningbo Municipal Finance Bureau,

Ningbo Junan GR202433102953 2024-2026 State Administration of Taxation Ningbo Municipal Taxation Bureau

Yunnan Provincial Department of Science and Technology, Yunnan Provincial Department of Finance,

Kunming Hi-Tech GR202453000258 2024-2026 State Administration of Taxation Yunnan Provincial Taxation Bureau

Guangdong Provincial Department of Science and Technology, Guangdong Provincial Department of Finance,

Shantou Hi-Tech GR202544002214 2025-2027 State Administration of Taxation Guangdong Provincial Taxation Bureau

Hunan Provincial Department of Science and Technology, Hunan Provincial Department of Finance,

Changsha Hi-Tech GR202543001679 2025-2027 State Administration of Taxation Hunan Provincial Taxation Bureau

Jiangsu Provincial Department of Science and Technology, Jiangsu Provincial Department of Finance,

Xuzhou Hi-Tech GR202532008093 2025-2027 State Administration of Taxation Jiangsu Provincial Taxation Bureau

The company, Shanghai Kexing, Shijiazhuang Hi-Tech, Tianjin Hi-Tech and Shenyang Hi-Tech are in the process of applying for high-tech enterprise certificates in 2026, and are subject to corporate income tax at a rate of 15%.

According to the "Announcement on the Continuation of the Corporate Income Tax Policy for the Development of the Western Region" (Announcement No. 23 of the National Development and Reform Commission of the Ministry of Finance, State Administration of Taxation and National Development and Reform Commission of 2020), the subsidiaries Chongqing High-Tech and Sichuan High-Tech will apply the preferential tax rate of 15% for the Western Development in 2026.

According to the relevant provisions of the "Announcement on Preferential Income Tax Policies for Small and Micro Enterprises and Individual Industrial and Commercial Households" (Announcement No. 6 of the Ministry of Finance and the State Administration of Taxation, 2023), the subsidiaries of Fuyuan Industry and Trade and Jinhui Radiation will include the annual taxable income of small and low-profit enterprises not exceeding 1 million yuan at a reduced rate of 25% as taxable income and pay corporate income tax at a rate of 20%. The implementation period of the announcement is from January 1, 2023 to December 31, 2027. According to the relevant provisions of the "Announcement of the Ministry of Finance and the State Administration of Taxation on Further Implementing Preferential Income Tax Policies for Small and Micro Enterprises" (Announcement No. 13 of the Ministry of Finance and the State Administration of Taxation in 2022), the annual taxable income of small and low-profit enterprises exceeding 1 million yuan but not exceeding 3 million yuan will be included in the taxable income at a reduced rate of 25%, and corporate income tax will be paid at a rate of 20%. The implementation period of the announcement is from January 1, 2022 to December 31, 2027.

2.2 Value-added tax

According to the "Announcement of the Ministry of Finance and the State Administration of Taxation on the Additional Value-Added Tax Credit Policy for Advanced Manufacturing Enterprises" (Announcement No. 43 of the Ministry of Finance and the State Administration of Taxation in 2023), enterprises will implement the additional VAT credit policy from January 1, 2023 to December 31, 2027. For advanced manufacturing industries, an additional 5% of the deductible input tax for the current period will be deducted from the value-added tax payable. This preferential policy applies to our company, Tianjin Hi-Tech, Shenyang Hi-Tech, Shanghai Kexing, Ningbo Junan, Guangzhou Hi-Tech, Chongqing Hi-Tech, and Nanning Hi-Tech.

5. Notes on main items of consolidated financial statements

For the financial statement data disclosed below, unless otherwise specified, the "beginning of the period" refers to January 1, 2026, the "end of the period" refers to June 30, 2026, the "current period" refers to the period from January 1 to June 30, 2026, and the "previous period" refers to the period from January 1 to June 30, 2025, and the currency unit is RMB.

Monetary funds

Item Ending balance Beginning balance

Bank deposits 25,966,751.24 6,357,025.06 Other monetary funds 12,000.00 3,604,342.59 Deposits with financial companies 622,212,950.00 647,677,721.54

Total 648,191,701.24 657,639,089.19

Including: total amount of money deposited abroad

Access to restricted monetary funds

Item Ending balance Beginning balance

Bank acceptance bill deposit 3,511,200.00 Performance deposit 12,000.00 93,000.00 Time deposit of more than three months

Total 12,000.00 3,604,200.00

Notes receivable

(1) Classified presentation of notes receivable

Item Ending balance Beginning balance

Bank acceptance bill 29,376,652.40 32,686,541.39 Commercial acceptance bill 1,449,728.23 2,569,589.54

Total 30,826,380.63 35,256,130.93

(2) Classified presentation according to bad debt accrual method

Ending balance

Category Book balance Bad debt provision

book value

Amount Proportion (%) Amount Provision Proportion (%)

Provision for bad debts on an individual basis

Provision for bad debts by portfolio 30,836,392.40 100.00 10,011.77 0.03 30,826,380.63 Among them: low-risk portfolio 29,376,652.40 95.27 29,376,652.40

General risk portfolio 1,459,740.00 4.73 10,011.77 0.69 1,449,728.23

Total 30,836,392.40 100.00 10,011.77 0.03 30,826,380.63

(continued)

Opening balance

Category Book balance Bad debt provision

book value

Amount Proportion (%) Amount Provision Proportion (%)

Provision for bad debts on an individual basis

Provision for bad debts by portfolio 35,271,061.39 100.00 14,930.46 0.04 35,256,130.93 Among them: low-risk portfolio 32,686,541.39 92.67 32,686,541.39

General risk portfolio 2,584,520.00 7.33 14,930.46 0.58 2,569,589.54

Total 35,271,061.39 100.00 14,930.46 0.04 35,256,130.93

Bad debt provisions are made individually for notes receivable

None.

Bad debt provisions are made for notes receivable on a group basis.

Ending balance

Aging

Book balance Bad debt provision Provision ratio (%) Low-risk portfolio 29,376,652.40

General risk portfolio 1,459,740.00 10,011.77 0.69

Total 30,836,392.40 10,011.77 0.03

(3) Bad debt provisions accrued, recovered or reversed in the current period for notes receivable

Amount of changes in the current period

balance at the beginning of the period

Category Recovery or transfer Closing balance Provision Write-off or write-off Others

return

Provision for bad debts based on portfolio

14,930.46 -4,918.69 10,011.77 Accounts receivable prepared

Of which: general risks

14,930.46 -4,918.69 10,011.77 combination

Total 14,930.46 -4,918.69 10,011.77

(4) Pledged notes receivable at the end of the period

None.

Accounts receivable

(1) Accounts receivable are presented based on aging

Aging Closing balance Opening balance

Within 1 year (including 1 year) 1,092,805,438.37 953,882,897.15 1-2 years 99,061,454.65 96,604,504.35 2-3 years 16,989,570.85 13,362,055.55 More than 3 years 73,218,448.38 74,109,647.49 Of which: 3-4 years 9,833,966.76 11,673,258.64 4-5 years 7,569,148.41 4,809,663.35

More than 5 years 55,815,333.21 57,626,725.50

Total 1,282,074,912.25 1,137,959,104.54

(2) Accounts receivable are classified and presented according to the bad debt accrual method

Ending balance

Book balance Bad debt provision

Category

Ratio Provision Ratio Book Value Amount Amount

(%) Example (%)

Provision for bad debts based on individual items

4,973,508.10 0.39 4,973,508.10 100.00

Prepare

Provision for bad debts on a group basis 94,059,846.97

1,277,101,404.15 99.61 7.37 1,183,041,557.18

Among them: low-risk portfolio 57,469,155.51 4.48 57,469,155.51 general risk group

1,219,632,248.64 95.13 94,059,846.97 7.71 1,125,572,401.67 combined

Total 1,282,074,912.25 100.00 99,033,355.07 7.72 1,183,041,557.18

(continued)

Opening balance

Book balance Bad debt provision

Category

Ratio Provision Ratio Book Value Amount Amount

(%) Example (%)

Provision for bad debts based on individual items

4,973,508.10 0.44 4,973,508.10 100.00

Prepare

Provision for bad debts based on combination

1,132,985,596.44 99.56 85,867,636.45 7.58 1,047,117,959.99

Among them: low-risk portfolio 47,836,633.50 4.20 47,836,633.50 general risk group

1,085,148,962.94 95.36 85,867,636.45 7.91 999,281,326.49 combined

Total 1,137,959,104.54 100.00 90,841,144.55 7.98 1,047,117,959.99

Provision for bad debts of accounts receivable on an individual basis

Ending balance

Provision ratio

Name

Book balance Bad debt provision Example Reason for provision

(%)

Peking University Stomatological Hospital 591,300.00 591,300.00 100.00 Hunan Huijia Cancer Hospital Co., Ltd. is not expected to be recovered 559,000.00 559,000.00 100.00 Beijing Yuanbo Xinchuang Biomedical Engineering Co., Ltd. is not expected to be recovered 520,395.41 520,395.41 100.00 Others are not expected to be recovered (single amount is less than 500,000) 3,302,812.69 3,302,812.69 100.00 are not expected to be recovered

Total 4,973,508.10 4,973,508.10 — —

Provision for bad debts of accounts receivable on a portfolio basis

①Accounts receivable for expected credit losses of general risk portfolio

Ending balance

Aging

Book balance Bad debt provision Proportion of provision (%) Within 1 year (including 1 year) 1,051,876,177.83 10,406,757.77 0.99 1 to 2 years 90,754,684.66 11,975,222.36 13.20 2 to 3 years 13,293,921.87 8,719,725.36 65.59 3 to 4 years 4,157,647.96 3,467,718.58 83.41 4 to 5 years 6,106,819.21 6,047,425.79 99.03 More than 5 years 53,442,997.11 53,442,997.11 100.00

Total 1,219,632,248.64 94,059,846.97 —

②Accounts receivable for expected credit losses of low-risk portfolio

Portfolio name Closing amount Reason for not accruing

Low risk portfolio 57,469,155.51 Related parties, no risk of recovery

Total 57,469,155.51

(3) Bad debt provisions for accounts receivable in the current period

Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off or write-off Others

Provision for bad debts 90,841,144.55 8,192,210.52 99,033,355.07

Total 90,841,144.55 8,192,210.52 99,033,355.07

(4) Accounts receivable actually written off in the current period

None.

(5) Accounts receivable and contract assets of the top five closing balances collected by debtors

accounts receivable

Contract accounts receivable and accounts receivable and balance at the end of the payment period

Accounts receivable at the end of the period Assets Contract assets Bad unit name Total amount of contract assets

Balance at the end of the period Proportion of the closing balance at the end of the account preparation period

Balance Balance

(%)

Oncologist, Chinese Academy of Medical Sciences

59,872,450.00 59,872,450.00 4.67 637,438.57 Hospital

Chengdu CNNC Qualcomm Isotope Stock

34,517,345.51 34,517,345.51 2.69

Co., Ltd.

Huazhong University of Science and Technology Tongji Medicine

21,047,110.20 21,047,110.20 1.64 317,631.25 Tongji Hospital Affiliated to the Hospital

Jiangxi Cancer Hospital 14,876,536.25 14,876,536.25 1.16 178,840.13 Fifth place 13,614,397.50 13,614,397.50 1.06 773,821.98

Total 143,927,839.46 143,927,839.46 11.22 1,907,731.93

(6) Accounts receivable derecognized due to transfer of financial assets

None.

(7) The amount of assets and liabilities resulting from the transfer of accounts receivable and continued involvement

None.

4.Contract assets

(1) Contract assets

None.

(2) The amount and reasons of significant changes in the book value of contract assets during the period

None.

(3) Bad debt provisions for contract assets

None.

(4) Contract assets actually written off in the current period

None.

Receivables Financing

(1) Classified presentation of financing receivables

Item Ending balance Beginning balance

Notes receivable 15,082,826.35 15,137,831.91

Total 15,082,826.35 15,137,831.91

Other receivables

Item Ending balance Beginning balance

Dividends receivable 29,828,047.91

Other receivables 16,676,833.33 11,336,817.03

Total 46,504,881.24 11,336,817.03

6.1 Dividends receivable

Item Ending balance Beginning balance

Dividends receivable 29,828,047.91

Total 29,828,047.91

6.2 Other receivables

(1) Other receivables are classified according to the nature of the payment

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Deposits and security deposits 8,436,795.60 7,693,093.06 Current accounts 3,406,429.49 1,108,211.84 Advances in social security and annuities 4,334,390.53 2,549,682.29 Others 2,014,173.06 1,484,777.72

Total 18,191,788.68 12,835,764.91

(2) Other receivables are listed based on aging

Aging Book balance at the end of the period

Within 1 year (including 1 year) 8,687,522.99 1-2 years 1,276,621.12 2-3 years 1,802,012.25 3-4 years 2,208,210.88 4-5 years 7,264.00 More than 5 years 4,210,157.44

Total 18,191,788.68

(3) Provision for bad debt provisions for other receivables

The first stage The second stage The third stage

Expected entire duration Expected bad debt provisions throughout the entire duration Expected total credit losses in the next 12 months (unissued credit losses (expired credit losses)

Credit impairment occurred) Credit impairment occurred) Balance on January 1, 2026 1,143,749.12 355,198.76 1,498,947.88 Other receivables on January 1, 2026 - - - Book balance in the current period

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision in this period 16,007.47 16,007.47 Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance on June 30, 2026 1,159,756.59 355,198.76 1,514,955.35

(4) Bad debt provisions for other receivables

Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or reversal Write-off or write-off Other bad debt provisions 1,498,947.88 16,007.47 1,514,955.35

Total 1,498,947.88 16,007.47 1,514,955.35

(5) Other receivables actually written off in the current period

None.

(6) Other receivables with top five closing balances based on debtors

Nature of payment Accounting for the closing balance of other receivables Name of bad debt provision unit Closing balance Aging

Quality Proportion of total amount (%) Closing balance Shandong Property Rights Trading Center

Security deposit 3,270,000.00 Within 1 year 17.98

Ltd.

China Nuclear Co., Ltd. (Changchun) Radiation

Security deposit 2,160,000.00 More than 3 years 11.87

Radiation Technology Co., Ltd.

Futurechem Co.,

Advance payment 1,374,104.81 More than 3 years 7.55

Ltd.

Hubei Zhongxun Medical Supplies Current account 1,300,582.66 1-3 years and 3 7.15 794,083.15 Industrial Co., Ltd. More than 1 year

Huiyuan Tongli (Beijing) Country Accounts Receivable Agency

919,969.70 Within 1 year 5.06

International Logistics Co., Ltd. Tax deduction

Total 9,024,657.17 49.61 794,083.15

(7) Accounts receivable involving government subsidies

None.

(8) Other receivables derecognized due to transfer of financial assets

None.

(9) Amount of assets and liabilities resulting from transfer of other receivables and continued involvement

None.

Advance payment

(1) Aging of prepayments

Ending balance Beginning balance

Project

Amount Proportion (%) Amount Proportion (%) Within 1 year 34,178,441.45 90.63 43,919,281.65 95.25 1-2 years 1,405,431.62 3.81 925,790.21 2.01 2-3 years 451,873.40 1.23 478,570.69 1.04 More than 3 years 999,128.97 4.33 786,136.18 1.70

Subtotal 37,034,875.44 100.00 46,109,778.73 100.00

Impairment provision 784,728.63 596,416.81

Total 36,250,146.81 — 45,513,361.92 —

Note: The Group’s prepayments for more than one year were RMB 2,856,433.99 (beginning of the period: RMB 2,190,497.08), which were mainly prepaid

Payment for purchasing materials or services, economic business has not been completed.

(2) Prepayments of the top five ending balances by prepayment objects

Unit name Closing balance Proportion of total closing balance of prepayments (%) Chongqing Aifan Information Technology Co., Ltd. 5,009,335.00 13.60 Beijing Sanjin Electronics Group Co., Ltd. 3,061,616.20 8.31 China Institute of Radiation Protection 2,746,000.00 7.45 Beijing Normal University 2,250,000.00 6.11 Ping An Property & Casualty Insurance Co., Ltd. of China

1,792,225.96 4.86Beijing Branch

Total 14,859,177.16 40.33

8.Inventory

(1) Inventory classification

Ending balance

Item Inventory depreciation provision/contract

Book balance Book value

Provision for impairment of performance costs

Raw materials 60,772,209.32 168,345.36 60,603,863.96 Self-made semi-finished products and products in progress 27,830,335.05 13,270,212.57 14,560,122.48 Inventory goods 23,235,040.90 10,041,769.07 13,193,271.83 Turnover materials 6,977,004.70 6,977,004.70 Contract performance costs 2,905,340.23 2,905,340.23 Goods shipped 35,943,197.33 35,943,197.33

Total 157,663,127.53 23,480,327.00 134,182,800.53

(continued)

Opening balance

Item Inventory depreciation provision/contract

Book balance Book value

Provision for impairment of performance costs

Raw materials 34,644,469.04 168,345.36 34,476,123.68 Self-made semi-finished products and products in progress 35,035,492.02 8,431,218.48 26,604,273.54 Inventory goods 22,653,783.07 10,041,769.07 12,612,014.00 Turnover materials 7,876,396.54 7,876,396.54 Contract performance costs 412,591.54 412,591.54 Goods shipped 5,689,783.60 5,689,783.60

Total 106,312,515.81 18,641,332.91 87,671,182.90

(2) Provision for inventory depreciation and provision for impairment of contract performance costs

Increase in this period Decrease in this period

Item Beginning balance Closing balance

Provision Others Reversal or write-off Others

Raw materials 168,345.36 168,345.36 Self-made semi-finished products

8,431,218.48 7,061,548.03 2,222,553.94 13,270,212.57 and products in progress

Inventory goods 10,041,769.07 10,041,769.07

Total 18,641,332.91 7,061,548.03 2,222,553.94 23,480,327.00

(3) There is no capitalized amount of borrowing costs in the closing balance of inventory.

None.

(4) Explanation of the amortization amount of contract performance costs for the current period

The contract performance costs are the service expenditures provided by the subsidiary Hubei Zhongxun in the design, manufacturing and installation of radiation protection equipment and construction projects, which are carried forward to operating costs according to the contract performance progress.

Other current assets

Item Ending balance Beginning balance

Input tax to be deducted 72,543,955.02 62,595,118.55 Prepaid tax 848,328.26 1,357,711.03

Total 73,392,283.28 63,952,829.58

Long-term receivables

(1) Long-term receivables

Ending balance Beginning balance

Bad discount items Bad debt rate area Book balance Book value Book balance Book value

Preparation time%

Prepare

Disposal of receivables

43,992,551.52 43,992,551.52 42,940,509.05 42,940,509.05 4.90 fee

Total 43,992,551.52 43,992,551.52 42,940,509.05 42,940,509.05

Note: The company purchased the production line from the China Institute of Atomic Energy (hereinafter referred to as the Institute of Atomic Energy). The Institute of Atomic Energy promised that when the company disposes of this part of the production line, the amount of the disposal fee will be 106,801,400.00 yuan based on the ratio of the institute's service life to the service life. The discount rate will be determined with reference to the bank's long-term loan interest rate for the same period.

(2) Bad debt provision accrual

The Group has not made any provision for bad debts for this long-term receivable.

(3) Long-term receivables derecognized due to transfer of financial assets

None.

(4) Amount of assets and liabilities formed by transferring long-term receivables and continuing to be involved

None.

Long-term equity investment

Increases and decreases in the current period

Impairment quasi-other comprehensive Other provision

Under the equity method, the investee announced the issuance of cash reserves. The opening balance is reduced. The joint equity is reduced. The closing balance is additional investment. The remaining investment income at the end of the period is adjusted to the value of the change. Others.

The amount of investment gains and losses, dividends or profits

Ready to move

1. Joint ventures

Shenzhen CNNC Haideway Biotechnology

Co., Ltd. (hereinafter referred to as Headway Corporation)

Shanghai Shenjing Pharmaceutical Technology Co., Ltd.

11,358,446.63 -1,173,811.23 10,184,635.40 (hereinafter referred to as Shanghai Shenjing Company)

Guangzhou Zhongshan Pharmaceutical Technology Development Co., Ltd.

Company (hereinafter referred to as Guangzhou Development Company)

Hubei Zhongxun Medical Supplies Industrial Co., Ltd.

Company (hereinafter referred to as Hubei Zhongxun Company 18,646,099.60 202,958.88 18,849,058.48 Company)

Total 542,882,255.78 34,795,772.58 29,828,047.91 547,849,980.45

Investment real estate

(1) Investment real estate using cost measurement model

Item Houses, buildings Total

1. Original book value

Balance at the beginning of the period 30,252,372.94 30,252,372.94 2. Increase in the current period

(1) Purchase

(2) Increase in business mergers

Reduction amount in this period
Ending balance 30,252,372.94 30,252,372.94

2. Accumulated depreciation and accumulated amortization

Opening balance 14,881,986.62 14,881,986.62 2. Increase in current period 1,932,759.60 1,932,759.60 (1) Provision or amortization 1,932,759.60 1,932,759.60 (2) Increase due to business combination
Reduction amount in this period
Ending balance 16,814,746.22 16,814,746.22

3. Impairment provision

Opening balance
Increase amount in this period
Reduction amount in this period
Ending balance

4. Book value

Book value at the end of the period 13,437,626.72 13,437,626.72 2. Book value at the beginning of the period 15,370,386.32 15,370,386.32
Fixed assets

Item Book value at the end of the period Book value at the beginning of the period

Fixed assets 1,333,462,945.13 1,089,187,139.84

1,089,187,139.84Total 1,333,462,945.13

13.1 Fixed assets

(1) Fixed assets

Items Houses and buildings Machinery and equipment Transportation Office equipment Others Total

1. Original book value

Opening balance 759,439,459.13 801,848,063.32 16,787,468.92 49,539,346.96 3,516,007.77 1,631,130,346.10 2. Increase in the current period 176,031,495.79 114,466,959.67 89,516.33 1,110,434.47 291,820,665.70

122,259.44

(1) Purchase 23,868,271.34 89,516.33 1,110,434.47 25,190,481.58

122,259.44

(2) Transfer of construction in progress 176,031,495.79 90,598,688.33 266,630,184.12 (3) Increase in business mergers

(4) Internal adjustment

(5) Other transfers

Decrease amount in this period 2,354,058.31 146,281.56 2,500,690.13

350.26

(1) Disposal or scrap 2,354,058.31 146,281.56 2,500,690.13

350.26

(2) Other reductions

Ending balance 935,470,954.92 913,960,964.68 16,876,985.25 50,503,499.87 3,637,916.95

1,920,450,321.67

2. Accumulated depreciation

Opening balance 98,105,122.12 392,486,935.79 10,687,328.46 37,303,456.20 3,317,250.96 541,900,093.53 2. Increase in the current period 10,436,173.10 33,674,112.38 769,174.13 2,494,456.70 47,418,408.47

44,492.16

(1) Provision 10,436,173.10 33,674,112.38 769,174.13 2,494,456.70 47,418,408.47

44,492.16

(2) Increase in business mergers

(3) Sub-item adjustment

Reduction amount in this period

2,234,571.00 139,667.19 - 2,374,238.19 (1) Disposal or scrapping

2,234,571.00 139,667.19 2,374,238.19 4. Closing balance 108,541,295.22 423,926,477.17 11,456,502.59 39,658,245.71

3,361,743.12 586,944,263.81

3. Impairment provision

Balance at the beginning of the period 43,112.73 43,112.73 2. Increase in the current period

(1) Provision

Reduction amount in this period

(1) Disposal or scrapping

Closing balance 43,112.73 43,112.73

4. Book value

Book value at the end of the period 826,929,659.70 489,991,374.78 5,420,482.66 10,845,254.16 276,173.83

1,333,462,945.13 2. Book value at the beginning of the period 661,334,337.01 409,318,014.80 6,100,140.46 12,235,890.76 198,756.81 1,089,187,139.84

(2) Temporarily idle fixed assets

None.

(3) Fixed assets leased through operating leases

None.

(4) Fixed assets liquidation

None.

(5) Fixed assets for which title certificates have not been obtained

Item Book value Reasons for not completing the property ownership certificate Houses and buildings 18,587,619.55 Note 1 Houses and buildings 8,023,746.23 Note 2 Houses and buildings 466,902.71 Note 3 Houses and buildings 74,220,536.35 Still in process

Total 101,298,804.84

Note 1: Since the subsidiary Jinan Hi-Tech has not yet obtained the property rights of the Jinan High-tech Zone Life Science City Development Center, the property rights of Jinan Hi-Tech have not been transferred successfully.

Note 2: The subsidiary Jinhui Radiation has not yet obtained the land use certificate, resulting in the inability to apply for the property ownership certificate.

Note 3: The Company purchased the assets of Isotope Company from the original controlling shareholder China Institute of Atomic Energy in 2003. The land use rights currently occupied by the assets are owned by China National Nuclear Corporation. The ownership certificate of the land has not yet been completed. However, the property rights of the surface buildings on the land have been transferred to the Company and the ownership certificate has not yet been completed.

14.Construction in progress

Item Closing balance Opening balance Construction in progress 540,891,617.68 702,247,101.61

Total 540,891,617.68 702,247,101.61

14.1 Projects under construction

(1) Projects under construction

Ending balance Beginning balance minus

Item impairment value

Book balance Book value Book balance Book value provision Approximate

Prepare

Zhuozhou Base Medical Center

301,838,152.40 301,838,152.40 279,158,459.25 279,158,459.25Construction

Shanghai Sinovac Molecular Targeting 1,373,333.30 1,373,333.30 179,914,180.71 179,914,180.71 New production base project

Tianjin Medical Center Project 70,315,171.74 70,315,171.74 69,850,478.51 69,850,478.51 Zhengzhou Isotope Medicine Center

39,755,671.90 39,755,671.90 38,068,487.74 38,068,487.74Heart project

Haikou Isotope Medicine Center

33,952,099.83 33,952,099.83 32,861,856.84 32,861,856.84Heart project

Huzhou Isotope Medical Center

41,433,163.35 41,433,163.35 31,024,523.64 31,024,523.64 projects

Xinjiang GMP project transformation 29,493,866.19 29,493,866.19 Changchun Isotope Pharmaceutical Center

19,578,980.38 19,578,980.38 18,560,403.01 18,560,403.01

Guangzhou Medical Atomic Technology

(Greater Bay Area) Pharmaceutical Base 9,270,284.85 9,270,284.85 5,869,648.43 5,869,648.43 Project

Nanyang Isotope Medical Center

7,710,150.57 7,710,150.57 4,512,692.11 4,512,692.11 projects

Newly added technetium real-time labeled drugs

4,147,130.09 4,147,130.09 4,033,015.78 4,033,015.78Production line project

Zhanjiang Isotope Medicine Center

4,496,437.69 4,496,437.69 3,987,553.61 3,987,553.61 projects

Nanchong Isotope Medical Center

3,807,296.40 3,807,296.40 3,080,430.63 3,080,430.63 projects

Production line expansion project 2,134,316.63 2,134,316.63 1,831,505.16 1,831,505.16 Others 1,079,428.55 1,079,428.55

Total 540,891,617.68 540,891,617.68 702,247,101.61 702,247,101.61 (2) Changes in important construction projects during the current period

Decrease in this period

Project name Beginning balance Increase in the current period Ending balance

Transferred to fixed assets Amount transferred to intangible assets in the current period

Construction of Zhuozhou Base Medical Center 279,158,459.25 22,679,693.15 301,838,152.40 Shanghai Sinovac Molecular Targeting New Production Base Project 179,914,180.71 56,746,998.20 235,287,845.61 1,373,333.30 Tianjin Medical Center Project 69,850,478.51 464,693.23 70,315,171.74 Zhanjiang Isotope Medical Center Project 3,987,553.61 508,884.08 4,496,437.69 Nanyang Isotope Medical Center Project 4,512,692.11 3,197,458.46 7,710,150.57 Guangzhou Medical Atomic High-tech (Greater Bay Area) Medical Base Project 5,869,648.43 3,400,636.42 9,270,284.85 Nanchong Isotope Medical Center Project 3,080,430.63 726,865.77 3,807,296.40 Haikou Isotope Medical Center Project 32,861,856.84 1,090,242.99 33,952,099.83

Total 579,235,300.09 88,815,472.30 235,287,845.61 432,762,926.78

(continued table)

Cumulative project investment Project progress Interest capitalization Including: Interest for the current period Interest for the current period

Project name Budget amount Source of funds

Proportion of budget (%) (%) Cumulative amount Capitalized amount Capitalization rate (%)

Construction of Zhuozhou base medical center 663,684,800.00 79.78 79.78 17,134,799.06 3,167,164.80 2.88 Self-raised and loaned Shanghai Sinovac molecular targeted new production base

293,847,500.00 81.16 100.00 47,805.63 16,279.32 2.40 Self-financing and loan projects

Tianjin Medical Center Project 93,771,400.00 75.50 98.00 2,364,629.85 456,389.30 2.10 Self-raised or loaned Zhanjiang Isotope Medical Center Project 78,000,000.00 5.65 5.65 Self-raised Nanyang Isotope Medical Center Project 75,429,200.00 10.22 10.22 Self-raised Guangzhou Medical Atomic High-Tech (Greater Bay Area)

485,438,500.00 1.91 1.91 Self-raised medical base project

Nanchong Isotope Medicine Center Project 70,216,700.00 5.43 5.43 Self-raised Haikou Isotope Medicine Center Project 93,962,700.00 36.13 36.13 29,550.18 29,491.28 2.85 Self-raised, loan

Total 1,854,350,800.00 — — 19,576,784.72 3,669,324.70 — (3) The Group has not made any impairment provision for construction in progress during the current period

Right-of-use assets

Projects Houses and Buildings Machinery Transportation Office Equipment Land Total

1. Original book value

Opening balance 20,993,027.78 5,924,162.31 4,039,391.18 30,956,581.27 2. Increase in the current period

(1) Increase in lease

(2) Other reductions

Decrease amount in the current period 1,440,707.96 1,440,707.96 (1) Disposal 1,440,707.96 1,440,707.96 (2) Other decreases
Closing balance 20,993,027.78 4,483,454.35 4,039,391.18 29,515,873.31

2. Accumulated depreciation

Opening balance 14,301,294.22 3,460,701.55 2,234,390.36 19,996,386.13 2. Increase in the current period 2,054,751.15 372,708.24 228,584.16 2,656,043.55 (1) Provision 2,054,751.15 372,708.24 228,584.16 2,656,043.55 3. Decrease amount in the current period 581,685.88 581,685.88 (1) Disposal 581,685.88 581,685.88 (2) Other reductions
Ending balance 16,356,045.37 3,251,723.91 2,462,974.52 22,070,743.80

3. Impairment provision

Opening balance
Increase amount in this period
Reduction amount in this period
Ending balance

4. Book value

Book value at the end of the period 4,636,982.41 1,231,730.44 1,576,416.66 7,445,129.51 2. Book value at the beginning of the period 6,691,733.56 2,463,460.76 1,805,000.82 10,960,195.14
Intangible assets

(1) Details of intangible assets

Items Land use rights Patent rights Non-patented technology Software Trademark rights Others Total

1. Original book value

Opening balance 211,643,442.16 11,850,309.99 58,864,697.17 15,830,164.36 3,520,000.00 23,300,000.00 325,008,613.68 2. Increase in the current period 128,615.57 128,615.57 (1) Purchase 128,615.57 128,615.57 (2) Internal research and development

(3) Transfer of projects under construction

Decrease amount in the current period 212,400.00 212,400.00 4. Closing balance 211,643,442.16 11,850,309.99 58,652,297.17 15,958,779.93 3,520,000.00 23,300,000.00 324,924,829.25

2. Accumulated amortization

Opening balance 14,426,953.94 6,585,063.06 13,038,760.52 11,989,999.85 2,376,000.00 12,430,432.96 60,847,210.33 2. Increase in the current period 2,291,197.95 146,405.58 1,387,525.22 1,070,215.89 176,000.00 31,138.45 5,102,483.09 (1) Provision 2,291,197.95 146,405.58 1,387,525.22 1,070,215.89 176,000.00 31,138.45 5,102,483.09 3. Decrease amount in the current period
Closing balance 16,718,151.89 6,731,468.64 14,426,285.74 13,060,215.74 2,552000.00 12,461,571.41 65,949,693.42

3. Impairment provision

Opening balance 727,175.00 10,838,428.59 11,565,603.59 2. Increase in the current period
Reduction amount in this period
Closing balance 727,175.00 10,838,428.59 11,565,603.59

4. Book value

Book value at the end of the period 194,925,290.27 5,118,841.35 43,498,836.43 2,898,564.19 968,000.00 0.00 247,409,532.24 2. Book value at the beginning of the period 197,216,488.22 5,265,246.93 45,098,761.65 3,840,164.51 1,144,000.00 31,138.45 252,595,799.76

At the end of the period, the intangible assets formed through the company's internal research and development accounted for 16.95% of the balance of intangible assets.

(2) Land use rights for which property rights certificates have not been obtained

None.

17.Goodwill

(1) Original value of goodwill

Name of invested unit

Balance at the beginning of the period Increase during the period Decrease during the period Ending balance

(or the formation of goodwill matters)

Goodwill formed by the acquisition of Pat Technology 3,794,761.28 3,794,761.28 Goodwill formed by the acquisition of Ningbo Junan 34,410,199.15 34,410,199.15

Total 38,204,960.43 38,204,960.43

(2) Goodwill impairment provision

Name of invested unit

Beginning balance Increase in the current period Decrease in the current period Ending balance (or goodwill formation events)

Goodwill resulting from the acquisition of Ningbo Junan 17,585,218.81 17,585,218.81

Total 17,585,218.81 17,585,218.81

Long-term deferred expenses

Increased in this issue

Item Opening balance Amortization for the period Other decreases Closing balance

Air system and installation fees

1,306,975.18 106,522.18 148,085.19 1,265,412.17 for use

Factory environment of the Institute of Atomic Energy

721,874.63 393,749.82 328,124.81 promotion

Renovation of R&D laboratory 468,525.07 281,114.94 187,410.13 Decoration of drug precursor workshop 276,173.93 138,087.00 138,086.93 Radioactive source library and packaging building

275,812.70 137,906.40 137,906.30 Hall decoration

Intelligent monitoring of power system

213,892.45 106,946.28 106,946.17Renovation

Office area decoration 208,786.42 37,961.16 170,825.26 Comprehensive GMP workshop dehumidification

68,540.15 34,269.96 34,270.19Renovation

Comprehensive renovation projects in 2024

234,341.93 117,171.00 117,170.93 items

Exterior wall decoration 222,625.73 74,208.58 148,417.15

Spare room renovation on the third floor

26,062.73 7,818.78 18,243.95 Decoration

Others 175,773.17 86,214.24 89,558.93

Total 3,976,758.36 329,147.91 1,563,533.35 2,742,372.92

Deferred income tax assets and deferred income tax liabilities

(1) Deferred income tax assets without offset

Ending balance Beginning balance

Items Deductible temporary deferred income tax Deductible temporary deferred income tax

Difference Asset Difference Asset accrued expenses 381,041,371.68 63,935,017.49 294,467,430.32 48,350,898.14 Credit impairment provision 99,455,083.60 16,852,912.78 78,135,271.01 12,113,323.74 Abandonment expenses 73,795,008.43 11,069,251.26 71,073,925.62 10,661,088.84 Asset impairment provisions 35,210,377.23 6,297,801.60 43,843,833.60 8,891,310.59 Preliminary salary 19,328,436.38 3,107,927.34 27,389,833.82 4,362,682.68 Deferred income 21,974,148.37 3,296,122.26 20,054,148.37 3,008,122.26 Deferred expenses arising from lease liabilities

8,817,013.84 1,304,125.05 9,533,570.20 1,449,461.59 Taxable assets

Capitalization tax on R&D projects will differ

8,266,152.74 1,239,922.91 8,266,152.74 1,239,922.91 different

Assessment impairment 53,098.67 7,964.80 55,268.87 8,290.33

Total 647,940,690.94 107,111,045.49 552,819,434.55 90,085,101.08

(2) Deferred income tax liabilities without offset

Ending balance Beginning balance

Item Taxable temporary deferred income tax Taxable temporary deferred income tax

Difference Liabilities Difference Increase in liability valuation 29,779,727.93 4,466,959.19 32,609,564.20 4,891,434.63 Deferred formation of right-of-use assets

6,446,270.88 890,817.29 9,105,283.62 1,403,932.59 Income tax liabilities

Fixed asset disposal fee 59,021.41 8,853.21 59,021.41 8,853.21

Total 36,285,020.22 5,366,629.69 41,773,869.23 6,304,220.43

(3) Deferred income tax assets or liabilities presented on a net basis after offsetting

Deferred income tax assets Deferred income after offset Deferred income tax assets Deferred income items after offset Assets and liabilities Tax assets or liabilities at the end of the period Assets and liabilities at the beginning of the period Tax assets or liabilities

Offset amount Closing balance Offset amount Beginning balance deferred income tax assets

899,670.50 106,211,374.99 1,412,785.80 88,672,315.28

Deferred income tax liability

899,670.50 4,466,959.19 1,412,785.80 4,891,434.63

(4) Details of deferred income tax assets not recognized

Item Ending balance Beginning balance

Deductible temporary differences 50,003,989.77 43,606,131.50 Deductible losses 52,255,115.29 38,571,439.00

Total 102,259,105.06 82,177,570.50

(5) Deductible losses that have not been recognized as deferred income tax assets will expire in the following years

Year Ending amount Beginning amount Note 2027 1,134,892.79

2028

2029 14,374,584.04 16,265,287.44

2030 13,326,803.52 16,174,878.86

2031 19,230,717.80

2035 5,323,009.93 4,996,379.91

Total 52,255,115.29 38,571,439.00

Other non-current assets

Ending balance Beginning balance

Item Book balance Impairment Book value Book balance Impairment allowance Book value

Prepare

Prepaid Equipment Worker

119,147,338.61 119,147,338.61 140,478,416.00 140,478,416.00 journey payment

Prepayment for factory building

Prepaid land payment 1,249,996.00 1,249,996.00 1,249,996.00 1,249,996.00

Total 120,397,334.61 120,397,334.61 141,728,412.00 141,728,412.00

Assets whose ownership or use rights are restricted

Item Closing book value Reason for restriction

Monetary funds 12,000.00 margin

Fixed assets 199,974,061.07 Mortgage loan

Intangible assets 11,175,048.14 Mortgage loans

Total 211,161,109.21

Short-term borrowing

(1) Classification of short-term loans

Borrowing category Closing balance Opening balance

mortgage loan

Guaranteed loans 6,802,361.11 2,001,375.00 Credit loans 309,192,826.90 312,145,571.19

Total 315,995,188.01 314,146,946.19

(2) Overdue short-term borrowings that have not been repaid

The Group had no overdue short-term borrowings at the end of the period.

Notes payable

(1) Classified presentation of notes payable

Item Ending balance Beginning balance

Bank acceptance bill 8,778,000.00 Commercial acceptance bill

Total 8,778,000.00

24.Accounts payable

(1) Presentation of accounts payable

Item Ending balance Beginning balance

Within 1 year (including 1 year) 64,305,957.07 61,838,228.12 1-2 years 440,445.35 1,879,634.94 2-3 years 490,492.30 353,021.82 More than 3 years 5,416,451.53 6,527,992.47

Total 70,653,346.25 70,598,877.35

(2) Important accounts payable aged more than 1 year

Unit name Closing balance Reason for outstanding or carry-over Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine 3,508,200.00 Not settled yet

total

Other payables

Item Ending balance Beginning balance

Dividends payable 94,099,116.15 3,750,000.00 Other payables 605,803,380.26 529,119,120.61

Total 699,902,496.41 532,869,120.61

25.1 Dividends payable

Item Ending balance Beginning balance

Dividends on ordinary shares 94,099,116.15 3,750,000.00

Total 94,099,116.15 3,750,000.00

25.2 Other payables

(1) Other payables are classified according to the nature of the payment

Nature of payment Ending balance Beginning balance

Promotional service fees payable 396,379,975.00 365,623,681.46 Accrued expenses 71,426,257.02 52,260,070.12 Security deposit payable 34,983,060.38 40,801,184.42 Factoring back to be paid 22,569,027.94 39,677,100.00 Equipment project payable 51,850,819.62 19,181,273.22 Party committee funds 6,411,948.56 6,076,378.47 Five insurances and one fund 2,424,981.62 2,381,793.19 Labor union funds 6,364,462.59

Borrowings from small shareholders 3,547,172.26

Others 9,845,675.27 3,117,639.73

Total 605,803,380.26 529,119,120.61

(2) Important other payables aged more than 1 year

Unit name Closing balance Reason for outstanding repayment or carry-over Beijing Shentu Technology and Trade Co., Ltd. 2,406,422.66 Not settled yet

Shenyang Yinhe Information Consulting Co., Ltd. 1,562,202.63 Not settled yet

Beijing Guoyuan New Technology Co., Ltd. 1,436,556.59 Not settled yet

Beijing Xinjidel Technology Co., Ltd. 1,276,476.73 Not settled yet

Zhangjiakou Phaeton Medical Technology Services Co., Ltd. 1,228,000.00 Not settled yet

Total 7,909,658.61

Advance payments

(1) Presentation of advance receipts

Category Closing Balance Opening Balance

Rent collected in advance

total

(2) Important advances from customers aged more than 1 year

None.

(3) Significant changes in book value during the current period

None.

27.Contract liabilities

Item Closing balance Opening balance Sales of radioactive sources 43,509,567.95 60,691,141.08 Sales of radioactive drugs 9,557,358.01 2,936,310.98 Irradiation services 626,772.12 675,669.40 Sales of other medical equipment 473,682.18 366,885.71

Total 54,167,380.26 64,670,007.17

Employee compensation payable

(1) Classification of employee compensation payable

Item Opening balance Increase in the current period Decrease in the current period Ending balance Short-term compensation 66,179,970.49 178,873,614.56 197,345,978.07 47,707,606.98 Post-employment benefits - defined contribution plan 2,244,175.77 28,923,245.96 28,766,150.08 2,401,271.65 Termination benefits 159,201.00 159,201.00 0.00 Other benefits due within one year 477,000.00 477,000.00

Total 68,901,146.26 207,956,061.52 226,271,329.15 50,585,878.63

(2) Short-term salary

Item Opening balance Increase in the current period Decrease in the current period Ending balance wages, bonuses, allowances and subsidies 54,865,180.63 122,265,373.59 144,146,786.45 32,983,767.77 Employee welfare fees 14,402,258.08 14,402,258.08 0.00 Social insurance premium 1,313,253.50 11,854,948.92 11,803,319.90 1,364,882.52 Including: medical insurance premium and maternity insurance

1,277,185.10 11,521,255.82 11,473,063.15 1,325,377.77 fee

Work injury insurance premium 36,068.40 534,901.28 531,464.93 39,504.75 Housing provident fund 158,583.65 14,185,590.48 14,111,460.48 232,713.65 Trade union funds and employee education funds 2,049,018.12 2,751,921.44 2,945,953.69 1,854,985.87 Other short-term compensation 7,793,934.59 13,413,522.05 9,936,199.47 11,271,257.17

Total 66,179,970.49 178,873,614.56 197,345,978.07 47,707,606.98

(3) Set up a withdrawal plan

Item Beginning balance Increase in the current period Decrease in the current period Ending balance Basic pension insurance 2,090,804.01 19,787,098.72 19,705,300.00 2,172,602.73 Unemployment insurance premium 65,096.79 824,379.43 821,823.15 67,653.07 Enterprise annuity payment 88,274.97 8,311,767.81 8,239,026.93 161,015.85

Total 2,244,175.77 28,923,245.96 28,766,150.08 2,401,271.65

Taxes payable

Item Ending balance Beginning balance

Corporate income tax 26,563,114.32 27,359,334.65 Value-added tax 27,189,319.51 11,164,287.37 Personal income tax 444,964.44 5,804,130.90 Property tax 1,448,179.29 1,456,848.71 Urban maintenance and construction tax 1,233,647.53 609,854.46 Education fee surcharge (including local education fee surcharge) 911,686.68 455,983.03 Land use tax 65,634.22 97,254.46 Other taxes and fees 185,189.18 555,650.85

Total 58,041,735.17 47,503,344.43

Non-current liabilities due within one year

Item Ending balance Beginning balance

Lease liabilities due within one year 4,653,263.63 5,844,537.44 Long-term payables due within one year 2,890,885.11 2,447,549.56 Long-term borrowings due within one year 6,079,806.69 7,637,075.14

Total 13,623,955.43 15,929,162.14

Other current liabilities

(1) Classification of other current liabilities

Project

Ending balance Beginning balance

Output tax to be transferred 7,234,100.23 8,352,055.54 Endorsed or discounted but not yet due 972,255.00 notes receivable

Total 7,234,100.23 9,324,310.54

Long-term borrowing

(1) Classification of long-term loans

Borrowing category Closing balance Opening balance

Credit loans 502,270,568.69 434,874,858.00 Guaranteed loans 104,252,282.35 122,236,731.29 Mortgage loans 30,051,602.99 30,656,152.61

Total 636,574,454.03 587,767,741.90

Note: The long-term borrowing interest rate range is 1.8%~4.4%.

Lease liabilities

Item Ending balance Beginning balance Lease payment 10,028,730.91 11,680,838.98 Less: Unrecognized financing costs 830,316.69 1,038,263.88 Less: Non-current liabilities due within one year 4,653,263.63 5,844,537.44

Total 4,545,150.59 4,798,037.66

Long-term payables

Item Ending balance Beginning balance

Long-term payables 11,487,272.19 13,233,707.17 Special payables 45,850,692.52 44,529,937.80

Total 57,337,964.71 57,763,644.97

34.1 Long-term payables are classified according to the nature of the payment

Nature of payment Ending balance Beginning balance

Sale and leaseback 11,487,272.19 13,233,707.17

Total 11,487,272.19 13,233,707.17

34.2 Special accounts payable

Less for this period

Item Opening balance Increase in the current period Ending balance Reason for formation

less

Oncology diagnosis and treatment drugs CNNC 68Ga-DOTATATE and 15,320,755.00 15,320,755.00 Focus on the research and development of 177Lu-DOTATATE

CNNC HTA-503 10,395,984.91 10,395,984.91 Centralized research and development funds

CNNC 6-[18F]fluoro-L-dopa injection

3,952,830.00 3,952,830.00 Centralized R&D

2,815,433.96 2,815,433.96 Target for melanoma diagnosis CNNC has invested in the development and clinical application of radioactive drugs 2,815,433.96

CNNC HTA-308 2,417,735.85 2,417,735.85 Centralized research and development funds

CNNC HTA-307 1,603,773.58 1,603,773.58 Concentrated talent fund

CNNC HTA-209 1,415,094.34 94,339.62 1,509,433.96 Concentrated talent fund

CNNC HTA-505 1,320,754.71 188,679.25 1,509,433.96 Concentrated Talent Fund

Technetium, an intraoperative tracer for breast cancer in the central core

[99mTc] Vulcanized colloid 1,292,452.83 group concentration

1,292,452.83

Study on key mass properties

Elite model

China Baoyuan HTA-601 863,415.09 863,415.09 Fund project funds

China Baoyuan HTA-506 827,056.60 827,056.60 Fund Project

money

China Baoyuan HTA-313 795,216.97 795,216.97 Fund project funds

Other projects of CNNC 1,509,433.96 1,037,735.85 2,547,169.81 Concentrated talents

money

Total 44,529,937.80 1,320,754.72 45,850,692.52 —

Long-term employee benefits payable

Item Ending balance Beginning balance

Post-employment benefits - net liabilities of defined benefit plan 32,994,781.76 28,569,781.76

Total 32,994,781.76 28,569,781.76

Note: In addition to providing basic pension and basic medical care systems stipulated by the state, the Group also provides post-employment benefits such as supplementary pension, supplementary medical care and funeral expenses for existing retirees, current retirees and current employees. This post-employment benefit plan is a defined benefit plan, and the Group does not pay any fees to an independent management fund.

Estimated liabilities

Item Ending balance Beginning balance Cause of formation Disposal expenses 117,474,183.67 114,735,203.43 Note

Total 117,474,183.67 114,735,203.43 —

Note: According to national laws and administrative regulations, international conventions, etc., enterprises have obligations such as environmental protection and ecological restoration. The company is responsible for the disposal or disposal of production line sites, radioactive source storage sites, and waste radioactive sources. In 2016, the Group determined the final value and accrual period of the disposal fee based on the "China Single Cost Standard for Disposal Fees for Fixed Assets and Waste Source Disposal Fees in China". It is assumed that the accrual period for disposal fees of production line sites and radioactive source storage sites is 70 years, and the accrual period of disposal fees for cobalt 60 radioactive sources used in irradiation stations is 20 years. The discount rate refers to the same period. Calculate the present value based on the long-term bank loan interest rate (4.9%), and use this to determine the original value of the fixed asset disposal fee. The fixed asset disposal fee will be accrued in the current period when the fixed asset reaches its intended usable state. At the same time, the actual interest rate method will be used to calculate the interest expense that should be included in the financial expenses, and the amount of the disposal fee included in the estimated liabilities will be determined. Fixed asset disposal costs are depreciated using the straight-line method, with a residual value rate of "0" and the depreciation period is implemented in accordance with the accounting regulations of CNNC.

Deferred income

(1) Classification of deferred income

Item Beginning balance Increase in the current period Decrease in the current period Ending balance Reason for formation Government subsidy 91,116,705.38 1,920,000.00 194,320.80 92,842,384.58 Government appropriation

Total 91,116,705.38 1,920,000.00 194,320.80 92,842,384.58 — (2) Government subsidy projects

The calculation for the current period is offset against the assets for the current period.

The new additions in the current period are included in the business. The current period is included in other customs/government subsidy projects. Opening balance Costs and expenses Closing balance

Amount of subsidy External income Amount of other income Change Amount corresponding to income

Amount related to assets Special subsidy from National Development and Reform Commission 64,610,000.00 64,610,000.00

Radioactivity for diagnosis of tumors and neurodegenerative diseases

Comparable to income 1,561,788.30 1,561,788.30

Drug development and clinical research

Haidian District High-Quality Development Project of Pharmaceutical and Health Industry-Fluoride

Corresponding to income 6,316,350.00 6,316,350.00

[18F] Stamin injection

F18 Material Support System Construction Project and Ministry of Industry and Information Technology Special Project

Compared with assets 1,484,615.38 74,230.78 1,410,384.60

funds

Asset subsidy project for industrial transformation and upgrading related to assets 992,941.63 70,090.02 922,851.61

Income related to original targeted α-nuclide therapeutic drugs 1,474,512.64 1,920,000.00 3,394,512.64

Based on new composite multifunctional yttrium-90 embolization microspheres

Relative to income 526,497.43 526,497.43

Research on programmed precision treatment of liver cancer and its mechanism

Special funds for enterprise development related to assets 225,000.00 50,000.00 175,000.00

Related to Income Brachytherapy using radionuclide labeled rare earth materials 175,000.00 175,000.00

Related and Income R&D of phase fluorine [18F] labeled drugs 10,000,000.00 10,000,000.00

Related molecular targeted diagnostic and therapeutic drug research and development and production base technological improvements

Corresponding to income 3,750,000.00 3,750,000.00

help

Total 91,116,705.38 1,920,000.00 194,320.80 92,842,384.58

Equity capital

Changes in the current period (+, -)

Item Beginning balance Closing balance

Issuance of new shares Bonus shares Conversion of public reserve funds Others Subtotal

Total shares 161,784,136.00 161,784,136.00

39.Capital reserve

Item Opening balance Increase in the current period Decrease in the current period Ending balance Equity premium 567,737,197.58 567,737,197.58 Other capital reserves

Total 567,737,197.58 567,737,197.58

40.Other comprehensive income

Amount incurred this period

Less: Included in the previous period Less: Included in the previous period

Income for the period at the beginning of the period Less: income tax attributable to other comprehensive income at the end of the period after tax attributable to other comprehensive income

Balance: Taxes and fees incurred before tax are small. The balance income is transferred to retained income in the current period. The parent company

Amount is used to count shareholders

Income profit and loss

Other comprehensive income that cannot be reclassified into profit or loss -17,771,600.00 -3,708,000.00 -21,479,600.00

Including: Changes in remeasurement of defined benefit plan -17,771,600.00 -3,708,000.00 -21,479,600.00

Total other comprehensive income -17,771,600.00 -3,708,000.00 -21,479,600.00

41.Special reserves

Item Beginning balance Increase in the current period Decrease in the current period Ending balance Safety production expenses 55,781,412.37 15,055,534.81 4,889,470.02 65,947,477.16

Total 55,781,412.37 15,055,534.81 4,889,470.02 65,947,477.16

Surplus reserve

Item Opening balance Increase in the current period Decrease in the current period Ending balance Statutory surplus reserve 81,512,642.07 81,512,642.07

Total 81,512,642.07 81,512,642.07

Undistributed profits

Projects in this issue Previous issue

Closing balance of the previous period 1,934,421,083.58 1,764,448,911.92 plus: adjustment to undistributed profits at the beginning of the period

Balance at the beginning of the current period 1,934,421,083.58 1,764,448,911.92 Plus: Net profit attributable to owners of the parent company for the current period 167,021,784.90 133,087,970.90 Less: Appropriation of statutory surplus reserve

Cash dividends distributed in this period 90,599,116.15 88,819,490.66

Others

Ending balance of the current period 2,010,843,752.33 1,808,717,392.16

Operating income and operating costs

(1) Operating income and operating costs

Amount for the current period Amount for the previous period

Project

revenue cost revenue cost

Main business 938,008,646.62 397,534,158.24 830,842,389.41 373,926,100.69

Total 938,008,646.62 397,534,158.24 830,842,389.41 373,926,100.69

(2) Income generated from the contract

Special equipment production total

Business segment: sales of radioactive pharmaceuticals, sales of radioactive sources and

Irradiation segment sales and other businesses

Department and Inspection Division Technical Service Division

service

Income 853,914,769.14 75,060,676.73 3,486,279.95 5,546,920.80 938,008,646.62Total 853,914,769.14 75,060,676.73 3,486,279.95 5,546,920.80 938,008,646.62

Taxes and surcharges

Items Amount incurred in the current period Amount incurred in the previous period Urban maintenance and construction tax 5,870,783.10 4,638,443.91 Education surcharge (including local education surcharge) 4,311,159.96 3,482,111.39 Real estate tax 3,485,823.92 1,863,954.54 Stamp tax 463,507.99 414,894.14Land use tax 139,581.39 96,717.23Other taxes and fees 359,924.20 388,495.66

Total 14,630,780.56 10,884,616.87

Selling expenses

Item Amount for the current period Amount for the previous period

Extension service fee 186,275,721.93 142,659,697.13 Employee compensation 9,597,398.07 9,602,348.49 Conference fee 1,657,112.44 1,528,448.34 Business expenses 293,911.35 242,209.75 Travel expenses 338,046.81 367,458.47 Communication expenses 238,639.97 230,468.09 Depreciation expenses 206,032.52 399,987.90 Advertising expenses 158,671.70 Repair expenses 177,148.57 Material expenses 25,499.89 10,374.05Office expenses 18,383.18 8,953.18Others 2,006,623.65 1,928,077.16

Total 200,657,369.81 157,313,842.83

Administrative expenses

Item Amount for the current period Amount for the previous period

Employee compensation 47,943,639.44 48,491,755.95 Depreciation and amortization expenses 1,562,324.62 7,852,053.78 Intermediary agency fees 7,479,551.26 8,365,946.23 Travel expenses 1,312,167.20 1,748,987.39 Leasing and property expenses 4,166,345.43 4,047,683.32 Communication expenses 541,659.15 427,579.74 Business entertainment expenses 527,263.27 916,565.86 Labor expenses 316,364.17 220,861.10 Office expenses 385,516.80 419,777.16 Material expenses 146,290.82 187,891.01 Technical service expenses 394,963.78 492,975.60 Repair expenses 165,490.70 928,982.67 Conference fees 292,330.19 346,138.75 Information system operation and maintenance fee 219,104.09 118,913.99 Power fee 406,919.83 432,667.99 Cleaning and security service fee 1,364,103.11 989,567.91 Director (Supervisor) Board fee 236,639.92 20,549.26 Others 6,132,426.80 3,212,408.46

Total 73,593,100.58 79,221,306.17

Research and development expenses

Item Amount for the current period Amount for the previous period

Employee compensation 28,097,397.10 30,222,903.83 Material fees 14,642,760.58 13,921,599.75 Technical service fees 12,485,736.74 11,546,083.19 Depreciation and amortization 5,531,952.70 4,219,749.20 Labor protection fees 1,302,996.63 1,111,219.09 Travel expenses 674,224.22 389,805.87 Power fees 543,875.19 494,922.79 Testing fees 63,035.91 77,660.56 Intermediary service fees 634,261.58 1,132,822.31 Labor expenses 137,987.00 123,852.42 Office expenses 10,928.68 64,586.53 Others 2,299,228.08 596,205.75

Total 66,424,384.41 63,901,411.29

49.Financial charges

Item Amount for the current period Amount for the previous period

Interest expense 9,079,995.65 7,100,884.99 Less: Interest income 1,382,817.16 1,215,609.37 Plus: Exchange loss -1,376,404.10 1,828,645.33 Other expenses 381,161.00 108,963.67

Total 6,701,935.39 7,822,884.62

Other income

Sources of other income Amount incurred in the current period Amount incurred in the previous period

Appropriation for scientific research projects 8,765,600.00 16,400.00 Additional deduction for value-added tax input tax 897,647.58 960,872.37 Special fund subsidy for enterprise development 619,990.02 157,985.80 Cashing in rewards for enterprises in the scientific and technological service industry above designated size 150,000.00 180,000.00 Personal tax fee refund 145,072.58 258,282.69 Others—amortization deferred income 124,230.78 144,320.78 Social security and employment-related subsidies 115,938.09 132,756.58 Others—one-time government subsidy 0.00 186,700.00 Others—job expansion subsidy 0.00 7,450.17

Total 10,818,479.05 2,044,768.39

Investment income

Item Amount for the current period Amount for the previous period

Long-term equity investment income calculated using the equity method 34,795,772.58 32,101,493.01

Total 34,795,772.58 32,101,493.01

Credit impairment losses (losses are listed with a “-” sign)

Item Amount for the current period Amount for the previous period

Bad debt losses on accounts receivable -8,192,210.52 -5,387,524.96 Bad debt losses on notes receivable 4,918.69 40,857.97 Bad debt losses on other receivables -16,007.47 -73,126.10

Total -8,203,299.30 -5,419,793.09

Asset impairment losses (losses are listed with "-")

Items Amount incurred in the current period Amount incurred in the previous period Inventory depreciation losses and contract performance cost impairment losses -7,061,548.03

Impairment losses on contract assets 3,016,177.39 Others -188,311.82

Total -7,249,859.85 3,016,177.39

Profit and loss from asset disposal (losses are listed with "-")

Item Amount incurred in the current period Amount incurred in the previous period Amount included in non-recurring gains and losses for the year Right-of-use assets -7,537.94 1,208,766.06 -7,537.94 Fixed assets 22,100.00

Total -7,537.94 1,230,866.06 -7,537.94

55.Non-operating income

(1) Details of non-operating income

Included in non-recurring items in the current period Amount incurred in the current period Amount incurred in the previous period

Amount of profit and loss Gains on damage and scrapping of non-current assets

Others 471,928.27 9,268.38 471,928.27

Total 471,928.27 9,268.38 471,928.27

56.Non-operating expenses

Included in extraordinary items for the current period Amount for the current period Amount for the previous period

Penalties and late payment fees for temporary gains and losses 47,217.55 74,129.72 47,217.55 Loss from damage and scrapping of non-current assets 6,483.72

Others 6,598.42 3,000.00 6,598.42

Total 53,815.97 83,613.44 53,815.97

Income tax expenses

(1) Income tax expenses

Item Amount incurred in the current period Amount incurred in the previous period Income tax expense for the year 40,808,837.90 23,623,930.62 Deferred income tax expense -17,963,535.15 -573,366.21

Total 22,845,302.75 23,050,564.41

(2) Adjustment process of accounting profits and income tax expenses

Items Amount incurred in the current period Total consolidated profits in the current period 209,038,584.47 Income tax expense calculated according to statutory/applicable tax rates 35,278,333.72 Impact of different tax rates applicable to subsidiaries -3,741,623.74 Impact of adjusting income tax in previous periods -6,074,925.22 Impact of non-taxable income -883,230.16 Impact of non-deductible costs, expenses and losses 3,639,405.78 The impact of using deductible losses that have not been recognized as deferred income tax assets in the previous period

The impact of deductible temporary differences or deductible losses of deferred income tax assets not recognized in the current period 2,396,494.74 R&D super deduction -7,769,152.36 The impact of tax rate changes on deferred income tax

Income tax expense 22,845,302.75 58. Other comprehensive income

For details, please refer to the relevant content of "V. 40 Other Comprehensive Income" in this note.

Cash flow statement items

Other cash received related to operating activities

Items Amount for the current period Amount for the previous period Current deposit deposit 5,593,413.93 4,666,926.13 Interest income 1,346,234.22 1,164,657.07 Government subsidies 11,578,308.38 4,329,658.84 Tax refund 2,620,310.27 Project allocation 16,750,377.36 Maternity allowance 547,185.69 Factoring payment 26,644,041.00 18,264,877.00 Advance payment returned 1,107,498.03 Others 1,416,592.55 2,272,506.73

Total 46,578,590.08 51,723,997.12

Other cash paid related to operating activities

Items Amount incurred in the current period Service fees incurred in the previous period 1,547,290.41 4,593,864.44 Security deposit 6,701,608.52 15,490,402.47 Current accounts 15,804,441.22 26,748,186.40 Repair, inspection and maintenance fees 9,972,638.00 8,728,713.38 Travel expenses 9,569,111.27 6,705,351.84 Water and electricity expenses 5,491,441.22 6,118,707.53 Rental expenses 2,635,744.71 2,408,523.59 Office expenses 2,865,685.73 2,340,501.68 Business entertainment fees 960,901.00 1,641,294.68 Conference fees 1,876,591.00 1,264,715.84 Security and cleaning fees 2,507,985.21 2,435,675.33 Intermediary fees 3,985,408.02 4,408,546.63 Labor fee 732,073.75 318,559.14 Board of Directors fee 72,592.13 8,280.00 Transportation fee 1,569,338.32 1,196,712.62 Research and development fee 495,310.00 164,655.00 Consulting fee 51,880.00 Advertising fee 61,250.40 176,745.80 Factoring fee 44,525,730.00 11,369,228.50 Others 6,727,283.65 4,492,608.09

Total 118,102,424.56 100,663,152.96

Other cash received related to investment activities

Item Amount incurred in the current period Amount incurred in the previous period Time deposit 86,261,411.25 0.00 Interest income, etc. 0.00 566,839.00

Total 86,261,411.25 566,839.00

Other cash paid related to investment activities

Item Amount for the current period Amount for the previous period

Expenditures under construction 0.00 transferred to one-year time deposit 30,700,000.00

Total 30,700,000.00

Other cash received related to financing activities

Item Amount for the current period Amount for the previous period

Sale and leaseback 8,000,000.00 Small shareholder borrowings 1,150,000.00 2,760,000.00

Total 1,150,000.00 10,760,000.00

Other cash paid related to financing activities

Item Amount for the current period Amount for the previous period

Payment of lease liabilities 3,241,822.43 6,184,130.06 Payment of equity acquisition 33,400,000.00

Total 3,241,822.43 39,584,130.06

Supplementary information to cash flow statement

(1) Supplementary information to the consolidated cash flow statement

Item Amount for the current period Amount for the previous period 1. Adjust net profit to cash flow from operating activities:

Net profit 186,193,281.72 147,620,829.23 Plus: asset impairment provision 7,249,859.85 -3,016,177.39 Credit impairment loss 8,203,299.30 5,419,793.09 Fixed asset depreciation, oil and gas asset depletion, productive biological assets

47,418,408.47 39,657,227.48 Depreciation

Depreciation of right-of-use assets 2,656,043.55 3,958,770.75 Amortization of intangible assets 5,102,483.09 5,229,613.14 Amortization of long-term prepaid expenses 1,563,533.35 1,939,777.37 Losses on disposal of fixed assets, intangible assets and other long-term assets

6,570.12 -1,230,866.06 (Income is listed with "-")

Losses from scrapping of fixed assets (income is listed as "-") - 6,483.72 Loss from changes in fair value (income is listed as "-") - 0.00 Financial expenses (income is listed as "-") 9,079,995.65 7,100,884.99 Investment losses (income is listed as "-") -34,795,772.58 -32,101,493.01 Decrease in deferred income tax assets (increases are indicated with "-") -17,539,059.71 -15,204.19 Increase in deferred income tax liabilities (decreases are indicated with "-") -424,475.44 -547,193.11 Decrease in inventories (increases are indicated with "-") -51,350,611.72 -15,414,228.10 Decrease in operating receivables (increases are indicated by "-") -135,778,866.07 -134,249,942.29 Increase in operating payables (decreases are indicated by "-") 12,941,819.67 -29,719,350.21 Others 15,015,058.18 7,229,446.72 Net cash flow generated from operating activities 55,541,567.43 1,868,372.13 2. Major investments and financing activities that do not involve cash receipts and payments:

debt to capital

Convertible corporate bonds due within one year

Financing leased fixed assets

Net changes in cash and cash equivalents:

Closing balance of cash 648,179,701.24 560,425,283.87 Less: Opening balance of cash 568,240,332.70 571,944,327.87 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents 79,939,368.54 -11,519,044.00

(2) Net cash paid in the current period to acquire subsidiaries

None.

(3) Net cash received from disposing of subsidiaries in the current period

None.

(4) Cash and cash equivalents

Item Closing balance Opening balance Cash 648,179,701.24 568,240,332.70 Including: cash on hand

Bank deposits that can be used for payment at any time 648,179,701.24 568,240,332.70 Cash equivalents

Including: Bond investments due within three months

Balance of cash and cash equivalents at the end of the period 648,179,701.24 568,240,332.70 Including: restricted cash and cash equivalents used by the parent company or subsidiaries within the group

Foreign currency monetary items

(1) Foreign currency monetary items

Item Foreign currency balance at the end of the period Conversion exchange rate Monetary funds converted into RMB at the end of the period - - 23,793.40 Including: US dollars 3,493.43 6.8109 23,793.40 Accounts receivable - - 585,211.33 Including: US dollars 85,922.76 6.8109 585,211.33 Accounts payable 21,253,604.41 Including: US dollars 2,339,486.50 6.8109 15,934,008.60 Euros 683,648.15 7.7671 5,309,963.55 Australian dollars 2,058.00 4.6804 9,632.26

6. R&D expenditures

Item Amount for the current period Amount for the previous period

Technical service fee 24,754,627.22 60,290,917.11 Employee compensation 33,447,973.27 37,755,316.59 Material fee 21,978,766.61 28,729,897.40 Depreciation and amortization 6,362,113.81 5,039,159.92 Labor protection fee 1,507,949.56 1,323,563.25 Intermediary service fee 634,261.58 1,326,531.61 Others 4,647,270.34 3,686,128.72 Total 93,332,962.39 138,151,514.60 Including: Expenditure R&D expenditure 66,424,384.41 63,901,411.29 Capitalized R&D expenditure 26,908,577.98 74,250,103.31

R&D projects that meet capitalization conditions

Increase amount in this period Decrease amount in this period

Confirm

transfer in

Item Opening balance It is Ending balance Internal development expenditure Current period Others

He is invisible

Profit and loss

assets

Lutetium[177Lu]Oxoctreotide

Drug development and clinical trials of injections 100,364,700.77 3,629,501.96 103,994,202.73

[18F]Florastamin injection

67,764,002.40 6,883,392.84 74,647,395.24 Research and development of liquid

Diagnostic iodine [131 I] benzyl

21,702,604.20 1,055,233.75 22,757,837.95 Guanidine injection project

Gallium [68Ga] Dotain Skin Injection

22,124,046.12 4,578,692.38 26,702,738.50 Drug research and development for ejaculation

Technetium [99mTc] Sulfur Colloidal Drug

24,287,932.95 1,297,414.19 25,585,347.14 Registration declaration of goods

6-[18F]fluoro-L-dopa injection

14,966,900.62 2,225,055.09 17,191,955.71 Liquid drug research and development

for Alzheimer's disease

Diagnostic Fluor[18F]Beta

8,535,991.84 7,239,287.77 15,775,279.61 Drug development for zine injection

and clinical trials

Total 259,746,178.90 26,908,577.98 286,654,756.88

(1) Important capitalized R&D projects:

Estimated completion Estimated economic benefits Commencement of capitalization Projects to begin capitalization R&D progress

time point of production method specific basis

Produce and sell

Development of diagnostic iodine [131I] benzylguanidine in progress

Drug production experience in December 2029 Injection project in January 2016

economic interests

Produce and sell

[18F]Florastamin injection research and development in progress

Drug production process in June 2030 Research and development in March 2023

economic interests

Produce and sell

Research and development of technetium [99mTc] sulfur colloidal drugs is in progress

December 2028 Drug Production Process January 2023 Registration Application

Obtain national pharmaceutical economic benefits

Supervise production and sales

Council's "Drug Pro 6-[18F] Fluoro-L-dopa Injection Research and Development Progress"

December 2028 Drug production process April 2023 Drug development for clinical trials In progress

Economic Interest Approval" and enter

Phase III clinical trial for Alzheimer's disease diagnosis, production and sales

R&D progress: Fluoro[18F]betazine injection December 2029 Drug production experience Mid-September 2024

Drug development and clinical trials Economic benefits

Produce and sell

Research and development of gallium [68Ga] Doteran injection is in progress

December 2027 Drug production process February 2023 drug development in progress

economic interests

Lutetium [177Lu] oxyoctreotide injection production and sales

R&D is carried out

Liquid drug development and clinical trials December 2029 Drug production experience Mid-May 2024

experience economic benefits

(2) There is no provision for impairment of development expenditures.

There are no important outsourced research projects.
Changes in the scope of merger 1. No merger of enterprises not under common control.
No merger of enterprises under common control.
Reverse takeover

None.

Disposal of subsidiaries

None.

There are no changes in the scope of consolidation due to other reasons.

8. Interests in other entities

Interests in subsidiaries

(1) Composition of enterprise groups

Shareholding ratio to voting rights ratio

Registered main business

Preface Subsidiary name Abbreviation Place of registration (%) Example (%) place

capital nature

Square

room

No. directly

formula

pick up

1 Beijing Shuangyuan Isotope Technology Co., Ltd. Shuangyuan Company 1,100.00 Beijing Beijing Sales of some radioactive sources 50.00 50.00 2 2 Jinan Atomic High-tech Pharmaceutical Co., Ltd. Jinan High-tech 4,100.00 Jinan Jinan Pharmaceutical production and sales 100.00 100.00 1 3 Nanning Atomic High-tech Pharmaceutical Co., Ltd. Nanning High-tech 5,260.00 Nanning Nanning Pharmaceutical production and sales 100.00 100.00 1 4 Kunming Atom Hi-Tech Pharmaceutical Co., Ltd. Kunming Hi-Tech 3,330.00 Kunming Kunming Pharmaceutical production and sales 100.00 100.00 1 5 Beijing Atomic Hi-Tech Fuyuan Industry and Trade Co., Ltd. Fuyuan Industry and Trade 66.00 Beijing Beijing Transportation of dangerous goods, etc. 100.00 100.00 1 6 Changsha Atom Hi-Tech Pharmaceutical Co., Ltd. Changsha Hi-Tech 3,690.00 Liuyang Liuyang Pharmaceutical production and sales 70.00 70.00 1 7 Chongqing Atomic Hi-Tech Pharmaceutical Co., Ltd. Chongqing Hi-Tech 3,685.00 Chongqing Chongqing Pharmaceutical production and sales 100.00 100.00 1 8 Wuhan Atom Hi-Tech Pharmaceutical Co., Ltd. Wuhan Hi-Tech 3,500.00 Wuhan Wuhan Pharmaceutical production and sales 60.00 60.00 1 9 Yichang Atomic Hi-Tech Pharmaceutical Co., Ltd. Yichang Hi-Tech 4,777.00 Yichang Yichang Pharmaceutical production and sales 80.00 80.00 1 10 Tianjin Atomic Hi-Tech Isotope Pharmaceutical Co., Ltd. Tianjin Hi-Tech 3,000.00 Tianjin Tianjin Pharmaceutical production and sales 100.00 100.00 1 11 Nanjing Atomic Hi-Tech Pharmaceutical Co., Ltd. Nanjing Hi-Tech 4,700.00 Nanjing Nanjing Pharmaceutical production and sales 80.00 80.00 1 12 Xuzhou Atomic Hi-Tech Pharmaceutical Co., Ltd. Xuzhou Hi-Tech 4,250.00 Xuzhou Xuzhou Pharmaceutical production and sales 80.00 80.00 1Beijing Atomic Hi-Tech Jinhui Radiation Technology Application Co., Ltd.

Jinhui Radiation 2,700.00 Beijing Beijing Development, transfer and application of radiation technology 51.00 51.00 1

Responsible company

14 Zhengzhou Atom Hi-Tech Pharmaceutical Co., Ltd. Zhengzhou Hi-Tech 6,060.00 Zhengzhou Zhengzhou Pharmaceutical production and sales 100.00 100.00 1 15 Shenyang Atomic Hi-Tech Pharmaceutical Co., Ltd. Shenyang Hi-Tech 1,535.00 Shenyang Shenyang Pharmaceutical production and sales 100.00 100.00 1 16 Shantou Atomic Hi-Tech Pharmaceutical Co., Ltd. Shantou Hi-Tech 3,350.00 Shantou Shantou Pharmaceutical production and sales 70.00 70.00 1 17 Guangzhou Atomic Hi-Tech Isotope Pharmaceutical Co., Ltd. Guangzhou Hi-Tech 1,680.00 Guangzhou Guangzhou Pharmaceutical production and sales 80.00 80.00 2 18 Sichuan Atomic Hi-Tech Pharmaceutical Co., Ltd. Sichuan Hi-Tech 3,764.00 Sichuan Sichuan Pharmaceutical production and sales 100.00 100.00 1 19 Atom Hi-Tech North China Pharmaceutical Co., Ltd. North China Hi-Tech 32,000.00 Zhuozhou Zhuozhou Pharmaceutical production and sales 100.00 100.00 1 20 Paite (Beijing) Technology Co., Ltd. Paite Technology 400.00 Beijing Beijing Production and sales of special equipment 51.00 51.00 3 21 Nanchang Atomic High-tech Pharmaceutical Co., Ltd. Nanchang High-tech 4,460.00 Nanchang Nanchang Pharmaceutical production and sales 70.00 70.00 1 22 Qingdao Atomic High-tech Pharmaceutical Co., Ltd. Qingdao High-tech 5,000.00 Qingdao Qingdao Pharmaceutical production and sales 100.00 100.00 1 23 Zhejiang Xinyuan Pharmaceutical Co., Ltd. Huzhou Hi-Tech 6,400.00 Hangzhou Hangzhou Pharmaceutical production and sales 51.00 51.00 1 24 Zhejiang Hengdian Atomic Hi-Tech Pharmaceutical Co., Ltd. Hengdian Hi-Tech 4,500.00 Zhejiang Zhejiang Pharmaceutical production and sales 51.00 51.00 1 25 Shijiazhuang Atom Hi-Tech Pharmaceutical Co., Ltd. Shijiazhuang Hi-Tech 4,200.00 Shijiazhuang Shijiazhuang Pharmaceutical production and sales 100.00 100.00 1 26 Lanzhou Atomic Hi-Tech Pharmaceutical Co., Ltd. Lanzhou Hi-Tech 6,000.00 Lanzhou Lanzhou Pharmaceutical production and sales 90.00 90.00 1 27 Changchun Atomic Hi-Tech Pharmaceutical Co., Ltd. Changchun High-tech 1,170.00 Changchun Changchun Pharmaceutical production and sales 100.00 100.00 1 28 Xi'an Atomic High-tech Pharmaceutical Co., Ltd. Xi'an High-tech 5,360.00 Xi'an Xi'an Pharmaceutical production and sales 75.75 75.75 1 29 Guiyang Atomic High-tech Pharmaceutical Co., Ltd. Guiyang High-tech 3,250.00 Guiyang Guiyang Pharmaceutical production and sales 85.00 85.00 1 30 Taiyuan Atomic High-Tech Pharmaceutical Co., Ltd. Taiyuan Hi-Tech 5,048.00 Taiyuan Taiyuan Pharmaceutical production and sales 100.00 100.00 1 31 Hefei Atomic High-tech Pharmaceutical Co., Ltd. Hefei Hi-Tech 4,410.00 Hefei Hefei Pharmaceutical production and sales 100.00 100.00 1 32 Hangzhou Atomic Hi-Tech Pharmaceutical Co., Ltd. Hangzhou Hi-Tech 100.00 Hangzhou Hangzhou Pharmaceutical production and sales 100.00 100.00 1 33 Shanghai Atomic Sinovac Pharmaceutical Co., Ltd. Shanghai Sinovac 8,432.00 Shanghai Shanghai Pharmaceutical production and sales 70.00 70.00 3 34 Xinjiang Atom Hi-Tech Pharmaceutical Co., Ltd. Xinjiang Hi-Tech 3,200.00 Xinjiang Xinjiang Pharmaceutical production and sales 76.00 76.00 1 35 Fuzhou Atomic Hi-Tech Pharmaceutical Co., Ltd. Fuzhou Hi-Tech 4,200.00 Fuzhou Fuzhou Pharmaceutical production and sales 70.00 70.00 1 36 Guangzhou Atomic Hi-Tech Pharmaceutical Technology Co., Ltd. Guangzhou Pharmaceutical 20,702.48 Guangzhou Guangzhou Technology promotion services 100.00 100.00 3 37 Zhanjiang Atom Hi-Tech Pharmaceutical Co., Ltd. Zhanjiang Hi-Tech 3,500.00 Guangdong Guangdong Pharmaceutical production and sales 100.00 100.00 1 38 Nanyang Atomic Hi-Tech Pharmaceutical Co., Ltd. Nanyang Hi-Tech 3,000.00 Henan Henan Pharmaceutical production and sales 100.00 100.00 1 39 Haikou Atom Hi-Tech Pharmaceutical Co., Ltd. Haikou Hi-Tech 3,750.00 Hainan Hainan Pharmaceutical production and sales 100.00 100.00 1 40 Nanchong Atomic Hi-Tech Pharmaceutical Co., Ltd. Nanchong Hi-Tech 2,750.00 Sichuan Sichuan Pharmaceutical production and sales 100.00 100.00 1 Ningbo Junan Pharmaceutical Technology Co., Ltd. Ningbo Junan 124.11 Ningbo Zhejiang Pharmaceutical production and sales 100.00 100.00 2

Acquisition method: 1. Investment establishment, 2. Business merger under the same control, 3. Business merger not under the same control

(2) Important non-wholly owned subsidiaries

The name of the subsidiary with minority shareholders' rights at the end of the period is attributed to minority shareholders in this period.

Share ratio Profit and loss of several shareholders Balance of dividends declared Guangzhou Hi-tech 20.00% 3,043,050.87 21,325,639.68 Shanghai Kexing 30.00% 5,637,532.55 93,575,696.53 (3) Main financial information of important non-wholly owned subsidiaries

Ending balance

Subsidiary name

Current assets Non-current assets Total assets Current liabilities Non-current liabilities Total liabilities Guangzhou Hi-tech 129,777,407.40 33,134,944.16 162,912,351.56 53,933,792.97 2,350,360.15 56,284,153.12 Shanghai Kexing 172,830,889.30 263,495,246.19 436,326,135.49 118,747,938.90 5,659,208.15 124,407,147.05 (continued)

Opening balance

Subsidiary name

Current assets Non-current assets Total assets Current liabilities Non-current liabilities Total liabilities Guangzhou Hi-tech 107,567,249.21 35,754,560.92 143,321,810.13 50,127,464.23 2,643,222.41 52,770,686.64 Shanghai Kexing 143,600,270.12 226,181,983.09 369,782,253.21 71,658,852.70 5,660,191.79 77,319,044.49 (continued)

Amount for the current period Amount for the previous period

Subsidiary name

Operating income Net profit Total comprehensive income Cash flow from operating activities Operating income Net profit Total comprehensive income Cash flow from operating activities Guangzhou Hi-Tech 59,591,329.70 15,215,254.36 15,215,254.36 30,585,315.34 59,504,242.76 20,762,108.16 20,762,108.10 28,886,657.56 Shanghai Sinovac 93,433,606.29 18,791,775.16 18,791,775.16 30,335,185.20 74,196,855.20 18,733,307.69 18,733,307.69 27,814,886.78

(4) Significant restrictions on the use of enterprise group assets and repayment of enterprise group debts

None.

(5) Financial support or other support provided to structured entities included in the scope of consolidated financial statements

None.

Situation where the ownership share of the subsidiary changes and the subsidiary is still controlled

(1) Changes in the owner’s equity share of subsidiaries

None.

(2) The impact of changes in the owner’s equity share of subsidiaries on equity

None.

Interests in joint ventures or associated enterprises

(1) Important joint ventures or associates

Shareholding ratio (%) to joint ventures

joint venture or major or associate

Name of associated enterprise Business nature Business

land directly indirect

Accountants Calling Camp Investments

Treatment method Headway Company Shenzhen Shenzhen Production and sales of pharmaceutical products 20.00 Equity method (2) Main financial information of important associates

Ending balance/amount of the current period Beginning balance/amount of the previous period

Headway Corporation Headway Corporation

current assets

3,591,748,605.74 3,909,677,086.99 Including: cash and cash, etc.

1,190,354,588.72 1,154,094,995.98 price

non-current assets

940,074,400.42 731,472,161.79 Total assets 4,531,823,006.16 4,641,149,248.78 Current liabilities 1,863,090,799.76 2,011,150,482.54 Non-current liabilities 112,966,022.35 114,754,884.83 Total liabilities 1,976,056,822.11 2,125,905,367.37 Total net assets 2,555,766,184.05 2,515,243,881.41 Including: minority shareholders’ equity 105,539,040.97 93,309,294.43 Attributable to shareholders of the parent company

2,450,227,143.08 2,421,934,586.98 profit

Net calculated based on shareholding ratio

490,045,428.61 484,386,917.40 Asset share

Adjustments

--Goodwill

--Unrealized profits from internal transactions

Run

--Others -5,725,160.25 -5,472,305.41 Equity investment in associates

Book value of 484,320,268.36 478,914,611.99

There is a publicly quoted pool

Fairness of corporate equity investment

value

Operating income 782,560,698.38 788,662,974.54Financial expenses -1,294,898.28 1,337,266.55Income tax expenses 52,845,564.59 47,933,933.99Net profit 188,430,470.18 182,456,779.45 Net profit from discontinued operations

other comprehensive income

Total comprehensive income 188,430,470.18 182,456,779.45 Received in this period from associates

corporate dividends

(3) Summary financial information of unimportant joint ventures and associates

Item Ending balance/amount of the current period Beginning balance/amount of the previous period

Current assets 116,832,527.02 104,781,423.51 Including: cash and cash, etc.

30,179,617.30 25,527,741.93 price

Non-current assets 58,908,520.51 62,272,617.65 Total assets 175,741,047.53 167,054,041.16 Current liabilities 78,037,958.37 64,539,220.35 Non-current liabilities 9,585,755.17 7,722,176.76 Total liabilities 87,623,713.54 72,261,397.11 Total net assets 88,117,333.99 94,792,644.05 Including: minority shareholders’ equity

Shareholders' rights vested in the parent company

88,117,333.99 94,792,644.05 profit

Net calculated based on shareholding ratio

27,162,066.41 29,024,779.07 Asset share

Adjustments

--Goodwill

--Unrealized profits from internal transactions

Run

--Others 3,037,479.56 1,612,698.60 Equity investment in associates

Book value of 30,199,545.97 30,637,477.67

There is a publicly quoted pool

Fairness of corporate equity investment

value

Operating income 23,339,358.76 1,761,132.06Financial expenses 304,744.19 -46,206.16Income tax expenses 89,540.67 36,807.65Net profit -6,590,391.20 -6,115,222.52Net profit from discontinued operations

other comprehensive income

Total comprehensive income -6,590,391.20 -6,115,222.52 Received in this period from associates

corporate dividends

(4) Significant restrictions on the ability of joint ventures or associates to transfer funds to the company

None.

(5) Excess losses incurred by joint ventures or associates

None.

(6) Unconfirmed commitments related to investment in joint ventures

None.

(7) Contingent liabilities related to investments in joint ventures or associates

None.

Important joint operations

None.

Structured entities not included in the scope of consolidated financial statements

None.

9. Risks related to financial instruments

The Group faces various financial instrument risks in its daily activities, mainly including market risk, credit risk and liquidity risk. The risks associated with these financial instruments, and the risk management policies adopted by the Group to mitigate these risks, are described below. The management of the Group manages and monitors these risk exposures to ensure that the above risks are controlled within limited limits.

The Group's goal in risk management is to achieve an appropriate balance between risks and returns, minimize the negative impact of risks on the Group's operating performance, and maximize the interests of shareholders and other equity investors. Based on this risk management objective, the Group's basic risk management strategy is to determine and analyze the various risks faced by the Group, establish an appropriate risk tolerance bottom line and conduct risk management, and supervise various risks in a timely and reliable manner to control risks within a limited range.

(1) Market risk

Exchange rate risk

The Group's exposure to exchange rate risks is mainly related to the US dollar, Euro and Australian dollar. Except for several of the Group's subsidiaries that purchase and sell in foreign currencies, the Group's other main business activities are denominated and settled in RMB. As of June 30, 2026, except for the balances of assets and liabilities in US dollars, euros and Australian dollars as described in the table below, the Group's assets and liabilities are all in RMB balances. The exchange rate risk arising from such foreign currency balance assets and liabilities may have an impact on the Group's operating results. Project June 30, 2026 December 31, 2025

Monetary funds - US dollars 3,493.43 287,332.54 Monetary funds - Euros 18,190.73 Accounts receivable - US dollars 85,922.76 161,469.76 Accounts payable - US dollars 2,339,486.50 3,224,151.56 Accounts payable - Euros 683,648.15 822,479.09

Accounts payable - Australian dollars 2,058.00 2,058.00

The Group pays close attention to the impact of exchange rate changes on the Group.

Interest rate risk

The Group's interest rate risk arises from bank borrowings. Financial liabilities with floating interest rates expose the Group to cash flow interest rate risk, while financial liabilities with fixed interest rates expose the Group to fair value interest rate risk. The Group determines the relative proportion of fixed-rate and floating-rate contracts based on the prevailing market environment. As of June 30, 2026, the Group's interest-bearing debts were mainly RMB-denominated fixed-rate contracts, with an amount of RMB 827,789,338.43 (December 31, 2025:

908,657,370.95 yuan).

(2) Credit risk

As of June 30, 2026, the maximum credit risk exposure that may cause the Group's financial losses mainly comes from the loss of the Group's financial assets due to the failure of the other party to the contract to perform its obligations and the financial guarantees undertaken by the Group, specifically including: the carrying amount of the financial assets recognized in the consolidated balance sheet; for financial instruments measured at fair value, the book value reflects its risk exposure, but not the maximum risk exposure, and its maximum risk exposure will change with changes in fair value in the future.

In order to reduce credit risks, the Group has established a special department to determine credit limits, conduct credit approval, and implement other monitoring procedures to ensure that necessary measures are taken to recover overdue claims. In addition, the Group reviews the recovery status of each individual receivable on each balance sheet date to ensure that sufficient bad debt provisions are made for unrecoverable amounts. Therefore, the management of the Group believes that the credit risk borne by the Group has been greatly reduced.

The Group's working capital is deposited in financial institutions such as banks with higher credit ratings, so the credit risk of working capital is low.

The Group has adopted necessary policies to ensure that all sales customers have good credit records. Except for the top five accounts receivable and contract assets, the Group has no other significant concentration of credit risk. Among the Group's accounts receivable and contract assets, the top five accounts totaled RMB 143,927,839.46, accounting for 11.22% of the Company's total accounts receivable and contract assets.

10. Disclosure of fair value

Closing fair value of assets and liabilities measured at fair value

Closing fair value

second floor

Project Level 1 Level 3

Sub-Fair Total Fair Value Fair Value

value measurement

Measurement Measurement

1. Continuous fair value measurement

(1) Accounts receivable financing 15,082,826.35 15,082,826.35

Total assets continuously measured at fair value 15,082,826.35 15,082,826.35

Total liabilities measured at fair value on an ongoing basis

2. Non-continuous fair value measurement

Total assets measured at fair value on an ongoing basis

Total liabilities measured at fair value on an ongoing basis

Basis for determining the market price of continuous and non-continuous first-level fair value measurement items

None.

Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters

None.

Continuous and non-continuous third-level fair value measurement projects, valuation techniques used and qualitative and quantitative information on important parameters

The Group's receivables are financed by bank acceptance bills from listed commercial banks with short terms. The fair value of the third level is determined based on the book value.

11. Related parties and related transactions

(1) Related party relationships

(1) Information about the company’s parent company

parent company to parent company

The name of the company’s parent company, the place of registration, the nature of the business, the registered capital, the company’s shareholdings

Voting rights ratio (%)

Example(%)

radiopharmaceuticals, radiation

China Tongfang Beijing 319.8749 million yuan 69.49 69.49 Source sales

Nuclear military industry, nuclear energy, nuclear

CNNC Beijing 59.5 billion yuan

technology industry

The ultimate controller of the company is CNNC.

(2) Information about the company’s subsidiaries

For details on subsidiaries, please refer to the relevant content in "VIII. 1. (1) Composition of the Enterprise Group" in this note.

(3) Information about the company’s joint ventures and associates

For details of the Company's important joint ventures or associates, please refer to the relevant content in "VIII. 3. (1) Important joint ventures or associates" of this note.

(4) Other related parties

Names of other related parties Relationship with the enterprise Beijing Sanjin Electronics Group Co., Ltd. The same controlling shareholder, Chengdu CNNC Qualcomm Isotope Co., Ltd. The same controlling shareholder, Shenzhen CNNC Haideway Biotechnology Co., Ltd. The same controlling shareholder, Sichuan CNNC Homology Technology Co., Ltd. The same controlling shareholder, China Uniform Radiation Co., Ltd. The same controlling shareholder, CNNC (Yulin) Irradiation Co., Ltd. The same controlling shareholder, CNNC High Energy (Tianjin) Equipment Co., Ltd. The same controlling shareholder, CNNC Lixin (Beijing) Technology Co., Ltd. The same controlling shareholder CNNC Tongren (Changchun) Radiation Technology Co., Ltd. The same controlling shareholder Sichuan CNNC Qualcomm Pharmaceutical Co., Ltd. The same controlling shareholder CNNC (Xinghua) Irradiation Technology Co., Ltd. The same controlling shareholder Beijing Guoyuan New Technology Co., Ltd. The same ultimate controller Beijing Nuclear Industry Hospital The same ultimate controller Beijing Tongfang Software Co., Ltd. The same ultimate controller Dalian CNNC Science and Technology Development Co., Ltd. The same ultimate controller Nuclear Industry Beijing Institute of Chemical Industry and Metallurgy The same ultimate controller Nuclear Industry 416 Hospital The same ultimate controller Nuclear Industry General Hospital The same ultimate controller China Baoyuan Investment Co., Ltd. The same ultimate controller China Institute of Radiation Protection. The same ultimate controller China Nuclear Power Engineering Co., Ltd. The same ultimate controller China Nuclear Power Research and Design Institute. The same ultimate controller China National Nuclear Industry Corporation 24 Construction Co., Ltd.. The same ultimate controller China National Nuclear Corporation. The same ultimate controller China Institute of Atomic Energy. The same ultimate controller CNNC (Shanghai) Supply Chain Management Co., Ltd.. The same ultimate controller CNNC Baotou Nuclear Fuel Elements Co., Ltd.. The same ultimate controller CNNC Finance Co., Ltd. The same ultimate controller, CNNC Seventh Research and Design Institute Co., Ltd. The same ultimate controller, CNNC Fourth Research and Design Engineering Co., Ltd. The same ultimate controller, CNNC Engineering Consulting Co., Ltd. The same ultimate controller, CNNC Information Technology (Beijing) Co., Ltd. The same ultimate controller, CNNC Kelly (Shenzhen) Catering Management Co., Ltd. The same ultimate controller, CNNC Control System Engineering Co., Ltd. The same ultimate controller, CNNC Lihua Fire Engineering Co., Ltd. The same ultimate controller, CNNC Energy Technology Co., Ltd. The same ultimate controller, CNNC Financial Leasing Co., Ltd. The same ultimate controller, CNNC Shandong Nuclear Energy Co., Ltd. The same ultimate controller, CNNC Suzhou Valve Co., Ltd. The same ultimate controller, CNNC 504 Hospital Management (Lanzhou) Co., Ltd. The same ultimate controller, CNNC Property Services Co., Ltd. The same ultimate controller, CNNC Medical Equipment (Suzhou) Co., Ltd. The same ultimate controller, CNNC Xinke (Tianjin) Technology Co., Ltd. The same ultimate controller, CNNC Nuclear Industry Management Cadre Academy. The same ultimate controller, CNNC Huawei Engineering Design Research Co., Ltd. The same ultimate controller, CNNC Nuclear Industry 230 Research Institute. The same ultimate controlling party CNNC Sichuan Environmental Protection Engineering Co., Ltd. The same ultimate controlling party CNNC Shaanxi Uranium Enrichment Co., Ltd. The same ultimate controlling party

Xingyuan Certification Center Co., Ltd. The same ultimate controlling party

Nuclear Industry Standardization Institute Same ultimate controlling party

CNNC (Ningxia) Tongxin Protection Technology Co., Ltd. The same ultimate controlling party

China Institute of Nuclear Science and Technology Information and Economics Same ultimate controlling party

CNNC (Beijing) Media Culture Co., Ltd. The same ultimate controlling party

Shanghai Xinke Pharmaceutical Co., Ltd. Controlling shareholder joint venture

Hubei Zhongxun Medical Supplies Industrial Co., Ltd. Associate Company

Guangzhou Zhongshan Pharmaceutical Technology Development Co., Ltd. Associate Company

(2) Related transactions

(1) Related transactions related to the purchase and sale of goods, provision and receipt of services

Purchasing goods/receiving services

Related parties Contents of related transactions Amount incurred in the current period Amount incurred in the previous period China Tongfu Co., Ltd. Purchase of goods or services 55,347,098.30 7,182,492.62 China Institute of Atomic Energy Purchase of goods or services 4,204,766.09 4,742,364.03 Beijing Sanjin Electronics Group Co., Ltd. Purchase of goods or services 2,823,197.23 1,163,463.24 Dalian CNNC Technology Development Co., Ltd. Purchase of fixed assets 1,252,831.86 0.00 Chengdu CNNC Qualcomm Isotope Co., Ltd. Purchase of goods or services 1,246,914.12 1,841,731.32 CNNC Property Services Co., Ltd. Purchase and construction of long-term assets 1,102,032.08 344,935.40 China Tongradio Co., Ltd. Purchase and construct long-term assets 283,185.84 771,238.94 Shenzhen CNNC Haideway Biotechnology Co., Ltd. Purchase goods or services 210,159.31 4,306,926.30 CNNC Engineering Consulting Co., Ltd. Purchase goods or services 95,101.51 264,620.75 CNNC (Shanghai) Supply Chain Management Co., Ltd. Purchase of fixed assets 41,626.55 297,106.62 China Institute of Radiation Protection Purchase of goods or services 0.00 2,098,176.66 China Nuclear Industry Ersi Construction Co., Ltd. Purchase and construction of long-term assets 0.00 1,336,127.38 Beijing Tongfang Software Co., Ltd. Purchase of goods or services 0.00 377,169.81 CNNC Lihua Fire Engineering Co., Ltd. Purchase goods or services 0.00 280,733.94 Dalian CNNC Technology Development Co., Ltd. Purchase goods or services 0.00 256,637.17 China National Nuclear Industry Huaxing Construction Co., Ltd. Purchase and construct long-term assets 0.00 0.00 CNNC Kelly (Shenzhen) Catering Management Co., Ltd. Purchase goods or services 0.00 53,806.00 Others Purchase of goods or services and

2,397,510.66 1,198,014.34

assets

Total 69,004,423.55 26,515,544.52

Selling goods/providing services

Related parties Contents of related transactions Amount for the current period Amount for the previous period China Institute of Atomic Energy Sales of goods or services 27,412,499.82 20,845,132.75 Chengdu CNNC Qualcomm Isotope Co., Ltd. Sales of goods or services 9,855,578.60 5,806,423.79 China Tongradio Co., Ltd. Sales of goods or services 8,641,237.81 5,496,188.18 Sichuan CNNC Homology Technology Co., Ltd. Sales of goods or services 6,853,539.83 0.00 Beijing Nuclear Industry Hospital Sales of goods or services 3,425,787.89 1,517,313.89 Shanghai Xinke Pharmaceutical Co., Ltd. Sales of goods or services 2,538,495.80 0.00 Nuclear Industry No. 416 Hospital Sales of goods or services 1,572,663.81 880,176.96 Nuclear Industry General Hospital Sales of goods or services 1,571,964.57 1,797,964.66 CNNC No. 504 Hospital Management (Lanzhou) Co., Ltd.

Sales of goods or services 440,654.90 424,053.09 Division

CNNC Control System Engineering Co., Ltd. Sales of goods or services 94,339.62 0.00 China Nuclear Industry Ersi Construction Co., Ltd. Sales of goods or services 0.00 16,461,179.07 CNNC (Yulin) Irradiation Co., Ltd. Sales of goods or services 0.00 5,146,157.30 China Nuclear Power Research and Design Institute Sales of goods or services 0.00 230,088.50 Others Sales of goods or services 117,933.86 116,493.58

Total 62,524,696.51 58,721,171.77

(2) Related entrusted management/contracting and entrusted management/outsourcing situation

None.

(3) Related leasing situation

Rental situation

None.

Leasing situation

①Operating lease

Name of the lessor Type of leased assets Lease fee recognized in the current period Lease fee recognized in the previous period Guangzhou Zhongshan Pharmaceutical Technology Development Co., Ltd.

House 324,736.26 334,073.41 Co., Ltd.

②Financial lease

Name of the lessor Type of leased assets Lease fees recognized in the current period Lease fees recognized in the previous period China Heli Financial Leasing Co., Ltd. Equipment 2,684,591.24 1,081,459.99 (4) Related guarantees

None.

(5) Fund lending by related parties

None.

(6) Related party financial services

Related party deposits and loans

①Related party deposits

Listed as "monetary funds", the amount of funds deposited into CNNC Finance Co., Ltd. is as follows:

Monetary Fund Project

Ending balance Opening balance Funds directly deposited into CNNC Finance Co., Ltd. 622,212,950.00 647,677,721.54 Funds collected from banks to CNNC Finance Co., Ltd.

Total 622,212,950.00 647,677,721.54

②Related party loans

Name of related party Loan amount Start date Maturity date Remarks

Long-term borrowing, credit borrowed from China National Nuclear Corporation Finance Co., Ltd. 2,650,000.00 2021-10-11 2029-10-11

loan, interest rate 3.00%

Long-term borrowings, mortgaged by China National Nuclear Corporation Finance Co., Ltd. 4,248,000.00 2022-5-27 2030-5-27

loan, interest rate 3.20%

Long-term borrowing, mortgaged by China National Nuclear Corporation Finance Co., Ltd. 6,050,000.00 2022-6-10 2030-6-10

loan, interest rate 3.15%

Long-term borrowing, mortgaged by China National Nuclear Corporation Finance Co., Ltd. 9,000,000.00 2022-10-10 2030-10-10

loan, interest rate 3.20%

Long-term borrowing, credit borrowed from China National Nuclear Corporation Finance Co., Ltd. 8,500,000.00 2022-10-13 2029-10-11

loan, interest rate 2.85%

Long-term borrowing, mortgaged by China National Nuclear Corporation Finance Co., Ltd. 4,300,000.00 2022-12-22 2030-6-10

loan, interest rate 3.15%

Long-term borrowing, mortgaged by China National Nuclear Corporation Finance Co., Ltd. 1,000,000.00 2023-3-6 2030-10-10

loan, interest rate 3.20%

Long-term borrowing, pledged to China National Nuclear Corporation Finance Co., Ltd. 2,600,000.00 2023-3-13 2030-6-10

loan, interest rate 3.15%

Long-term borrowing, mortgaged by China National Nuclear Corporation Finance Co., Ltd. 1,900,000.00 2023-5-23 2030-6-10

loan, interest rate 3.15%

Long-term loan, guaranteed loan from CNNC Finance Co., Ltd. 4,950,000.00 2023-11-30 2030-11-30

loan, interest rate 2.75%

Long-term loan, guaranteed loan from China National Nuclear Corporation Finance Co., Ltd. 4,400,000.00 2024-1-15 2031-1-15

loan, interest rate 2.75%

Long-term loan, guaranteed loan from CNNC Finance Co., Ltd. 1,000,000.00 2024-1-23 2030-11-30

loan, interest rate 2.75%

Long-term loan, guaranteed loan from China National Nuclear Corporation Finance Co., Ltd. 4,000,000.00 2024-3-8 2030-11-30

loan, interest rate 2.75%

Long-term borrowing, guaranteed borrowing from CNNC Finance Co., Ltd. 2,000,000.00 2024-5-10 2030-11-30

loan, interest rate 2.75%

Long-term loan, guaranteed loan from China National Nuclear Corporation Finance Co., Ltd. 6,000,000.00 2024-6-3 2030-11-30

loan, interest rate 2.75%

Long-term loan, guaranteed loan from CNNC Finance Co., Ltd. 4,000,000.00 2024-10-9 2030-11-30

loan, interest rate 2.75%

Long-term borrowing, credit borrowed from CNNC 48,100,000.00 2025-12-31 2028-12-31

loan, interest rate 1.80%

Short-term borrowings, credit borrowed from Headway Company 150,000,000.00 2025-11-24 2026-11-24

loan, interest rate 2.10%

Short-term borrowing, credit borrowed from Headway Company 150,000,000.00 2025-12-5 2026-11-24

loan, interest rate 2.10%

Total 537,058,000.00 — — —

(7) Asset transfer and debt restructuring of related parties

None.

(8) Other related transactions

None.

(3) Balances receivable and payable from related parties

(1) Items receivable

Ending balance Beginning balance

Project name Related parties

Book balance Provision for bad debts Book balance Provision for bad debts

Chengdu CNNC Qualcomm Isotope Stock

Accounts receivable 33,946,645.51 26,301,378.50

Co., Ltd.

Accounts receivable China Institute of Atomic Energy 13,614,397.50 773,821.98

Accounts receivable China Tonghe Co., Ltd. 9,669,340.00 15,037,355.00

China Nuclear High Energy (Tianjin) Equipment Co., Ltd.

Accounts receivable 6,048,000.00 6,048,000.00

Ltd.

Accounts receivable Beijing Nuclear Industry Hospital 4,660,968.00 48,450.76 3,515,852.30 37,285.61 Accounts receivable Beijing Nuclear Industry 416 Hospital 3,375,810.00 38,258.28 2,808,960.00 32,948.69 Accounts receivable General Hospital of Nuclear Industry 2,647,980.00 14,226.43 2,477,100.00 10,793.05 Accounts receivable Shanghai Xinke Pharmaceutical Co., Ltd. 2,196,500.00 22,832.62 1,535,500.00 16,283.98 Accounts receivable China Nuclear Power Research and Design Institute 1,250,000.00 723,949.80 1,337,500.00 228,010.13

CNNC 504 Hospital Management (Lanzhou

Accounts receivable 1,234,870.00 52,481.74 924,130.00 44,032.46zhou) Co., Ltd.

CNNC Medical Equipment (Suzhou) has

Accounts receivable 1,100,000.00 11,434.50 1,100,000.00 11,665.50 Co., Ltd.

1,030,427.3 Accounts receivable CNNC Energy Technology Co., Ltd. 1,030,427.35 1,028,825.04 1,030,427.35

Accounts receivable China Nuclear Power Engineering Co., Ltd. 0.00 0.00 1,545,100.00 11,124.72 Accounts receivable Others 100,000.00 1,039.50 558,300.00 87,577.98 Accounts receivable Subtotal

80,874,938.36 2,715,320.65 64,219,603.15 1,510,149.47

China National Nuclear Power Co., Ltd. (Changchun) Radiation Technology

Other receivables 2,160,000.00 2,160,000.00

technology co., ltd.

Hubei Zhongxun Medical Supplies Industry

Other receivables 1,300,582.66 776,218.54 1,234,684.66 776,218.54

Ltd.

Other receivables CNNC Financial Leasing Co., Ltd. 481,400.00 562,800.00

Sichuan CNNC Homology Technology Co., Ltd.

Other receivables 286,237.20 0.00

company

China National Nuclear Corporation Co., Ltd.

Other receivables 230,000.00 0.00

Division

Other receivables China Tonghe Co., Ltd. 198,400.00 0.00

Other receivables China Institute of Atomic Energy 277,699.00 181,674.23 261,594.95 181,674.23 Other receivables CNNC Suzhou Valve Co., Ltd. 157,778.28 0.00

Guangzhou Zhongshan Pharmaceutical Technology Development

Other receivables 0.00 129,100.00

Ltd.

Other receivables Dalian CNNC Technology Development Co., Ltd. 0.00 90,900.00

company

Other receivables Others 96,443.50 0.00

Other receivables Subtotal 5,188,540.64 957,892.77 4,439,079.61 957,892.77

Shenzhen CNNC Haideway Biology

Dividends receivable 29,828,047.91 0.00

Technology Co., Ltd.

Dividends receivable Subtotal 29,828,047.91 0.00 Prepayment China Institute of Radiation Protection 2,746,000.00 2,740,000.00

CNNC Lixin (Beijing) Technology Co., Ltd.

Prepayment 2,112,200.00 1,275,000.00 Co., Ltd.

Beijing Sanjin Electronics Group Co., Ltd.

Prepayment 3,537,075.70 0.00

company

Prepayments China Institute of Atomic Energy 1,128,985.16 105,434.10 Prepayments China Nuclear Power Research and Design Institute 0.00 378,000.00 Prepayments Others 239,683.00 45,465.35

Prepayments Subtotal 9,763,943.86 4,543,899.45

Long-term receivables China Institute of Atomic Energy 43,992,551.52 42,940,509.05

Long-term receivables Subtotal 43,992,551.52 42,940,509.05 Other non-current CNNC Nuclear Information Technology (Beijing)

1,084,009.43 0.00 Assets Beijing) Co., Ltd.

Other non-current

China Tongfang Co., Ltd. 146,250.00 146,250.00 Assets

Other non-current Dalian CNNC Technology Development Co., Ltd.

129,986.50 252,900.00 Assets Company

Other non-current CNNC Fourth Research and Design Project

0.00 273,584.90 Assets Co., Ltd.

Other non-current

Others 7,957.00 0.00Assets

Other non-current

Subtotal 1,368,202.93 672,734.90

assets

total

171,016,225.22 3,673,213.42 116,815,826.16 2,468,042.24

(2) Payable items

Project name Related parties Book balance at the end of the period Book balance at the beginning of the period Accounts payable China Tongradio Co., Ltd. 23,864,902.65 2,781,911.54 Accounts payable Shenzhen CNNC Haideway Biotechnology Co., Ltd. 2,846,945.85 4,624,110.00 Accounts payable Chengdu CNNC Qualcomm Isotope Co., Ltd. 3,556,631.58 2,563,581.00 Accounts payable Others 694,874.31 53,717.70

Accounts payable Subtotal 30,963,354.39 10,023,320.24 Contract liabilities CNNC Shandong Nuclear Energy Co., Ltd. 34,499,177.70 34,499,177.70 Contract liabilities CNNC Baotou Nuclear Fuel Elements Co., Ltd. 4,292,035.40 4,292,035.40 Contract liabilities China National Nuclear Corporation 391,259.19 0.00 Contract liabilities China Institute of Atomic Energy 242,110.53 8,290,606.11 Contract liabilities China National Nuclear Corporation 0.00 1,068,625.80 Contract liabilities Others 8,849.56 9,734.52

Contract liabilities Subtotal 39,433,432.38 48,160,179.53

Other payables China Institute of Atomic Energy 11,619,986.95 5,983,052.55 Other payables Beijing Sanjin Electronics Group Co., Ltd. 5,875,477.79 1,799,512.66 Other payables CNNC Radiation (Changchun) Radiation Technology Co., Ltd. 4,116,796.79 4,111,852.80 Other payables Chengdu CNNC Qualcomm Isotope Co., Ltd. 2,540,000.00 2,553,991.70 Other payables Dalian CNNC Technology Development Co., Ltd. 773,545.00 1,184,470.00 Other payables CNNC Seventh Research and Design Institute Co., Ltd. 636,757.05 636,757.05 Other payables China Tongradio Co., Ltd. 636,551.00 340,441.00 Other payables Nuclear Industry Beijing Research Institute of Chemical Industry and Metallurgy 398,000.00 398,000.00 Other payables CNNC Fourth Research and Design Engineering Co., Ltd. 316,800.00 446,800.00 Other payables CNNC Lixin (Beijing) Technology Co., Ltd. 225,600.00 150,100.00 Other payables Beijing Guoyuan New Technology Co., Ltd. 36,000.00 16,870,337.67 Other payables China National Nuclear Corporation Co., Ltd. 0.00 1,219,160.00 Other payables China Nuclear Power Engineering Co., Ltd. 0.00 1,130,000.00 Other payables Others 265,734.49 205,743.92 Other payables Subtotal 27,441,249.07 37,030,219.35 Dividends payable China Tongfang Co., Ltd. 62,956,522.72 0.00 Dividends payable CNNC Fourth Research and Design Engineering Co., Ltd. 2,240,000.00

Dividends payable Subtotal 65,196,522.72 0.00 Long-term payables China National Nuclear Corporation Co., Ltd. 43,365,003.86 42,044,249.14 Long-term payables CNNC Financial Leasing Co., Ltd. 11,487,272.19 13,233,707.17 Long-term payables China Baoyuan Investment Co., Ltd. 2,485,688.66 2,485,688.66 Long-term payables Subtotal 57,337,964.71 57,763,644.97 Lease liabilities China National Nuclear Corporation 1,671,615.66 1,631,640.44 Lease liabilities China Institute of Atomic Energy 0.00 20,795.34

Lease liabilities Subtotal 1,671,615.66 1,652,435.78

Non-payments due within one year

China Institute of Atomic Energy 2,971,061.42 2,881,591.58 Current liabilities

Non-payments due within one year

CNNC Financial Leasing Co., Ltd. 2,890,885.11 1,151,328.39 Current liabilities

Non-payments due within one year

China National Nuclear Corporation Co., Ltd. 127,207.56 124,165.51 Current liabilities

Non-payments due within one year

Subtotal 5,989,154.09 4,157,085.48

current liabilities

Total 228,033,293.02 158,786,885.35

(4) Related party commitments

(1) Guarantee details within the group

Guaranteed party Name of the guaranteed party Whether the guarantee has guaranteed amount Guarantee start date Guarantee expiry date

Name: Completed

The Company Guiyang Hi-Tech 26,618,882.63 2023-9-12 2033-10-30 No The Company Fuzhou Hi-Tech 20,650,000.00 2023-8-4 2033-8-3 No The Company Xinjiang Hi-Tech 17,628,395.73 2023-11-16 2033-11-16 No The company Nanjing Hi-Tech 17,520,000.00 2023-11-30 2030-11-30 No The company Nanjing Hi-Tech 14,800,000.00 2022-6-10 2030-6-10 No The company Xi'an Hi-Tech 8,963,057.65 2023-7-17 2031-7-16 No The company Guiyang Hi-Tech 5,780,000.00 2025-7-30 2026-7-29 No The company Xuzhou Hi-Tech 4,148,000.00 2022-5-27 2030-5-27 No The company Xuzhou Hi-Tech 3,520,000.00 2024-1-15 2031-1-15 No The company Haikou Hi-Tech 3,510,036.70 2025-12-30 2040-12-29 No The company Nanjing Hi-Tech 2,400,000.00 2026-3-6 2027-3-6 No this company Shantou Hi-Tech 2,100,000.00 2023-1-12 2028-1-12 No this company Zhengzhou Hi-Tech 1,723,231.80 2024-6-13 2033-6-1 No this company Shanghai Kexing 1,386,033.37 2024-10-18 2030-10-17 No

(5) Others

None.

12. Share-based payment

None.

13. Contingencies

None.

14. Commitments

None.

15. Events after the balance sheet date

None.

16. Other important matters

Correction and impact of early errors

None.

Debt restructuring

None.

Asset replacement

None.

Annuity plan

The Group has implemented the annuity plan since February 1, 2018 in accordance with the "Enterprise Annuity Implementation Rules of Atomic High-Tech Co., Ltd." approved on July 24, 2020.

Enterprise annuity payments are jointly borne by the enterprise and individual employees, and the annual total shall not exceed 12% of the total employee wages of the group for that year. Corporate contributions are accrued by the Group at the rate of 8% of the annual total employee wages and are expensed from costs. Individual employee contributions are 2% of their own contribution base. Under the condition that sufficient funds in the enterprise account are ensured, enterprise contributions based on 6% of the annual total employee wages will be recorded into the employees' personal accounts; the Group's Enterprise Annuity Management Committee regularly adjusts the benchmark value based on the use of enterprise accounts. Based on the actual salary income of employees in the previous period (determined based on employees’ social insurance contributions), the Group regularly determines the employee enterprise annuity payment base.

The Group's annuity plan did not undergo major changes during this period. 1. Termination of operations

None.

Other important transactions and matters that have an impact on investors’ decision-making

None.

Notes on main items in the parent company’s financial statements 1. Accounts receivable

(1) Accounts receivable are classified and presented according to the bad debt accrual method

Ending balance

Book balance Bad debt provision

Category

Ratio Provision Ratio Book Value Amount Amount

(%) Example (%)

Provision for bad debts on an individual basis 3,883,588.60 0.52 3,883,588.60 100 0.00 Provision for bad debts on a portfolio basis 738,933,289.29 99.47 54,795,828.15 7.42 684,137,461.14 Among them: general risk portfolio 453,591,261.58 61.06 54,795,828.15 12.08 398,795,433.43 Low-risk portfolio 285,342,027.71 38.41 0.00 0.00 285,342,027.71

Total 742,816,877.89 100 58,679,416.75 7.90 684,137,461.14

(continued)

Opening balance

Book balance Bad debt provision

Category

Ratio Provision Ratio Book Value Amount Amount

(%) Example (%)

Provision for bad debts based on individual items 3,883,588.60 0.67 3,883,588.60 100 0 Provision for bad debts based on combinations 580,030,357.73 99.33 53,010,906.59 9.14 527,019,451.14 Among them: general risk portfolio 390,770,553.03 66.92 53,010,906.59 13.57 337,759,646.44

Low-risk portfolio 189,259,804.70 32.41 189,259,804.70

Total 583,913,946.33 100.00 56,894,495.19 9.74 527,019,451.14

Provision for bad debts of accounts receivable on an individual basis

Ending balance

Name Provision Ratio

Book balance Bad debt provision Reason for provision (%)

It is estimated that the amount cannot be collected from Peking University Stomatological Hospital 591,300.00 591,300.00 100.00

return

Beijing Yuanbo Xinchuang Biomedical Engineering predicts that the payment will not be collected

520,395.41 520,395.41 100.00

Co., Ltd. back

It is estimated that the amount cannot be collected from Tianjin Medical University Second Hospital 458,898.00 458,898.00 100.00

return

It is expected that the amount cannot be collected Fuzhou Jiayi Pharmaceutical Co., Ltd. 411,000.00 411,000.00 100.00

return

It is estimated that the amount cannot be collected Hebi Jingli Hospital Co., Ltd. 337,400.00 337,400.00 100.00

return

It is estimated that the amount cannot be collected from Xiyuan Hospital of China Academy of Chinese Medical Sciences 166,320.00 166,320.00 100.00

return

The Seventh General Hospital of the Chinese People's Liberation Army 117,348.00 117,348.00 100.00 The estimated amount cannot be collected from the Medical Center Return

Joint Logistics Support Department of the Chinese People's Liberation Army It is estimated that the amount cannot be collected 116,300.00 116,300.00 100.00

Team 968 Hospital Return

It is estimated that the amount cannot be collected from Beijing Jishuitan Hospital 82,500.00 82,500.00 100.00

return

It is estimated that the amount cannot be collected from the First Affiliated Hospital of Sun Yat-sen University 71,241.90 71,241.90 100.00

return

It is estimated that the amount cannot be collected from Xuzhou Central Hospital 63,700.00 63,700.00 100.00

return

It is estimated that the amount cannot be collected from Beijing Sixth Hospital 63,000.00 63,000.00 100.00

return

It is estimated that the amount cannot be collected from the Capital Institute of Pediatrics 59,800.00 59,800.00 100.00

return

It is estimated that the amount cannot be collected from Yuzhou People's Hospital 56,850.00 56,850.00 100.00

return

It is estimated that the amount cannot be collected from Dongou Hospital, Wenzhou City, Zhejiang Province 51,700.00 51,700.00 100.00

return

The total estimated amount of the Eastern Theater Command of the Chinese People's Liberation Army cannot be collected 43,200.00 43,200.00 100.00

Hospital back

It is estimated that the amount cannot be collected from Yulin Third People's Hospital 40,931.00 40,931.00 100.00

return

It is estimated that the amount cannot be collected from Tsinghua University 40,250.00 40,250.00 100.00

return

It is estimated that the amount cannot be collected from Guilin Hospital of Integrated Traditional Chinese and Western Medicine 34,055.00 34,055.00 100.00

return

It is estimated that the amount cannot be collected Wenzhou Jintian Plastic Industry Co., Ltd. 31,000.00 31,000.00 100.00

return

It is estimated that the amount cannot be collected from Zhanjiang Central People's Hospital 25,600.00 25,600.00 100.00

return

It is expected that the amount cannot be collected from Yuzhou City Health and Epidemic Prevention Station of Henan Province 21,050.00 21,050.00 100.00

return

It is estimated that the amount cannot be collected from Zhangzhou Hospital of Fujian Province 20,000.00 20,000.00 100.00

return

No other payments are expected (single amount is less than 20,000) 459,749.29 459,749.29 100.00

return

Total 3,883,588.60 3,883,588.60 100.00 ——

Provision for bad debts of accounts receivable on a portfolio basis

①Accounts receivable for expected credit losses of general risk portfolio

Ending balance

Aging

Book balance Bad debt provision Proportion (%) Within 1 year (including 1 year) 377,983,256.29 3,929,289.59 1.04 1 to 2 years 28,839,035.46 4,611,794.36 15.99 2 to 3 years 3,927,558.50 3,447,610.85 87.78 3 to 4 years 1,703,436.96 1,674,495.57 98.30 4 to 5 years 3,431,889.55 3,426,552.96 99.84 More than 5 years 37,706,084.82 37,706,084.82 100.00

Total 453,591,261.58 54,795,828.15——

②Accounts receivable for expected credit losses of low-risk portfolio

Portfolio name Closing amount Reason for not accruing

Related parties within the scope of merger and convergence in China 189,259,804.70 Related parties, no risk of recovery

Total 189,259,804.70——

(2) Accounts receivable are presented based on aging

Aging Closing Balance

Within 1 year (including 1 year) 620,260,831.07 1-2 years 57,720,494.12 2-3 years 6,485,919.45 3-4 years 11,646,558.28 4-5 years 4,962,047.55 More than 5 years 41,741,027.42

Total 742,816,877.89

(3) Bad debt provisions for accounts receivable in the current period

Amount of changes in the current period Closing balance category Opening balance

Provision Recovery or transfer Write-off or write-off Others

Provision for bad debts 56,894,495.19 1,784,921.56 58,679,416.75

Total 56,894,495.19 1,784,921.56 58,679,416.75

(4) Accounts receivable actually written off in the current period

None.

(5) Accounts receivable with top five closing balances by debtors

Unit name Closing balance Accounting for the closing balance of accounts receivable Bad debt provision

Proportion of the total (%) Closing balance Chinese Academy of Medical Sciences Cancer Hospital 59,321,750.00 7.99 636,738.57 Jiangxi Cancer Hospital 9,976,616.25 1.34 108,671.03 Chinese Academy of Medical Sciences Peking Union Medical College Hospital 8,397,866.99 1.13 296,925.81 Peking University First Hospital 6,172,662.81 0.83 311,277.32 Weifang People’s Hospital 5,883,800.00 0.79 92,651.01Total 89,752,696.05 12.08 1,446,263.75

(6) Accounts receivable derecognized due to transfer of financial assets

None.

(7) The amount of assets and liabilities resulting from the transfer of accounts receivable and continued involvement

None.

Other receivables

Item Ending balance Beginning balance

Dividends receivable 30,028,047.91 200,000.00 Other receivables 65,697,023.16 56,675,973.12

Total 95,725,071.07 56,875,973.12

(1) Other receivables are classified according to the nature of the payment

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Deposits and security deposits 908,767.01 1,774,186.00 Advances in social security, annuities, etc. 59,849,278.08 49,290,054.28 Current accounts 5,858,000.30 6,685,637.86 Others 570,933.12 400,042.86

Total 67,186,978.51 58,149,921.00

(2) Provision for bad debt provisions for other receivables

The first stage The second stage The third stage

Next 12 months Lifetime expectations Lifetime expectations

Provision for bad debts Total expected credit Credit losses (have not occurred Credit losses (have occurred

Loss Credit Impairment) Credit Impairment)

Balance on January 1, 2026 1,143,749.12 330,198.76 1,473,947.88 Other dues on January 1, 2026 — — —

—

The book balance of receipts in the current period

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision in this period 16,007.47 16,007.47 Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance on June 30, 2026 1,159,756.59 330,198.76 1,489,955.35

(3) Other receivables are listed based on aging

Aging Book balance at the end of the period

Within 1 year (including 1 year) 19,872,875.46 1-2 years 18,813,078.95 2-3 years 16,115,234.84 3-4 years 6,252,703.07 4-5 years 12,500.00 More than 5 years 6,120,586.19

Total 67,186,978.51

(4) Bad debt provisions for other receivables

Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off or write-off Others

Provision for bad debts 1,473,947.88 16,007.47 1,489,955.35

Total 1,473,947.88 16,007.47 1,489,955.35

(5) Other receivables actually written off in the current period

None.

(6) Other receivables with top five closing balances based on debtors

Proportion of provision at the end of the period (%) to the total amount of other receivables during the period. Name of the quasi-unit for bad debts. Nature of the payment. Ending balance. Aging. Balance.

Advance social security,

Atomic Hi-Tech North China Pharmaceutical Co., Ltd.

54,484,059.02 Within 4 years 81.09

company

annuity

Related parties to

Beijing Atomic High-Tech Golden Radiation

2,500,000.00 More than 3 years 3.72

Technology Applications LLC

Incoming payment

China National Nuclear Power Co., Ltd. (Changchun) Radiation Technology

Security deposit 2,160,000.00 More than 3 years 3.21

technology co., ltd.

Receivable withholding

Futurechem Co., Ltd. 1,374,104.81 Within 3 years 2.05 tax

Advance social security, 1-3 years and 3 Hubei Zhongxun Medical Supplies Industry

1,300,582.66 1.94 Co., Ltd.

Annuity years and above

Total — 61,818,746.49 — 92.01%

(7) Accounts receivable involving government subsidies

None.

(8) Other receivables derecognized due to transfer of financial assets

None.

(9) Amount of assets and liabilities resulting from transfer of other receivables and continued involvement

None.

Long-term equity investment

(1) Classification of long-term equity investments

Closing balance Opening balance Book balance minus Book value Book balance minus Book value item Value Value accurate Accurate

Prepare for subsidiaries

1,485,616,669.39 1,485,616,669.39 1,460,621,669.39 1,460,621,669.39Investment

to joint ventures

506,797,600.97 506,797,600.97 502,362,796.95 502,362,796.95 Industrial investment

Total 1,992,414,270.36 1,992,414,270.36 1,962,984,466.34 1,962,984,466.34

(2) Investment in subsidiaries

Impairment allowance for current period

This issue

Invested unit Opening balance Increase during the period Ending balance Impairment Provision Decrease at the end of the period

Preparation Balance North China Hi-tech

200,700,000.00 - 200,700,000.00 Guangzhou Pharmaceutical

179,218,246.84 - 179,218,246.84Zhengzhou Hi-Tech

60,600,000.00 - 60,600,000.00 Qingdao Hi-Tech

54,100,000.00 - 54,100,000.00 Lanzhou Hi-Tech

54,000,000.00 - 54,000,000.00Nanning Hi-Tech

51,971,200.00 - 51,971,200.00 Taiyuan High-Tech

50,480,000.00 - 50,480,000.00Ningbo Junan

48,152,296.36 - 48,152,296.36Hefei Hi-Tech

43,238,900.00 - 43,238,900.00Shijiazhuang Hi-Tech

42,000,000.00 - 42,000,000.00Jinan Hi-Tech

33,725,000.00 7,275,000.00 41,000,000.00Xi'an Hi-Tech

40,602,697.00 - 40,602,697.00 Sichuan High-Tech

39,924,000.00 - 39,924,000.00 Yichang Hi-Tech

38,216,000.00 - 38,216,000.00Nanjing Hi-Tech

37,600,000.00 - 37,600,000.00Haikou Hi-Tech

35,775,000.00 1,000,000.00 36,775,000.00Xuzhou Hi-Tech

34,000,000.00 - 34,000,000.00Kunming Hi-Tech

32,700,000.00 - 32,700,000.00 Nanchang Hi-Tech

31,220,000.00 - 31,220,000.00 Chongqing Hi-Tech

30,892,000.00 - 30,892,000.00Tianjin Hi-Tech

30,000,000.00 - 30,000,000.00Fuzhou Hi-Tech

25,200,000.00 4,200,000.00 29,400,000.00 Guiyang Hi-Tech

27,625,000.00 - 27,625,000.00 Changsha Hi-Tech

25,830,000.00 - 25,830,000.00Xinjiang Hi-Tech

24,320,000.00 - 24,320,000.00 Zhejiang Xinyuan

23,256,000.00 1,020,000.00 24,276,000.00 Shantou Hi-Tech

23,450,000.00 - 23,450,000.00 Hengdian High-Tech

22,950,000.00 - 22,950,000.00 Wuhan Hi-Tech

21,000,000.00 - 21,000,000.00Nanyang Hi-Tech

8,100,000.00 8,200,000.00 16,300,000.00Golden Radiation

13,770,000.00 - 13,770,000.00 Guangzhou Hi-Tech

13,297,870.96 - 13,297,870.96Shanghai Kexing

12,666,046.30 - 12,666,046.30 Shenyang Hi-Tech

12,350,000.00 - 12,350,000.00Changchun Hi-Tech

11,700,000.00 - 11,700,000.00 Zhanjiang Hi-Tech

9,100,000.00 - 9,100,000.00Pat Technology

8,415,000.00 - 8,415,000.00 Nanchong Hi-Tech

4,050,000.00 3,300,000.00 7,350,000.00 Shuangyuan Company

2,829,794.60 - 2,829,794.60

Hangzhou Hi-Tech

1,000,000.00 - 1,000,000.00

Fuyuan Industry and Trade

596,617.33 - 596,617.33

total

1,460,621,669.39 24,995,000.00 0.00 1,485,616,669.39

(3) Investment in associates and joint ventures

Increases and decreases in the current period

reduce it

Worthy of his plans

Quasi-investment, chase, subtract, comprehensive, raise

At the beginning of the period, under the equity method, the capital reserve was announced, plus less, the equity, less the balance, the balance at the end of the period, the confirmed investment cash dividends, the investment income value of the period, and others.

Capital gains and losses or profits The last position of capital changes to the standard

Remaining mobilized and prepared

Amount

1. Joint ventures

sea

Got

Wei 478,914,611.99 35,233,704.28 29,828,047.91 484,320,268.36 public

Division

sea

deep

11,358,446.63 -1,173,811.23 10,184,635.40 scenes

Public

Division

lake

north

12,089,738.33 202,958.88 12,292,697.21

combine

502,362,796.95 34,262,851.93 29,828,047.91 506,797,600.97

plan

Operating income and operating costs

Amount for the current period Amount for the previous period

Project

revenue cost revenue cost

Main business 447,124,744.78 235,104,611.54 395,908,397.24 203,228,325.07

Total 447,124,744.78 235,104,611.54 395,908,397.24 203,228,325.07

Investment income

Item Amount incurred in the current period Amount incurred in the previous period Long-term equity investment income calculated by equity method 34,262,851.93 31,105,172.74 Long-term equity investment income calculated by cost method 5,000,000.00

Others 277,884.74 134,152.83

Total 39,540,736.67 31,239,325.57

Atomic Hi-Tech Co., Ltd.

Appendix I of August 27, 2026: Adjustments and Differences in Accounting Information

1. Changes in accounting policies, changes in accounting estimates or correction of major errors, etc.

(1) Retrospective adjustments or restatements of accounting data

□Changes in accounting policies □Correction of accounting errors □Other reasons √Not applicable

(2) Reasons and effects of changes in accounting policies, accounting estimates or correction of major accounting errors

□Applicable √Not applicable

2. Non-recurring profit and loss items and amounts

Unit: Yuan

Item Amount Gains and losses on disposal of non-current assets (including offsets for which asset impairment provisions have been made)

-14,108.06 pin part)

Government subsidies included in the current profit and loss (closely related to the company’s normal operating business)

Except for government subsidies that are relevant, comply with national policies and regulations, are enjoyed in accordance with determined standards, and have a lasting impact on the company’s profits and losses) 9,806,580.83

Other non-operating income and expenses other than the above

424,682.42

Total non-recurring gains and losses 10,217,155.19 Less: Income tax impact 1,536,559.60 Impact on minority shareholders’ equity (after tax) 78,747.02

Net non-recurring gains and losses 8,601,848.57

3. Differences in accounting data under domestic and overseas accounting standards

□Applicable √Not applicable

Appendix II Financing situation

1. Issuance of common shares and use of raised funds during the reporting period

(1) Stock issuance during the reporting period

□Applicable √Not applicable

(2) Usage of raised funds that lasted to the reporting period

□Applicable √Not applicable

2. Relevant information on preference shares surviving to the current period

□Applicable √Not applicable

3. Bond financing that lasts to the current period

□Applicable √Not applicable

Convertible bonds surviving to the current period □Applicable √Not applicable